{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:12:45Z","timestamp":1793722365150,"version":"4.6.1"},"reference-count":646,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The global pharmaceutical landscape remains dynamic and competitive, shaped by advancements in first-in-class therapies and breakthrough technologies. The United States has maintained its leadership in first-in-class therapies and breakthrough technologies, driven by advanced regulatory pathways, significant multinational corporation investments, a robust Research and Development (R&amp;D) workforce, and continuous technological innovation. Additionally, global impact of the Food and Drug Administration (FDA) is further amplified through collaborations like Project Orbis, which facilitates simultaneous reviews of cancer treatments by multiple regulatory authorities worldwide. Europe, while historically strong, faces growing challenges in maintaining its competitive edge, particularly due to protracted regulatory timelines and complex coordination among its member states. In this competitive global environment, China has rapidly transformed from a generics-dominated market to a key player in innovative drug development. This article reviews China\u2019s progress in innovative drug R&amp;D from 2019 to 2023, emphasizing regulatory modernization, clinical trial advancements, and the emergence of novel therapies. By comparing China\u2019s developments with above global counterparts, this review highlights the country\u2019s achievements in regulatory efficiency, clinical trial progress, and the development of innovative therapies such as biologics and cell and gene therapies. Through this comparative analysis, the article underscores how China\u2019s evolving policy-driven innovation ecosystem has positioned it as a growing leader in global drug development. The review examines how enhanced regulatory efficiency, clinical trial progress, manufacturing capabilities, and international collaboration have bolstered China\u2019s growing influence, while also discussing the future opportunities and challenges it faces in shaping global pharmaceutical innovation and development.<\/jats:p>","DOI":"10.1038\/s41392-025-02267-y","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T23:08:34Z","timestamp":1753139314000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Current landscape of innovative drug development and regulatory support in China"],"prefix":"10.1038","volume":"10","author":[{"given":"Ruirong","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junning","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"2267_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41392-024-01770-y","volume":"9","author":"L Zheng","year":"2024","unstructured":"Zheng, L., Wang, W. & Sun, Q. Targeted drug approvals in 2023: breakthroughs by the FDA and NMPA. Signal Transduction Targeted Ther. 9, 46 (2024).","journal-title":"Signal Transduction Targeted Ther."},{"key":"2267_CR2","doi-asserted-by":"publisher","first-page":"178","DOI":"10.54361\/Ljmr18-1.18","volume":"18","author":"M Shmela","year":"2024","unstructured":"Shmela, M. & Habbassi, M. Overview in EMA and FDA approved novel drugs in thE YEARS 2020, 2021 and 2022. Libyan. J. Med. 18, 178\u2013192 (2024).","journal-title":"Libyan. J. Med."},{"key":"2267_CR3","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41573-023-00723-4","volume":"22","author":"EC Scott","year":"2023","unstructured":"Scott, E. C. et al. Trends in the approval of cancer therapies by the FDA in the twenty-first century. Nat. Rev. Drug Discov. 22, 625\u2013640 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2267_CR4","doi-asserted-by":"publisher","first-page":"103966","DOI":"10.1016\/j.drudis.2024.103966","volume":"29","author":"MS Kinch","year":"2024","unstructured":"Kinch, M. S., Kraft, Z. & Schwartz, T. 2023 in review: FDA approvals of new medicines. Drug Discov. Today. 29, 103966 (2024).","journal-title":"Drug Discov. Today."},{"key":"2267_CR5","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1093\/ajhp\/zxad220","volume":"80","author":"MH Rim","year":"2023","unstructured":"Rim, M. H., Barada, F. & Levitsky, A. M. Recent and anticipated novel drug approvals for 2023 and 2024. Am. J. Health Syst. Pharm. 80, 1729\u20131732 (2023).","journal-title":"Am. J. Health Syst. Pharm."},{"key":"2267_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/d41573-022-00190-3","volume":"22","author":"PA Hines","year":"2023","unstructured":"Hines, P. A. et al. Artificial intelligence in European medicines regulation. Nat. Rev. Drug Discov. 22, 81\u201382 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2267_CR7","doi-asserted-by":"publisher","first-page":"105388","DOI":"10.1016\/j.yrtph.2023.105388","volume":"140","author":"S Thakkar","year":"2023","unstructured":"Thakkar, S. et al. Artificial intelligence and real-world data for drug and food safety\u2014a regulatory science perspective. Regul. Toxicol. Pharmacol. 140, 105388 (2023).","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"2267_CR8","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s10198-023-01639-x","volume":"25","author":"DT Michaeli","year":"2024","unstructured":"Michaeli, D. T. et al. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy. Eur. J. Health. Econ. 25, 979\u2013997 (2024).","journal-title":"Eur. J. Health. Econ."},{"key":"2267_CR9","doi-asserted-by":"publisher","first-page":"e2331753","DOI":"10.1001\/jamanetworkopen.2023.31753","volume":"6","author":"AK Wong","year":"2023","unstructured":"Wong, A. K. et al. Use of expedited regulatory programs and clinical development times for FDA-approved novel therapeutics. JAMA Netw. Open. 6, e2331753 (2023).","journal-title":"JAMA Netw. Open."},{"key":"2267_CR10","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1021\/acs.jmedchem.3c02165","volume":"67","author":"DG Brown","year":"2024","unstructured":"Brown, D. G. A Drug discovery perspective on FDA expedited development and incentive programs. J. Med. Chem. 67, 1690\u20131700 (2024).","journal-title":"J. Med. Chem."},{"key":"2267_CR11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S1470-2045(23)00020-7","volume":"24","author":"DJ Benjamin","year":"2023","unstructured":"Benjamin, D. J. & Lythgoe, M. P. Modernising the US FDA\u2019s accelerated approval pathway. Lancet Oncol 24, 203\u2013205 (2023).","journal-title":"Lancet Oncol"},{"key":"2267_CR12","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1007\/s43441-022-00480-3","volume":"57","author":"P Franco","year":"2023","unstructured":"Franco, P. et al. Regulatory pathways supporting expedited drug development and approval in ICH member countries. Ther. Innov. Regul. Sci. 57, 484\u2013514 (2023).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"2267_CR13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s43441-023-00574-6","volume":"58","author":"M Ghadanian","year":"2024","unstructured":"Ghadanian, M. & Schafheutle, E. Comparison between European Medicines Agency and US Food and Drug Administration in granting accelerated marketing authorizations for Covid-19 medicines and their utilized regulations. Ther. Innov. Regul. Sci. 58, 79\u2013113 (2024).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"2267_CR14","doi-asserted-by":"publisher","first-page":"6412","DOI":"10.1158\/1078-0432.CCR-20-3292","volume":"26","author":"RA de Claro","year":"2020","unstructured":"de Claro, R. A. et al. Project Orbis: global collaborative review program. Clin. Cancer Res. 26, 6412\u20136416 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2267_CR15","doi-asserted-by":"publisher","first-page":"S238","DOI":"10.1016\/j.jval.2023.03.2634","volume":"26","author":"J Beca","year":"2023","unstructured":"Beca, J. et al. HPR161 international comparisons of health technology assessment and reimbursement outcomes for oncology drugs with regulatory review through project Orbis. Value Health 26, S238 (2023).","journal-title":"Value Health"},{"key":"2267_CR16","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S1470-2045(24)00210-9","volume":"25","author":"A Tibau","year":"2024","unstructured":"Tibau, A. & Kesselheim, A. S. Global cooperation and early access\u2014clinical outcomes matter. Lancet Oncol 25, 687\u2013688 (2024).","journal-title":"Lancet Oncol"},{"key":"2267_CR17","doi-asserted-by":"publisher","first-page":"5062","DOI":"10.1158\/1078-0432.CCR-19-3979","volume":"26","author":"S Arora","year":"2020","unstructured":"Arora, S. et al. FDA approval summary: pembrolizumab plus lenvatinib for endometrial carcinoma, a collaborative international review under project orbis. Clin. Cancer Res. 26, 5062\u20135067 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2267_CR18","doi-asserted-by":"publisher","first-page":"6638","DOI":"10.1158\/1078-0432.CCR-21-1034","volume":"27","author":"AL Koch","year":"2021","unstructured":"Koch, A. L. et al. FDA approval summary: osimertinib for adjuvant treatment of surgically resected non\u2013small cell lung cancer, a Collaborative Project Orbis Review. Clin. Cancer Res. 27, 6638\u20136643 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2267_CR19","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/S1470-2045(24)00286-9","volume":"25","author":"K Jenei","year":"2024","unstructured":"Jenei, K., Gentilini, A., Haslam, A. & Prasad, V. Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis. Lancet Oncol 25, 979\u2013988 (2024).","journal-title":"Lancet Oncol"},{"key":"2267_CR20","unstructured":"EMA. EMA to support establishment of the African Medicines Agency, <https:\/\/www.ema.europa.eu\/en\/news\/ema-support-establishment-african-medicines-agency> (2024)."},{"key":"2267_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s40545-020-00281-9","volume":"14","author":"BM Ncube","year":"2021","unstructured":"Ncube, B. M., Dube, A. & Ward, K. Establishment of the African Medicines Agency: progress, challenges and regulatory readiness. J. Pharm. Policy Pract. 14, 29 (2021).","journal-title":"J. Pharm. Policy Pract."},{"key":"2267_CR22","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/hcs2.117","volume":"3","author":"AA Abdulwahab","year":"2024","unstructured":"Abdulwahab, A. A. et al. The African Medicines Agency and Medicines Regulation: Progress, challenges, and recommendations. Health Care Sci 3, 350\u2013359 (2024).","journal-title":"Health Care Sci"},{"key":"2267_CR23","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.1002\/puh2.96","volume":"2","author":"MU Ogbodum","year":"2023","unstructured":"Ogbodum, M. U. et al. African Medicines Agency: How it will change the landscape of medicines in Africa. Public Health Chall 2, e96 (2023).","journal-title":"Public Health Chall"},{"key":"2267_CR24","doi-asserted-by":"publisher","first-page":"e1088","DOI":"10.1016\/S2214-109X(22)00243-1","volume":"10","author":"L Hwenda","year":"2022","unstructured":"Hwenda, L., Sidibe, M. & Makanga, M. The African Medicines Agency: the key to unlocking clinical research in Africa. Lancet Glob. Health. 10, e1088\u2013e1089 (2022).","journal-title":"Lancet Glob. Health."},{"key":"2267_CR25","doi-asserted-by":"publisher","first-page":"11758","DOI":"10.3390\/ijerph182211758","volume":"18","author":"VK Chattu","year":"2021","unstructured":"Chattu, V. K. et al. Advancing African Medicines Agency through global health diplomacy for an equitable pan-African universal health coverage: a scoping review. Int. J. Env. Res. Public Health. 18, 11758 (2021).","journal-title":"Int. J. Env. Res. Public Health."},{"key":"2267_CR26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/d41573-022-00167-2","volume":"22","author":"L Kong","year":"2023","unstructured":"Kong, L., Li, Q., Kaitin, K. I. & Shao, L. Innovation in the Chinese pharmaceutical industry. Nat. Rev. Drug Discov. 22, 12\u201313 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2267_CR27","doi-asserted-by":"crossref","unstructured":"Jia, R., Ma, X., Yang, J. & Zhang, Y. Improving Regulation for Innovation: Evidence from China\u2019s Pharmaceutical Industry (National Bureau of Economic Research, 2023).","DOI":"10.3386\/w31976"},{"key":"2267_CR28","unstructured":"CHINADAILY. China advances new drug innovations <https:\/\/global.chinadaily.com.cn\/a\/202204\/25\/WS6265f594a310fd2b29e590ae.html> (2022)."},{"key":"2267_CR29","unstructured":"Deloitte. Outlook on biopharma innovation trends in China <https:\/\/www2.deloitte.com\/cn\/en\/pages\/life-sciences-and-healthcare\/articles\/china-biopharma-innovation-trends.html> (2024)."},{"key":"2267_CR30","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1016\/j.apsb.2022.08.004","volume":"12","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. Evolution of drug regulations and regulatory innovation for anticancer drugs in China. Acta Pharm. Sin. B. 12, 4365\u20134377 (2022).","journal-title":"Acta Pharm. Sin. B."},{"key":"2267_CR31","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1111\/cts.12987","volume":"14","author":"W Tang","year":"2021","unstructured":"Tang, W. et al. Evolving drug regulatory landscape in China: a clinical pharmacology perspective. Clin. Transl. Sci. 14, 1222\u20131230 (2021).","journal-title":"Clin. Transl. Sci."},{"key":"2267_CR32","first-page":"124","volume":"03","author":"Y Hu","year":"2023","unstructured":"Hu, Y. Retrospection of drug regulatory system reform in china through 1998-2023. Chin. Food Drug Adm. Mag. 03, 124\u2013125 (2023).","journal-title":"Chin. Food Drug Adm. Mag."},{"key":"2267_CR33","unstructured":"NMPA. NMPA Held 2023 ICH in China: Progress and Outlook Symposium <https:\/\/english.nmpa.gov.cn\/2023-09\/13\/c_963948.htm> (2023)."},{"key":"2267_CR34","unstructured":"NMPA. NMPA holds symposium on process and prospects of ICH in China <https:\/\/english.nmpa.gov.cn\/2021-04\/10\/c_610224.htm#:~:text=China%27s%20drug%20regulatory%20authority%20joined%20the%20ICH%20in,member%20of%20the%20ICH%20Management%20Committee%20in%202018> (2021)."},{"key":"2267_CR35","unstructured":"ICH. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) <https:\/\/www.ich.org\/> (2024)."},{"key":"2267_CR36","doi-asserted-by":"publisher","first-page":"e251","DOI":"10.1002\/mco2.251","volume":"4","author":"J Lu","year":"2023","unstructured":"Lu, J., Xu, L., Wei, W. & He, W. Advanced therapy medicinal products in China: regulation and development. MedComm 4, e251 (2023).","journal-title":"MedComm"},{"key":"2267_CR37","first-page":"904","volume":"46","author":"Q Zhu","year":"2024","unstructured":"Zhu, Q. et al. Expedited program and utilization for anticancer drug approval in China and the United States. Chin. J. Oncol. 46, 904\u2013910 (2024).","journal-title":"Chin. J. Oncol."},{"key":"2267_CR38","unstructured":"The Ministry of Health. The \u201cMajor New Drug Development\u201d National Science and Technology Major Project Officially Launched <https:\/\/www.gov.cn\/gzdt\/2008-08\/29\/content_1082804.htm> (2008)."},{"key":"2267_CR39","unstructured":"National Medical Products Administration. The NMPA launched the China Drug Regulatory Science Action Plan <http:\/\/www.gov.cn\/xinwen\/2019-05\/02\/content_5388253.htm> (2019)."},{"key":"2267_CR40","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13045-024-01602-0","volume":"17","author":"R Tan","year":"2024","unstructured":"Tan, R. et al. Redefining chimeric antigen receptor T-cell (CAR-T) regulation: China\u2019s responses to address secondary cancer risks of CAR-T therapy. J. Hematol. Oncol. 17, 90 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"2267_CR41","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ccell.2020.12.005","volume":"39","author":"S Wang","year":"2021","unstructured":"Wang, S. et al. The landscape of cell and gene therapies for solid tumors. Cancer Cell 39, 7\u20138 (2021).","journal-title":"Cancer Cell"},{"key":"2267_CR42","first-page":"507","volume":"54","author":"J Zhao","year":"2024","unstructured":"Zhao, J. et al. Scientific progress of drug regulation and development of drug regulatory science in China. Sci. Sin. Vitae. 54, 507\u2013524 (2024).","journal-title":"Sci. Sin. Vitae."},{"key":"2267_CR43","first-page":"3","volume":"40","author":"J Zhao","year":"2024","unstructured":"Zhao, J. Prospect for the construction and development of China\u2019s drug regulatory science system. Pharmacol. Clin. Chin. Mater. Med. 40, 3\u201317 (2024).","journal-title":"Pharmacol. Clin. Chin. Mater. Med."},{"key":"2267_CR44","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/d41573-022-00058-6","volume":"21","author":"G Li","year":"2022","unstructured":"Li, G. et al. Evolution of innovative drug R&D in China. Nat. Rev. Drug Discov. 21, 553\u2013554 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2267_CR45","doi-asserted-by":"publisher","first-page":"e2439080","DOI":"10.1001\/jamanetworkopen.2024.39080","volume":"7","author":"X Luo","year":"2024","unstructured":"Luo, X. et al. Clinical benefit, price, and regulatory approval of cancer drugs granted breakthrough therapy designation in China, 2020-2024. JAMA Netw. Open. 7, e2439080 (2024).","journal-title":"JAMA Netw. Open."},{"key":"2267_CR46","doi-asserted-by":"publisher","first-page":"e2033004","DOI":"10.1001\/jamanetworkopen.2020.33004","volume":"4","author":"V Arciero","year":"2021","unstructured":"Arciero, V. et al. Assessment of Food and Drug Administration\u2013and European Medicines Agency\u2013approved systemic oncology therapies and clinically meaningful improvements in quality of life: a systematic review. JAMA Netw. Open. 4, e2033004 (2021).","journal-title":"JAMA Netw. Open."},{"key":"2267_CR47","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1200\/JCO.2021.39.15_suppl.1575","volume":"39","author":"M Lythgoe","year":"2021","unstructured":"Lythgoe, M. et al. Time intervals between US Food and Drug Administration (FDA) and European Medicines Agency (EMA) new cancer therapy approvals. J. Clin. Oncol. 39, 15 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2267_CR48","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jval.2023.01.017","volume":"26","author":"A Gnanasakthy","year":"2023","unstructured":"Gnanasakthy, A. et al. A review of labeling based on patient-reported outcome endpoints for new oncology drugs approved by the European medicines agency (2017\u20132021). Value Health 26, 893\u2013901 (2023).","journal-title":"Value Health"},{"key":"2267_CR49","unstructured":"Drug Administration Law of the People\u2019s Republic of China, <https:\/\/www.gov.cn\/xinwen\/2019-08\/26\/content_5424780.htm> (2019)."},{"key":"2267_CR50","unstructured":"Opinions on Reforming the Review and Approval System for Drugs and Medical Devices <https:\/\/www.gov.cn\/zhengce\/content\/2015-08\/18\/content_10101.htm> (2015)."},{"key":"2267_CR51","unstructured":"Drug Registration Management Act, <https:\/\/www.gov.cn\/gongbao\/content\/2020\/content_5512563.htm> (2020)."},{"key":"2267_CR52","unstructured":"Notice of the NMPA on the release of chemical drug registration classification and declaration data requirements, <https:\/\/www.nmpa.gov.cn\/xxgk\/ggtg\/ypggtg\/ypqtggtg\/20200630180301525.html> (2020)."},{"key":"2267_CR53","unstructured":"Announcement of the NMPA on Issuing the Classification and Documentation Requirements for the Registration of Biological Products, <https:\/\/www.nmpa.gov.cn\/xxgk\/ggtg\/ypggtg\/ypqtggtg\/20200630175301552.html> (2020)."},{"key":"2267_CR54","unstructured":"Announcement of the National Medical Products Administration on Issuing the \u201cClassification and Documentation Requirements for the Registration of Traditional Chinese Medicines\u201d <https:\/\/www.nmpa.gov.cn\/xxgk\/ggtg\/ypggtg\/ypqtggtg\/20200928164311143.html> (2020)."},{"key":"2267_CR55","unstructured":"FDA. Drug Development and Review Definitions <https:\/\/www.fda.gov\/drugs\/investigational-new-drug-ind-application\/drug-development-and-review-definitions> (2015)."},{"key":"2267_CR56","unstructured":"FDA. Novel Drug Approvals at FDA <https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/novel-drug-approvals-fda> (2024)."},{"key":"2267_CR57","unstructured":"FDA. New Molecular Entity (NME) Drug and New Biologic Approvals <https:\/\/www.fda.gov\/drugs\/nda-and-bla-approvals\/new-molecular-entity-nme-drug-and-new-biologic-approvals> (2024)."},{"key":"2267_CR58","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1021\/acs.jmedchem.0c01516","volume":"64","author":"DG Brown","year":"2021","unstructured":"Brown, D. G. & Wobst, H. J. A decade of FDA-approved drugs (2010\u20132019): trends and future directions. J. Med. Chem. 64, 2312\u20132338 (2021).","journal-title":"J. Med. Chem."},{"key":"2267_CR59","doi-asserted-by":"publisher","first-page":"35","DOI":"10.4155\/fmc.09.8","volume":"1","author":"P Pevarello","year":"2009","unstructured":"Pevarello, P. Recent drug approvals from the US FDA and EMEA: what the future holds. Future Med. Chem. 1, 35\u201348 (2009).","journal-title":"Future Med. Chem."},{"key":"2267_CR60","unstructured":"SSRN. FDA\u2019s Approvable and Related NDA\/BLA Actions <https:\/\/ssrn.com\/abstract=1105509> (2008)."},{"key":"2267_CR61","doi-asserted-by":"publisher","first-page":"8729","DOI":"10.1021\/jm402001w","volume":"57","author":"SK Branch","year":"2014","unstructured":"Branch, S. K. & Agranat, I. \u201cNew drug\u201d designations for new therapeutic entities: New active substance, new chemical entity, new biological entity, new molecular entity. J. Med. Chem. 57, 8729\u20138765 (2014).","journal-title":"J. Med. Chem."},{"key":"2267_CR62","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1016\/j.drudis.2017.06.011","volume":"22","author":"RH Griesenauer","year":"2017","unstructured":"Griesenauer, R. H. & Kinch, M. S. 2016 in review: FDA approvals of new molecular entities. Drug Discov. Today. 22, 1593\u20131597 (2017).","journal-title":"Drug Discov. Today."},{"key":"2267_CR63","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/j.drudis.2019.05.022","volume":"24","author":"MS Kinch","year":"2019","unstructured":"Kinch, M. S. & Griesenauer, R. H. 2018 in review: FDA approvals of new molecular entities. Drug Discov. Today. 24, 1710\u20131714 (2019).","journal-title":"Drug Discov. Today."},{"key":"2267_CR64","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.drudis.2018.05.011","volume":"23","author":"MS Kinch","year":"2018","unstructured":"Kinch, M. S. & Griesenauer, R. H. 2017 in review: FDA approvals of new molecular entities. Drug Discov. Today. 23, 1469\u20131473 (2018).","journal-title":"Drug Discov. Today."},{"key":"2267_CR65","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/pds.744","volume":"11","author":"J Cross","year":"2002","unstructured":"Cross, J. et al. Postmarketing drug dosage changes of 499 FDA\u2010approved new molecular entities, 1980\u20131999. Pharmacoepidemiol. Drug Saf. 11, 439\u2013446 (2002).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"2267_CR66","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.drudis.2014.03.018","volume":"19","author":"MS Kinch","year":"2014","unstructured":"Kinch, M. S., Haynesworth, A., Kinch, S. L. & Hoyer, D. An overview of FDA-approved new molecular entities: 1827\u20132013. Drug Discov. Today. 19, 1033\u20131039 (2014).","journal-title":"Drug Discov. Today."},{"key":"2267_CR67","unstructured":"REPROCELL. What you should know about the FDA\u2019s Biological License Application Process <https:\/\/www.reprocell.com\/blog\/what-you-should-know-about-the-fdas-biological-license-application-process> (2024)."},{"key":"2267_CR68","unstructured":"FDA. Biologics License Applications (BLA) Process (CBER) <https:\/\/www.fda.gov\/vaccines-blood-biologics\/development-approval-process-cber\/biologics-license-applications-bla-process-cber> (2021)."},{"key":"2267_CR69","unstructured":"FDA. Submitting Biologics Advertising & Promotional Labeling <https:\/\/www.fda.gov\/vaccines-blood-biologics\/labeling-cber-regulated-products\/submitting-biologics-advertising-promotional-labeling> (2018)."},{"key":"2267_CR70","unstructured":"FDA. Biological Approvals by Year <https:\/\/www.fda.gov\/vaccines-blood-biologics\/development-approval-process-cber\/biological-approvals-year> (2024)."},{"key":"2267_CR71","unstructured":"FDA. Frequently Asked Questions About Therapeutic Biological Products <https:\/\/www.fda.gov\/drugs\/therapeutic-biologics-applications-bla\/frequently-asked-questions-about-therapeutic-biological-products> (2024)."},{"key":"2267_CR72","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1080\/23299460.2020.1807669","volume":"7","author":"TA Hemphill","year":"2020","unstructured":"Hemphill, T. A. Biologics regulation, second-to-market competition, and the use of blockchain technology: an opportunity for the FDA to support responsible biotechnology innovation. J. Respons. Innov. 7, 689\u2013696 (2020).","journal-title":"J. Respons. Innov."},{"key":"2267_CR73","doi-asserted-by":"publisher","first-page":"e0178104","DOI":"10.1371\/journal.pone.0178104","volume":"12","author":"L-C Chang","year":"2017","unstructured":"Chang, L.-C., Mahmood, R., Qureshi, S. & Breder, C. D. Patterns of use and impact of standardised MedDRA query analyses on the safety evaluation and review of new drug and biologics license applications. PLoS One 12, e0178104 (2017).","journal-title":"PLoS One"},{"key":"2267_CR74","doi-asserted-by":"publisher","first-page":"e2236149","DOI":"10.1001\/jamanetworkopen.2022.36149","volume":"5","author":"SJ Lau","year":"2022","unstructured":"Lau, S. J. et al. Participation of older adults in clinical trials for new drug applications and biologics license applications from 2010 through 2019. JAMA Netw. Open. 5, e2236149 (2022).","journal-title":"JAMA Netw. Open."},{"key":"2267_CR75","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.drudis.2014.09.003","volume":"20","author":"MS Kinch","year":"2015","unstructured":"Kinch, M. S. An overview of FDA-approved biologics medicines. Drug Discov. Today. 20, 393\u2013398 (2015).","journal-title":"Drug Discov. Today."},{"key":"2267_CR76","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1158\/1078-0432.CCR-21-2639","volume":"28","author":"B Arondekar","year":"2022","unstructured":"Arondekar, B. et al. Real-world evidence in support of oncology product registration: a systematic review of new drug application and biologics license application approvals from 2015\u20132020. Clin. Cancer Res. 28, 27\u201335 (2022).","journal-title":"Clin. Cancer Res."},{"key":"2267_CR77","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1007\/s13361-016-1531-9","volume":"28","author":"S Rogstad","year":"2016","unstructured":"Rogstad, S. et al. A retrospective evaluation of the use of mass spectrometry in FDA biologics license applications. J. Am. Soc. Mass Spectrom. 28, 786\u2013794 (2016).","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"2267_CR78","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/cpt.2474","volume":"111","author":"CA Purpura","year":"2022","unstructured":"Purpura, C. A. et al. The role of real\u2010world evidence in FDA\u2010approved new drug and biologics license applications. Clin. Pharmacol. Ther. 111, 135\u2013144 (2022).","journal-title":"Clin. Pharmacol. Ther."},{"key":"2267_CR79","unstructured":"EMA. Innovative medicine <https:\/\/www.ema.europa.eu\/en\/glossary-terms\/innovative-medicine?utm_source=chatgpt.com> (2024)."},{"key":"2267_CR80","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3389\/fphar.2011.00057","volume":"2","author":"L Annemans","year":"2011","unstructured":"Annemans, L., Cleemput, I., Hulstaert, F. & Simoens, S. Valorising and creating access to innovative medicines in the European Union. Front. Pharmacol. 2, 57 (2011).","journal-title":"Front. Pharmacol."},{"key":"2267_CR81","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/j.1365-2125.2006.02700.x","volume":"62","author":"D Motola","year":"2006","unstructured":"Motola, D. et al. An update on the first decade of the European centralized procedure: how many innovative drugs? Br. J. Clin. Pharmacol. 62, 610\u2013616 (2006).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"2267_CR82","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/annonc\/mdv547","volume":"27","author":"L Bergmann","year":"2016","unstructured":"Bergmann, L. et al. Access to innovative oncology medicines in Europe. Ann. Oncol. 27, 353\u2013356 (2016).","journal-title":"Ann. Oncol."},{"key":"2267_CR83","doi-asserted-by":"publisher","first-page":"1215431","DOI":"10.3389\/fphar.2023.1215431","volume":"14","author":"A Vallano","year":"2023","unstructured":"Vallano, A., Pontes, C. & Agust\u00ed, A. The challenges of access to innovative medicines with limited evidence in the European Union. Front. Pharmacol. 14, 1215431 (2023).","journal-title":"Front. Pharmacol."},{"key":"2267_CR84","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.yrtph.2016.05.033","volume":"80","author":"H Enzmann","year":"2016","unstructured":"Enzmann, H. New trends and challenges in the European regulation of innovative medicines. Regul. Toxicol. Pharmacol. 80, 314\u2013320 (2016).","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"2267_CR85","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/clpt.2011.321","volume":"91","author":"M Goldman","year":"2012","unstructured":"Goldman, M. The innovative medicines initiative: a European response to the innovation challenge. Clin. Pharmacol. Ther. 91, 418\u2013425 (2012).","journal-title":"Clin. Pharmacol. Ther."},{"key":"2267_CR86","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/2168479016662682","volume":"51","author":"H Kondo","year":"2017","unstructured":"Kondo, H. et al. The current status of Sakigake designation in Japan, PRIME in the European Union, and breakthrough therapy designation in the United States. Ther. Innov. Regul. Sci. 51, 51\u201354 (2017).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"2267_CR87","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/bcp.14130","volume":"86","author":"R Joppi","year":"2020","unstructured":"Joppi, R. et al. Food and Drug Administration vs European Medicines Agency: review times and clinical evidence on novel drugs at the time of approval. Br. J. Clin. Pharmacol. 86, 170\u2013174 (2020).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"2267_CR88","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nrd.2017.57","volume":"16","author":"A Mullard","year":"2017","unstructured":"Mullard, A. PRIME time at the EMA. Nat. Rev. Drug Discov. 16, 226\u2013228 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2267_CR89","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s10198-017-0944-0","volume":"19","author":"F Anto\u00f1anzas","year":"2018","unstructured":"Anto\u00f1anzas, F., Ju\u00e1rez-Castell\u00f3, C. & Rodr\u00edguez-Ibeas, R. EMA Priority Medicines scheme (PRIME): will more paying-for-performance agreements be needed due to immature data? Eur. J. Health Econ. 19, 905\u2013907 (2018).","journal-title":"Eur. J. Health Econ."},{"key":"2267_CR90","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/cpt.1669","volume":"107","author":"E Neez","year":"2020","unstructured":"Neez, E., Hwang, T. J., Sahoo, S. A. & Naci, H. European Medicines Agency\u2019s priority medicines scheme at 2 years: an evaluation of clinical studies supporting eligible drugs. Clin. Pharmacol. Ther. 107, 541\u2013552 (2020).","journal-title":"Clin. Pharmacol. Ther."},{"key":"2267_CR91","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1007\/s00228-016-2104-3","volume":"72","author":"D Boucaud-Maitre","year":"2016","unstructured":"Boucaud-Maitre, D. & Altman, J.-J. Do the EMA accelerated assessment procedure and the FDA priority review ensure a therapeutic added value? 2006\u20132015: a cohort study. Eur. J. Clin. Pharmacol. 72, 1275\u20131281 (2016).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"2267_CR92","doi-asserted-by":"publisher","first-page":"A469","DOI":"10.1016\/j.jval.2016.09.710","volume":"19","author":"L Parviainen","year":"2016","unstructured":"Parviainen, L. et al. Early market access for pharmaceuticals in EU: what is the impact of EMA\u2019s accelerated assessment procedure? Value Health 19, A469 (2016).","journal-title":"Value Health"},{"key":"2267_CR93","first-page":"443","volume":"12","author":"X Li","year":"2019","unstructured":"Li, X., Yang, Q. & Zhou, B. Empirical analysis on the policies of drug accelerated assessment in the European Union. China Pharm 12, 443\u2013447 (2019).","journal-title":"China Pharm"},{"key":"2267_CR94","unstructured":"EMA. Accelerated assessment <https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/marketing-authorisation\/accelerated-assessment> (2021)."},{"key":"2267_CR95","unstructured":"Center, N. M. P. A. D. E. 2023 Annual Drug Evaluation Report <https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/9506710a7471174ab169e98b0bbb9e23> (2024)."},{"key":"2267_CR96","unstructured":"2022 Annual Drug Evaluation Report <https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/849b5a642142fc00738aff200077db11> (2023)."},{"key":"2267_CR97","unstructured":"2021 Annual Drug Evaluation Report <https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/f92b7bdf775bbf4c4dc3a762f343cdc8> (2022)."},{"key":"2267_CR98","unstructured":"2020 Annual Drug Evaluation Report <https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/876bb5300cce2d3a5cf4f68c97c8a631> (2021)."},{"key":"2267_CR99","unstructured":"2019 Annual Drug Evaluation Report <https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/327a9e456913626826bc4cbdfd5354ce> (2020)."},{"key":"2267_CR100","unstructured":"FDA. IND Receipts <https:\/\/www.fda.gov\/drugs\/ind-activity\/ind-receipts?utm_source=chatgpt.com> (2024)."},{"key":"2267_CR101","unstructured":"CardinalHealth. Key trends in IND applications <https:\/\/www.cardinalhealth.com\/en\/services\/manufacturer\/biopharmaceutical\/drug-development-and-regulatory\/resources-for-regulatory-consulting\/fda-insights\/key-trends-in-ind-applications.html> (2024)."},{"key":"2267_CR102","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1136\/jim-2015-000010","volume":"64","author":"L Lapteva","year":"2016","unstructured":"Lapteva, L. & Pariser, A. R. Investigational New Drug applications: a 1-year pilot study on rates and reasons for clinical hold. J. Investig. Med. 64, 376\u2013382 (2016).","journal-title":"J. Investig. Med."},{"key":"2267_CR103","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s11948-015-9662-0","volume":"22","author":"V Giannuzzi","year":"2016","unstructured":"Giannuzzi, V., Altavilla, A., Ruggieri, L. & Ceci, A. Clinical trial application in Europe: what will change with the new regulation? Sci. Eng. Ethics. 22, 451\u2013466 (2016).","journal-title":"Sci. Eng. Ethics."},{"key":"2267_CR104","doi-asserted-by":"publisher","first-page":"1600939","DOI":"10.1080\/20016689.2019.1600939","volume":"7","author":"C Eder","year":"2019","unstructured":"Eder, C. & Wild, C. Technology forecast: advanced therapies in late clinical research, EMA approval or clinical application via hospital exemption. J. Mark. Access Health Policy. 7, 1600939 (2019).","journal-title":"J. Mark. Access Health Policy."},{"key":"2267_CR105","unstructured":"EMA. Clinical Trials Regulation <https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/clinical-trials-human-medicines\/clinical-trials-regulation> (2022)."},{"key":"2267_CR106","unstructured":"NIH. ClinicalTrials.gov <https:\/\/clinicaltrials.gov\/> (2023)."},{"key":"2267_CR107","unstructured":"BIO, P. A very interesting undertaking: international multi-center clinical trials <https:\/\/www.pbmcbioshandong.com\/hyxw\/269.html> (2024)."},{"key":"2267_CR108","unstructured":"TIMES, F. Europe falls behind China in playing host to clinical drug trials <https:\/\/www-ft-com.ezphost.dur.ac.uk\/content\/3d861acb-8e7d-4157-b845-81124254da8a> (2024)."},{"key":"2267_CR109","unstructured":"TIMES, F. Europe falling behind US and China in pharma innovation, warns AstraZeneca chief <https:\/\/www.ft.com\/content\/2c0d4917-f837-4aad-be54-6a727800c3e4> (2024)."},{"key":"2267_CR110","unstructured":"Pharmaphorum. Europe\u2019s share of clinical trials falling, with China rising <https:\/\/pharmaphorum.com\/news\/europes-share-clinical-trials-falling-china-rising> (2024)."},{"key":"2267_CR111","doi-asserted-by":"publisher","first-page":"e000410","DOI":"10.1136\/bmjonc-2024-000410","volume":"3","author":"AD VanHelene","year":"2024","unstructured":"VanHelene, A. D. et al. As bleak as it sounds? Analysing trends in oncology clinical trial initiation in the UK from 2010 to 2022. BMJ Oncol. 3, e000410 (2024).","journal-title":"BMJ Oncol."},{"key":"2267_CR112","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1002\/cpt.2534","volume":"111","author":"F Lasch","year":"2022","unstructured":"Lasch, F. et al. The impact of COVID\u201019 on the initiation of clinical trials in Europe and the United States. Clin. Pharmacol. Ther. 111, 1093\u20131102 (2022).","journal-title":"Clin. Pharmacol. Ther."},{"key":"2267_CR113","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/d41573-024-00085-5","volume":"23","author":"G Capone","year":"2024","unstructured":"Capone, G. et al. Accelerating clinical trials in the EU (ACT EU): transforming the EU clinical trials landscape. Nat. Rev. Drug Discov. 23, 797\u2013798 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2267_CR114","unstructured":"Center for Drug Evaluation, NMPA 2020 Annual report on the progress of clinical trials for new drug registration in China <https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/d670723dd2f646722097b03cf005e052> (2021)."},{"key":"2267_CR115","unstructured":"Center for Drug Evaluation, NMPA 2021 Annual report on the progress of clinical trials for new drug registration in China, <https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/1839a2c931e1ed43eb4cc7049e189cb0> (2022)."},{"key":"2267_CR116","unstructured":"Center for Drug Evaluation, NMPA 2022 Annual report on the progress of clinical trials for new drug registration in China <https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/46260e34bfe67292bfae1de8863d20fe> (2023)."},{"key":"2267_CR117","unstructured":"Center for Drug Evaluation, NMPA 2023 Annual report on the progress of clinical trials for new drug registration in China, <https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/d25e2879906bd2d3ae6c929aece41e34> (2024)."},{"key":"2267_CR118","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41392-020-0164-4","volume":"5","author":"W Wang","year":"2020","unstructured":"Wang, W. & Sun, Q. Novel targeted drugs approved by the NMPA and FDA in 2019. Signal Transduct. Target. Ther. 5, 65 (2020).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2267_CR119","unstructured":"FDA. Novel Drug Approvals for 2023, <https:\/\/www.fda.gov\/drugs\/novel-drug-approvals-fda\/novel-drug-approvals-2023> (2024)."},{"key":"2267_CR120","doi-asserted-by":"publisher","first-page":"115476","DOI":"10.1016\/j.ejmech.2023.115476","volume":"256","author":"S Ali","year":"2023","unstructured":"Ali, S. & Zhou, J. Highlights on US FDA-approved fluorinated drugs over the past five years (2018\u20132022). Eur. J. Med. Chem. 256, 115476 (2023).","journal-title":"Eur. J. Med. Chem."},{"key":"2267_CR121","doi-asserted-by":"publisher","first-page":"237110","DOI":"10.6004\/jnccn.2023.7110","volume":"22","author":"DT Michaeli","year":"2024","unstructured":"Michaeli, D. T. & Michaeli, T. Breakthrough therapy cancer drugs and indications with FDA approval: development time, innovation, trials, clinical benefit, epidemiology, and price. J. Natl. Compr. Canc. Netw. 22, 237110 (2024).","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"2267_CR122","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/cpt.2378","volume":"110","author":"J Corrigan\u2010Curay","year":"2021","unstructured":"Corrigan\u2010Curay, J. & Stein, P. FDA Breakthrough therapy designation\u2013trial design and more\u2013commentary. Clin. Pharmacol. Ther. 110, 869\u2013870 (2021).","journal-title":"Clin. Pharmacol. Ther."},{"key":"2267_CR123","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1162\/rest_a_01434","volume":"2024","author":"A Chandra","year":"2024","unstructured":"Chandra, A., Kao, J., Miller, K. L. & Stern, A. D. Regulatory incentives for innovation: the FDA\u2019s breakthrough therapy designation. Rev. Econ. Stat. 2024, 1\u201346 (2024).","journal-title":"Rev. Econ. Stat."},{"key":"2267_CR124","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3390\/pharmacy10050126","volume":"10","author":"MC Herink","year":"2022","unstructured":"Herink, M. C. et al. Pharmacists\u2019 knowledge and perceptions of FDA approval standards and the breakthrough therapy designation. Pharmacy. 10, 126 (2022).","journal-title":"Pharmacy."},{"key":"2267_CR125","doi-asserted-by":"publisher","first-page":"2389120","DOI":"10.1080\/20523211.2024.2389120","volume":"17","author":"S Lingaratnam","year":"2024","unstructured":"Lingaratnam, S. et al. Australian access to FDA-approved breakthrough therapy designation medicines: a 10-year review. J. Pharm. Policy and Pract. 17, 2389120 (2024).","journal-title":"J. Pharm. Policy and Pract."},{"key":"2267_CR126","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1093\/oncolo\/oyab021","volume":"27","author":"RS Paquin","year":"2022","unstructured":"Paquin, R. S., Boudewyns, V., O\u2019Donoghue, A. C. & Aikin, K. J. Physician perceptions of the FDA\u2019s breakthrough therapy designation: an update. Oncologist. 27, e85\u2013e88 (2022).","journal-title":"Oncologist."},{"key":"2267_CR127","unstructured":"Vokinger, K. N., Kesselheim, A. S., Glaus, C. E. & Hwang, T. J. in JAMA Health Forum. e222685 (American Medical Association)."},{"key":"2267_CR128","doi-asserted-by":"publisher","first-page":"n1959","DOI":"10.1136\/bmj.n1959","volume":"374","author":"B Gyawali","year":"2021","unstructured":"Gyawali, B., Rome, B. N. & Kesselheim, A. S. Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study. BMJ. 374, n1959 (2021).","journal-title":"BMJ."},{"key":"2267_CR129","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1001\/jamainternmed.2021.4604","volume":"181","author":"B Gyawali","year":"2021","unstructured":"Gyawali, B., Ross, J. S. & Kesselheim, A. S. Fulfilling the mandate of the US Food and Drug Administration\u2019s accelerated approval pathway: the need for reforms. JAMA Intern. Med. 181, 1275\u20131276 (2021).","journal-title":"JAMA Intern. Med."},{"key":"2267_CR130","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1001\/jamainternmed.2020.8441","volume":"181","author":"A Cherla","year":"2021","unstructured":"Cherla, A. et al. Assessment of coverage in England of cancer drugs qualifying for US Food and Drug Administration accelerated approval. JAMA Intern. Med. 181, 490\u2013498 (2021).","journal-title":"JAMA Intern. Med."},{"key":"2267_CR131","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1158\/1078-0432.CCR-20-3119","volume":"27","author":"S Wahby","year":"2021","unstructured":"Wahby, S. et al. FDA approval summary: accelerated approval of sacituzumab govitecan-hziy for third-line treatment of metastatic triple-negative breast cancer. Clin. Cancer Res. 27, 1850\u20131854 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2267_CR132","doi-asserted-by":"publisher","first-page":"13618","DOI":"10.3390\/ijms241713618","volume":"24","author":"HY Choi","year":"2023","unstructured":"Choi, H. Y. & Chang, J.-E. Targeted therapy for cancers: from ongoing clinical trials to FDA-approved drugs. Int. J. Mol. Sci. 24, 13618 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2267_CR133","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.3390\/biomedicines12091992","volume":"12","author":"AC Martins","year":"2024","unstructured":"Martins, A. C., Oshiro, M. Y., Albericio, F. & de la Torre, B. G. Food and Drug Administration (FDA) approvals of biological drugs in 2023. Biomedicines. 12, 1992 (2024).","journal-title":"Biomedicines."},{"key":"2267_CR134","doi-asserted-by":"publisher","first-page":"e1254","DOI":"10.1002\/prp2.1254","volume":"12","author":"H Moon","year":"2024","unstructured":"Moon, H. et al. FDA regulatory considerations for oncology drug development. Pharmacol. Res. Perspect. 12, e1254 (2024).","journal-title":"Pharmacol. Res. Perspect."},{"key":"2267_CR135","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1158\/1078-0432.CCR-20-3213","volume":"27","author":"PG Kluetz","year":"2021","unstructured":"Kluetz, P. G. et al. FDA oncology center of excellence project renewal: engaging the oncology community to update product labeling for older oncology drugs. Clin. Cancer Res. 27, 916\u2013921 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2267_CR136","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.jval.2020.06.006","volume":"23","author":"BA Feinberg","year":"2020","unstructured":"Feinberg, B. A. et al. Use of real-world evidence to support FDA approval of oncology drugs. Value Health 23, 1358\u20131365 (2020).","journal-title":"Value Health"},{"key":"2267_CR137","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1158\/2159-8290.CD-22-1185","volume":"12","author":"ES Duke","year":"2022","unstructured":"Duke, E. S. et al. Highlights of FDA oncology approvals in 2022: tissue-agnostic indications, dosage optimization, and diversity in drug development. Cancer Discov 12, 2739\u20132746 (2022).","journal-title":"Cancer Discov"},{"key":"2267_CR138","doi-asserted-by":"publisher","first-page":"100364","DOI":"10.1016\/j.jcpo.2022.100364","volume":"34","author":"A Walia","year":"2022","unstructured":"Walia, A., Haslam, A. & Prasad, V. FDA validation of surrogate endpoints in oncology: 2005\u20132022. J. Cancer Policy. 34, 100364 (2022).","journal-title":"J. Cancer Policy."},{"key":"2267_CR139","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1602\/neurorx.1.3.307","volume":"1","author":"R Katz","year":"2004","unstructured":"Katz, R. FDA: evidentiary standards for drug development and approval. NeuroRx. 1, 307\u2013316 (2004).","journal-title":"NeuroRx."},{"key":"2267_CR140","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/bph.16337","volume":"181","author":"A Papapetropoulos","year":"2024","unstructured":"Papapetropoulos, A. et al. Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: a year in review. Br. J. Pharmacol. 181, 1553\u20131575 (2024).","journal-title":"Br. J. Pharmacol."},{"key":"2267_CR141","doi-asserted-by":"publisher","first-page":"116762","DOI":"10.1016\/j.ejmech.2024.116762","volume":"277","author":"Y Xia","year":"2024","unstructured":"Xia, Y. et al. Synthetic routes and clinical application of new drugs approved by EMA during 2023. Eur. J. Med. Chem. 277, 116762 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"2267_CR142","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.1016\/S1470-2045(22)00701-X","volume":"24","author":"MP Lythgoe","year":"2023","unstructured":"Lythgoe, M. P. et al. From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit. Lancet Oncol 24, e150\u2013e160 (2023).","journal-title":"Lancet Oncol"},{"key":"2267_CR143","unstructured":"EMA. Human Medicinesin 2024, <https:\/\/www.ema.europa.eu\/en\/documents\/report\/human-medicines-2024_en.pdf> (2024)."},{"key":"2267_CR144","doi-asserted-by":"publisher","first-page":"797","DOI":"10.2147\/CIA.S325026","volume":"17","author":"M Vaz","year":"2022","unstructured":"Vaz, M., Silva, V., Monteiro, C. & Silvestre, S. Role of aducanumab in the treatment of Alzheimer\u2019s disease: challenges and opportunities. Clin. Interv. Aging. 17, 797\u2013810 (2022).","journal-title":"Clin. Interv. Aging."},{"key":"2267_CR145","unstructured":"Padda, I. S. & Parmar, M. in StatPearls [Internet] (StatPearls Publishing, 2024)."},{"key":"2267_CR146","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s40265-021-01569-z","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon, S. Aducanumab: first approval. Drugs. 81, 1437\u20131443 (2021).","journal-title":"Drugs."},{"key":"2267_CR147","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny, J. et al. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature. 537, 50\u201356 (2016).","journal-title":"Nature."},{"key":"2267_CR148","doi-asserted-by":"publisher","first-page":"398","DOI":"10.14283\/jpad.2021.41","volume":"8","author":"J Cummings","year":"2021","unstructured":"Cummings, J. et al. Aducanumab: appropriate use recommendations. J. Prev. Alzheim. 8, 398\u2013410 (2021).","journal-title":"J. Prev. Alzheim."},{"key":"2267_CR149","doi-asserted-by":"publisher","first-page":"n1682","DOI":"10.1136\/bmj.n1682","volume":"374","author":"S Walsh","year":"2021","unstructured":"Walsh, S., Merrick, R., Milne, R. & Brayne, C. Aducanumab for Alzheimer\u2019s disease? BMJ. 374, n1682 (2021).","journal-title":"BMJ."},{"key":"2267_CR150","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings, J. et al. Lecanemab: appropriate use recommendations. J. Prev. Alzheim. 10, 362\u2013377 (2023).","journal-title":"J. Prev. Alzheim."},{"key":"2267_CR151","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH Van Dyck","year":"2023","unstructured":"Van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 388, 9\u201321 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2267_CR152","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson, C. J. et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alzheimers Res. Ther. 13, 1\u201314 (2021).","journal-title":"Alzheimers Res. Ther."},{"key":"2267_CR153","first-page":"039463202312098","volume":"37","author":"S Chowdhury","year":"2023","unstructured":"Chowdhury, S. & Chowdhury, N. S. Novel anti-amyloid-beta (A\u03b2) monoclonal antibody lecanemab for Alzheimer\u2019s disease: a systematic review. Int. J. Immunopath. Ph. 37, 03946320231209839 (2023).","journal-title":"Int. J. Immunopath. Ph."},{"key":"2267_CR154","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1136\/bmj.o3010","volume":"379","author":"S Walsh","year":"2022","unstructured":"Walsh, S. et al. Lecanemab for Alzheimer\u2019s disease. BMJ. 379, 3010 (2022).","journal-title":"BMJ."},{"key":"2267_CR155","doi-asserted-by":"publisher","first-page":"1169499","DOI":"10.3389\/fnagi.2023.1169499","volume":"15","author":"Y Qiao","year":"2023","unstructured":"Qiao, Y., Chi, Y., Zhang, Q. & Ma, Y. Safety and efficacy of lecanemab for Alzheimer\u2019s disease: a systematic review and meta-analysis of randomized clinical trials. Front. Aging Neurosci. 15, 1169499 (2023).","journal-title":"Front. Aging Neurosci."},{"key":"2267_CR156","doi-asserted-by":"publisher","first-page":"e069780","DOI":"10.1136\/bmj-2021-069780","volume":"376","author":"MP Lythgoe","year":"2022","unstructured":"Lythgoe, M. P., Jenei, K. & Prasad, V. Regulatory decisions diverge over aducanumab for Alzheimer\u2019s disease. BMJ. 376, e069780 (2022).","journal-title":"BMJ."},{"key":"2267_CR157","doi-asserted-by":"publisher","first-page":"q1692","DOI":"10.1136\/bmj.q1692","volume":"386","author":"E Mahase","year":"2024","unstructured":"Mahase, E. Lecanemab: European drug agency rejects Alzheimer\u2019s drug amid debate over efficacy and safety. BMJ. 386, q1692 (2024).","journal-title":"BMJ."},{"key":"2267_CR158","unstructured":"WHO. WHO Guidelines on Good Reliance Practices: applicability and prospects for implementation, <https:\/\/cdn.who.int\/media\/docs\/default-source\/health-products-policy-and-standards\/7_who-guidelines-on-good-reliance-practices--applicability-and-prospects-for-implementation_samuel-azatyan.pdf?sfvrsn=2e31f8ca_1> (2023)."},{"key":"2267_CR159","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/S0140-6736(23)01132-7","volume":"402","author":"MP Lythgoe","year":"2023","unstructured":"Lythgoe, M. P. & Sullivan, R. Outsourcing UK regulatory decisions\u2014a double-edged sword? Lancet. 402, 24\u201325 (2023).","journal-title":"Lancet."},{"key":"2267_CR160","unstructured":"Wu, S. et al. A review of the research report on the high-quality development of China\u2019s pharmaceutical industry (2021\u20132023). CFDA Mag. 4\u201317, (2024)."},{"key":"2267_CR161","first-page":"0731","volume":"2024","author":"Z Chen","year":"2024","unstructured":"Chen, Z. et al. Chinese innovative drug R&D trends in 2024. Nat. Rev. Drug Discov. 2024, 0731 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2267_CR162","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1517\/14656566.2014.906940","volume":"15","author":"E Luscombe","year":"2014","unstructured":"Luscombe, E. Is being the first ever \u2018better\u2019than being the best? Expert Opin. Pharmacother. 15, 1\u20132 (2014).","journal-title":"Expert Opin. Pharmacother."},{"key":"2267_CR163","doi-asserted-by":"crossref","unstructured":"Agten, S. & Wu, B. in Biopharma in China: Innovation, Trends and Dealmaking 71\u201399 (Springer, 2024).","DOI":"10.1007\/978-981-97-1471-1_4"},{"key":"2267_CR164","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/S1359-6446(05)03498-7","volume":"10","author":"UA Betz","year":"2005","unstructured":"Betz, U. A. How many genomics targets can a portfolio afford? Drug Discov. Today. 10, 1057\u20131063 (2005).","journal-title":"Drug Discov. Today."},{"key":"2267_CR165","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/nrd4035","volume":"12","author":"U Schulze","year":"2013","unstructured":"Schulze, U. & Ringel, M. What matters most in commercial success: first-in-class or best-in-class? Nat. Rev. Drug Discov. 12, 419 (2013).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2267_CR166","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/clpt.2013.126","volume":"94","author":"B Munos","year":"2013","unstructured":"Munos, B. A forensic analysis of drug targets from 2000 through 2012. Clin. Pharmacol. Ther. 94, 407\u2013411 (2013).","journal-title":"Clin. Pharmacol. Ther."},{"key":"2267_CR167","doi-asserted-by":"crossref","unstructured":"Stocks, M. in Introduction to Biological and Small Molecule Drug Research and Development 81\u2013126 (Elsevier, 2013).","DOI":"10.1016\/B978-0-12-397176-0.00003-0"},{"key":"2267_CR168","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1109\/TCOMM.2016.2628037","volume":"65","author":"T Nakano","year":"2016","unstructured":"Nakano, T. et al. Performance evaluation of leader\u2013follower-based mobile molecular communication networks for target detection applications. IEEE Trans. Commun. 65, 663\u2013676 (2016).","journal-title":"IEEE Trans. Commun."},{"key":"2267_CR169","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/9783527677047.ch08","volume":"2016","author":"Y Jiang","year":"2016","unstructured":"Jiang, Y., Liu, Z., Holenz, J. & Yang, H. Competitive intelligence\u2013based lead generation and fast follower approaches. Lead Gen 2016, 183\u2013220 (2016).","journal-title":"Lead Gen"},{"key":"2267_CR170","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.drudis.2007.02.014","volume":"12","author":"F Sams-Dodd","year":"2007","unstructured":"Sams-Dodd, F. Research & market strategy: how choice of drug discovery approach can affect market position. Drug Discov. Today. 12, 314\u2013318 (2007).","journal-title":"Drug Discov. Today."},{"key":"2267_CR171","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1111\/bcp.14327","volume":"86","author":"JK Aronson","year":"2020","unstructured":"Aronson, J. K. & Green, A. R. Me\u2010too pharmaceutical products: history, definitions, examples, and relevance to drug shortages and essential medicines lists. Br. J. Clin. Pharmacol. 86, 2114\u20132122 (2020).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"2267_CR172","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s10729-013-9225-3","volume":"16","author":"S R\u00e9gnier","year":"2013","unstructured":"R\u00e9gnier, S. What is the value of \u2018me-too\u2019drugs? Health Care Manage. Sci 16, 300\u2013313 (2013).","journal-title":"Health Care Manage. Sci"},{"key":"2267_CR173","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/11318770-000000000-00000","volume":"28","author":"B Pekarsky","year":"2010","unstructured":"Pekarsky, B. Should financial incentives be used to differentially reward \u2018me-too\u2019and innovative drugs? Pharmacoeconomics. 28, 1\u201317 (2010).","journal-title":"Pharmacoeconomics."},{"key":"2267_CR174","unstructured":"Hollis, A. Me-Too Drugs: Is There a Problem. WHO Report, (2004)."},{"key":"2267_CR175","doi-asserted-by":"publisher","first-page":"e13791","DOI":"10.1111\/cpr.13791","volume":"58","author":"Z Zhou","year":"2024","unstructured":"Zhou, Z. et al. Revolutionising cancer immunotherapy: advancements and prospects in non\u2010viral CAR\u2010NK cell engineering. Cell Prolif 58, e13791 (2024).","journal-title":"Cell Prolif"},{"key":"2267_CR176","doi-asserted-by":"publisher","first-page":"e13683","DOI":"10.1111\/cpr.13683","volume":"57","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. Comparison of seven CD19 CAR designs in engineering NK cells for enhancing anti\u2010tumour activity. Cell Prolif 57, e13683 (2024).","journal-title":"Cell Prolif"},{"key":"2267_CR177","unstructured":"Citeline. Citeline Pharma R&D Annual Review 2023 <https:\/\/www.citeline.com\/en\/resources\/citeline-rd-annual-review-2023> (2023)."},{"key":"2267_CR178","unstructured":"VBDATA.CN. 2023 Pharmaceutical R&D Annual Review: with 5402 pipelines, China has become the world\u2019s second largest pharmaceutical research country <https:\/\/www.vbdata.cn\/1518917850> (2023)."},{"key":"2267_CR179","first-page":"233","volume":"5","author":"X Lyu","year":"2022","unstructured":"Lyu, X. et al. The global landscape of approved antibody therapies. Antib. Ther. 5, 233\u2013257 (2022).","journal-title":"Antib. Ther."},{"key":"2267_CR180","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu, Z. et al. Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy. Signal Transduct. Target. Ther. 7, 93 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2267_CR181","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41392-021-00868-x","volume":"7","author":"S Jin","year":"2022","unstructured":"Jin, S. et al. Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduct. Target. Ther. 7, 39 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2267_CR182","doi-asserted-by":"publisher","first-page":"D1097","DOI":"10.1093\/nar\/gkad831","volume":"52","author":"L Shen","year":"2024","unstructured":"Shen, L. et al. ADCdb: the database of antibody\u2013drug conjugates. Nucleic Acids Res 52, D1097\u2013D1109 (2024).","journal-title":"Nucleic Acids Res"},{"key":"2267_CR183","doi-asserted-by":"crossref","unstructured":"Huang, Z., Li, J. & Zhang, M. in New Anti-cancer Drug Development and Evaluation 115\u2013139 (Springer, 2024).","DOI":"10.1007\/978-981-97-7274-2_6"},{"key":"2267_CR184","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/cac2.12517","volume":"44","author":"DY Ruan","year":"2024","unstructured":"Ruan, D. Y., Wu, H. X., Meng, Q. & Xu, R. H. Development of antibody\u2010drug conjugates in cancer: overview and prospects. Cancer Commun 44, 3\u201322 (2024).","journal-title":"Cancer Commun"},{"key":"2267_CR185","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.3390\/cancers15041003","volume":"15","author":"V Wang","year":"2023","unstructured":"Wang, V. et al. Systematic review on CAR-T cell clinical trials up to 2022: academic center input. Cancers. 15, 1003 (2023).","journal-title":"Cancers."},{"key":"2267_CR186","doi-asserted-by":"publisher","first-page":"104889","DOI":"10.1016\/j.phrs.2020.104889","volume":"158","author":"W Wu","year":"2020","unstructured":"Wu, W. et al. Regulatory oversight of cell therapy in China: government\u2019s efforts in patient access and therapeutic innovation. Pharmacol. Res. 158, 104889 (2020).","journal-title":"Pharmacol. Res."},{"key":"2267_CR187","unstructured":"IQVIA. Global pharmaceutical R&D outlook for 2023 <https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/china\/viewpoints\/global-trends-in-r-and-d-2023-cn.pdf> (2024)."},{"key":"2267_CR188","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1002\/phar.2167","volume":"38","author":"MC Herink","year":"2018","unstructured":"Herink, M. C., Irwin, A. N. & Zumach, G. M. FDA breakthrough therapy designation: Evaluating the quality of the evidence behind the drug approvals. Pharmacotherapy. 38, 967\u2013980 (2018).","journal-title":"Pharmacotherapy."},{"key":"2267_CR189","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nbt.2864","volume":"32","author":"S Aggarwal","year":"2014","unstructured":"Aggarwal, S. A survey of breakthrough therapy designations. Nat. Biotechnol. 32, 323\u2013330 (2014).","journal-title":"Nat. Biotechnol."},{"key":"2267_CR190","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s43441-023-00589-z","volume":"58","author":"A Poddar","year":"2024","unstructured":"Poddar, A., Raggio, M. & Concato, J. Decisions on non-oncology breakthrough therapy designation requests in 2017\u20132019. Ther. Innov. Regul. Sci. 58, 214\u2013221 (2024).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"2267_CR191","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1634\/theoncologist.2017-0152","volume":"22","author":"GM Blumenthal","year":"2017","unstructured":"Blumenthal, G. M. et al. Oncology drug approvals: evaluating endpoints and evidence in an era of breakthrough therapies. Oncologist. 22, 762\u2013767 (2017).","journal-title":"Oncologist."},{"key":"2267_CR192","doi-asserted-by":"publisher","first-page":"e810","DOI":"10.1200\/JOP.2016.012161","volume":"12","author":"KA Kern","year":"2016","unstructured":"Kern, K. A. Trial design and efficacy thresholds for granting breakthrough therapy designation in oncology. J. Oncol. Pract. 12, e810\u2013e817 (2016).","journal-title":"J. Oncol. Pract."},{"key":"2267_CR193","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/nrd.2016.19","volume":"15","author":"M Shea","year":"2016","unstructured":"Shea, M. et al. Impact of breakthrough therapy designation on cancer drug development. Nat. Rev. Drug Discov. 15, 152\u2013153 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2267_CR194","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1158\/1078-0432.CCR-13-1428","volume":"19","author":"JC Yao","year":"2013","unstructured":"Yao, J. C., Meric-Bernstam, F., Lee, J. J. & Eckhardt, S. G. Accelerated approval and breakthrough therapy designation: oncology drug development on speed? Clin. Cancer Res. 19, 4305\u20134308 (2013).","journal-title":"Clin. Cancer Res."},{"key":"2267_CR195","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1158\/1078-0432.CCR-13-0523","volume":"19","author":"SJ Horning","year":"2013","unstructured":"Horning, S. J. et al. Developing standards for breakthrough therapy designation in oncology. Clin. Cancer Res. 19, 4297\u20134304 (2013).","journal-title":"Clin. Cancer Res."},{"key":"2267_CR196","unstructured":"EMA. Brexit: the United Kingdom\u2019s withdrawal from the European Union <https:\/\/www.ema.europa.eu\/en\/about-us\/history-ema\/brexit-united-kingdoms-withdrawal-european-union> (2019)."},{"key":"2267_CR197","doi-asserted-by":"publisher","first-page":"e2216183","DOI":"10.1001\/jamanetworkopen.2022.16183","volume":"5","author":"MP Lythgoe","year":"2022","unstructured":"Lythgoe, M. P. et al. Cancer therapy approval timings, review speed, and publication of pivotal registration trials in the US and Europe, 2010\u20132019. JAMA Netw. Open. 5, e2216183 (2022).","journal-title":"JAMA Netw. Open."},{"key":"2267_CR198","unstructured":"GreenbergTraurig. China on the move: breaking barriers and accelerating growth: clinical trials, drug approvals, and cross-border data transfers in biotech <https:\/\/www.gtlaw.com\/en\/insights\/2024\/7\/china-on-the-move-breaking-barriers-and-accelerating-growth-clinical-trials?utm_source=chatgpt.com> (2024)."},{"key":"2267_CR199","unstructured":"Linical. Maximizing clinical trial opportunities in China <https:\/\/www.linical.com\/articles-research\/maximizing-clinical-trial-opportunities-in-china?utm_source=chatgpt.com> (2024)."},{"key":"2267_CR200","unstructured":"Arena, C. T. The Great Wall: why overseas sponsors are yet to fully tap into China\u2019s clinical trial resources <https:\/\/www.clinicaltrialsarena.com\/features\/china-clinical-trial-challenges-cta-exclusive\/> (2022)."},{"key":"2267_CR201","unstructured":"Leader, C. Report reflects huge growth of clinical trials in China <https:\/\/www.clinicalleader.com\/doc\/report-reflects-huge-growth-of-clinical-trials-in-china-0001> (2021)."},{"key":"2267_CR202","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(22)00071-7","volume":"23","author":"H Singh","year":"2022","unstructured":"Singh, H. & Pazdur, R. Importing oncology trials from China: a bridge over troubled waters? Lancet Oncol 23, 323\u2013325 (2022).","journal-title":"Lancet Oncol"},{"key":"2267_CR203","doi-asserted-by":"crossref","unstructured":"Zhang, J. Z. In Biotechnology Entrepreneurship 567\u2013582 (Elsevier, 2020).","DOI":"10.1016\/B978-0-12-815585-1.00038-3"},{"key":"2267_CR204","first-page":"100670","volume":"32","author":"X Luo","year":"2023","unstructured":"Luo, X. et al. The price, efficacy, and safety of within-class targeted anticancer medicines between domestic and imported drugs in China: a comparative analysis. Lancet. Reg. Health. West. Pac. 32, 100670 (2023).","journal-title":"Lancet. Reg. Health. West. Pac."},{"key":"2267_CR205","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1001\/jamaoncol.2022.3856","volume":"8","author":"S Wang","year":"2022","unstructured":"Wang, S. et al. Evolution of early-phase anticancer drug investigations in China. JAMA Oncol 8, 1692\u20131694 (2022).","journal-title":"JAMA Oncol"},{"key":"2267_CR206","unstructured":"FDA. PDUFA reauthorization performance goals and procedures fiscal years 2023 through 2027 <https:\/\/www.fda.gov\/media\/151712\/download> (2023)."},{"key":"2267_CR207","unstructured":"FDA. Performance report to congress for the generic drug user fee amendments <https:\/\/www.fda.gov\/media\/151618\/download> (2020)."},{"key":"2267_CR208","doi-asserted-by":"publisher","first-page":"103771","DOI":"10.1016\/j.drudis.2023.103771","volume":"28","author":"J Williamson","year":"2023","unstructured":"Williamson, J. & Spicer, A. J. Review of the impact of the FDA\u2019s fast track designation on biotechnology companies\u2019 share prices. Drug Discov. Today. 28, 103771 (2023).","journal-title":"Drug Discov. Today."},{"key":"2267_CR209","unstructured":"EMA. The evaluation of medicines, step-by-step <https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/marketing-authorisation\/evaluation-medicines-step-step?utm_source=chatgpt.com> (2024)."},{"key":"2267_CR210","unstructured":"EMA. Clinical Trials Information System <https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/clinical-trials-human-medicines\/clinical-trials-information-system> (2022)."},{"key":"2267_CR211","doi-asserted-by":"publisher","first-page":"1296737","DOI":"10.3389\/fphar.2023.1296737","volume":"14","author":"X Zhu","year":"2024","unstructured":"Zhu, X. & Chen, Y. Bridging the new drug access gap between China and the United States and its related policies. Front. Pharmacol. 14, 1296737 (2024).","journal-title":"Front. Pharmacol."},{"key":"2267_CR212","first-page":"101055","volume":"45","author":"Y Wei","year":"2024","unstructured":"Wei, Y. et al. Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001\u20132020. Lancet. Reg. Health. West. Pac. 45, 101055 (2024).","journal-title":"Lancet. Reg. Health. West. Pac."},{"key":"2267_CR213","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40257-021-00649-w","volume":"23","author":"AM Le","year":"2022","unstructured":"Le, A. M. & Torres, T. New topical therapies for psoriasis. Am. J. Clin. Dermatol. 23, 13\u201324 (2022).","journal-title":"Am. J. Clin. Dermatol."},{"key":"2267_CR214","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/14656566.2021.2016699","volume":"23","author":"ST Lu","year":"2022","unstructured":"Lu, S. T., Kelly, K. A. & Feldman, S. R. An overview of benvitimod for the treatment of psoriasis: a narrative review. Expert Opin. Pharmacother. 23, 327\u2013333 (2022).","journal-title":"Expert Opin. Pharmacother."},{"key":"2267_CR215","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.therap.2021.09.005","volume":"77","author":"L Chen","year":"2022","unstructured":"Chen, L. et al. Application of benvitimod on psoriasis: a systematic review and meta-analysis of randomized controlled trials. A systematic review of benvitimod on psoriasis. Therapies 77, 339\u2013347 (2022).","journal-title":"Therapies"},{"key":"2267_CR216","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1016\/j.jaad.2021.10.053","volume":"86","author":"J Zhang","year":"2022","unstructured":"Zhang, J., Cai, L. & Zheng, M. A novel topical treatment for plaque psoriasis: benvitimod\/tapinarof. J. Am. Acad. Dermatol. 86, e137\u2013e138 (2022).","journal-title":"J. Am. Acad. Dermatol."},{"key":"2267_CR217","doi-asserted-by":"publisher","first-page":"e15957","DOI":"10.1111\/dth.15957","volume":"35","author":"M Ehsan","year":"2022","unstructured":"Ehsan, M. et al. Benvitimod for the treatment of psoriasis: a systematic review and meta\u2010analysis of randomized controlled trials. Dermatol. Ther. 35, e15957 (2022).","journal-title":"Dermatol. Ther."},{"key":"2267_CR218","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1097\/CM9.0000000000001221","volume":"133","author":"L Cai","year":"2020","unstructured":"Cai, L. et al. A double-blind, randomized, placebo-and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis. Chin. Med. J. 133, 2905\u20132909 (2020).","journal-title":"Chin. Med. J."},{"key":"2267_CR219","doi-asserted-by":"publisher","first-page":"A10111","DOI":"10.1161\/circ.146.suppl_1.10111","volume":"146","author":"Y Huo","year":"2022","unstructured":"Huo, Y. et al. Efficacy and safety of tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial. Circulation. 146, A10111\u2013A10111 (2022).","journal-title":"Circulation."},{"key":"2267_CR220","doi-asserted-by":"publisher","first-page":"ehaa946.3327","DOI":"10.1093\/ehjci\/ehaa946.3327","volume":"41","author":"Y Cui","year":"2020","unstructured":"Cui, Y. et al. Tafolecimab, a novel potential long-acting PCSK9 monoclonal antibody: efficacy and safety in healthy and hypercholesterolemia subjects. Eur. Heart J. 41, ehaa946.3327 (2020).","journal-title":"Eur. Heart J."},{"key":"2267_CR221","first-page":"100907","volume":"41","author":"Y Huo","year":"2023","unstructured":"Huo, Y. et al. Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial. Lancet. Reg. Health. West. Pac. 41, 100907 (2023).","journal-title":"Lancet. Reg. Health. West. Pac."},{"key":"2267_CR222","first-page":"636","volume":"3","author":"L Qi","year":"2023","unstructured":"Qi, L. et al. Tafolecimab in Chinese patients with hypercholesterolemia (CREDIT-4) a randomized, double-blind, placebo-controlled phase 3 trial. JACC: Asia 3, 636\u2013645 (2023).","journal-title":"JACC: Asia"},{"key":"2267_CR223","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1007\/s40265-023-01952-y","volume":"83","author":"SJ Keam","year":"2023","unstructured":"Keam, S. J. Tafolecimab: first approval. Drugs. 83, 1545\u20131549 (2023).","journal-title":"Drugs."},{"key":"2267_CR224","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02797-8","volume":"21","author":"M Chai","year":"2023","unstructured":"Chai, M. et al. Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2). BMC Med 21, 77 (2023).","journal-title":"BMC Med"},{"key":"2267_CR225","doi-asserted-by":"publisher","first-page":"v911","DOI":"10.1093\/annonc\/mdz394.073","volume":"30","author":"J Xu","year":"2019","unstructured":"Xu, J. et al. Efficacy and safety of surufatinib in patients with well-differentiated advanced extrapancreatic neuroendocrine tumors (NETs): results from the randomized phase III study (SANET-ep). Ann. Oncol. 30, v911 (2019).","journal-title":"Ann. Oncol."},{"key":"2267_CR226","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1089\/thy.2019.0453","volume":"30","author":"J Chen","year":"2020","unstructured":"Chen, J. et al. Surufatinib in Chinese patients with locally advanced or metastatic differentiated thyroid cancer and medullary thyroid cancer: a multicenter, open-label, phase II trial. Thyroid. 30, 1245\u20131253 (2020).","journal-title":"Thyroid."},{"key":"2267_CR227","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1158\/1078-0432.CCR-18-2994","volume":"25","author":"J Xu","year":"2019","unstructured":"Xu, J. et al. Surufatinib in advanced well-differentiated neuroendocrine tumors: a multicenter, single-arm, open-label, phase Ib\/II trial. Clin. Cancer Res. 25, 3486\u20133494 (2019).","journal-title":"Clin. Cancer Res."},{"key":"2267_CR228","doi-asserted-by":"publisher","first-page":"4610","DOI":"10.1200\/JCO.2020.38.15_suppl.4610","volume":"38","author":"A Dasari","year":"2020","unstructured":"Dasari, A. et al. Efficacy and safety of surufatinib in United States (US) patients (pts) with neuroendocrine tumors (NETs). J. Clin. Oncol. 38, 4610\u20134610 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2267_CR229","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1002\/cncr.33803","volume":"127","author":"J Xu","year":"2021","unstructured":"Xu, J. et al. A single\u2010arm, multicenter, open\u2010label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer. Cancer. 127, 3975\u20133984 (2021).","journal-title":"Cancer."},{"key":"2267_CR230","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/S1470-2045(20)30496-4","volume":"21","author":"J Xu","year":"2020","unstructured":"Xu, J. et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 21, 1500\u20131512 (2020).","journal-title":"Lancet Oncol"},{"key":"2267_CR231","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s40265-021-01489-y","volume":"81","author":"YY Syed","year":"2021","unstructured":"Syed, Y. Y. Surufatinib: first approval. Drugs. 81, 727\u2013732 (2021).","journal-title":"Drugs."},{"key":"2267_CR232","doi-asserted-by":"publisher","first-page":"175883592110426","DOI":"10.1177\/17588359211042689","volume":"13","author":"J Xu","year":"2021","unstructured":"Xu, J. Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs). Ther. Adv. Med. Oncol. 13, 17588359211042689 (2021).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"2267_CR233","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41574-020-00439-0","volume":"17","author":"A Koumarianou","year":"2021","unstructured":"Koumarianou, A. & Kaltsas, G. Surufatinib\u2014a novel oral agent for neuroendocrine tumours. Nat. Rev. Endocrinol. 17, 9\u201310 (2021).","journal-title":"Nat. Rev. Endocrinol."},{"key":"2267_CR234","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S1470-2045(20)30493-9","volume":"21","author":"J Xu","year":"2020","unstructured":"Xu, J. et al. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 21, 1489\u20131499 (2020).","journal-title":"Lancet Oncol"},{"key":"2267_CR235","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1016\/j.clinthera.2020.07.010","volume":"42","author":"H Qian","year":"2020","unstructured":"Qian, H. et al. Effects of food on the pharmacokinetic properties of surufatinib: a phase I, single-dose, randomized, open-label crossover study in healthy subjects. Clin. Ther. 42, 1778\u20131786 (2020).","journal-title":"Clin. Ther."},{"key":"2267_CR236","doi-asserted-by":"publisher","first-page":"S1003","DOI":"10.1016\/j.annonc.2022.07.1114","volume":"33","author":"M Wang","year":"2022","unstructured":"Wang, M. et al. 987\u2009P Sunvozertinib for NSCLC patients with EGFR exon 20 insertion mutations: preliminary analysis of WU-KONG6, the first pivotal study. Ann. Oncol. 33, S1003\u2013S1004 (2022).","journal-title":"Ann. Oncol."},{"key":"2267_CR237","first-page":"NA-NA","volume":"2023","author":"N Tucker","year":"2023","unstructured":"Tucker, N. Sunvozertinib Yields Tolerability, Efficacy in EGFR + NSCLC. Cancer Netw. 2023, NA-NA (2023).","journal-title":"Cancer Netw."},{"key":"2267_CR238","doi-asserted-by":"publisher","first-page":"S765","DOI":"10.1016\/j.annonc.2023.09.2358","volume":"34","author":"J-H Yang","year":"2023","unstructured":"Yang, J.-H. et al. 1325\u2009P Sunvozertinib as first-line treatment in NSCLC patients with EGFR Exon20 insertion mutations. Ann. Oncol. 34, S765 (2023).","journal-title":"Ann. Oncol."},{"key":"2267_CR239","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2213-2600(23)00419-8","volume":"12","author":"H Hayashi","year":"2024","unstructured":"Hayashi, H. Sunvozertinib: the next candidate of TKI for NSCLC. Lancet Respir. Med. 12, 185\u2013186 (2024).","journal-title":"Lancet Respir. Med."},{"key":"2267_CR240","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1007\/s40265-023-01959-5","volume":"83","author":"S Dhillon","year":"2023","unstructured":"Dhillon, S. Sunvozertinib: first approval. Drugs. 83, 1629\u20131634 (2023).","journal-title":"Drugs."},{"key":"2267_CR241","doi-asserted-by":"publisher","first-page":"S410","DOI":"10.1016\/j.jtho.2022.07.711","volume":"17","author":"J-H Yang","year":"2022","unstructured":"Yang, J.-H. et al. EP08. 02-029 sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations: effect of prior treatment. J. Thorac. Oncol. 17, S410\u2013S411 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"2267_CR242","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S2213-2600(23)00379-X","volume":"12","author":"M Wang","year":"2024","unstructured":"Wang, M. et al. Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial. Lancet Respir. Med. 12, 217\u2013224 (2024).","journal-title":"Lancet Respir. Med."},{"key":"2267_CR243","doi-asserted-by":"publisher","first-page":"9002","DOI":"10.1200\/JCO.2023.41.16_suppl.9002","volume":"41","author":"M Wang","year":"2023","unstructured":"Wang, M. et al. Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: the first pivotal study results. J. Clin. Oncol. 41, 9002\u20139002 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2267_CR244","doi-asserted-by":"publisher","first-page":"9015","DOI":"10.1200\/JCO.2022.40.16_suppl.9015","volume":"40","author":"PA Janne","year":"2022","unstructured":"Janne, P. A. et al. Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD (L) 1 treatment failures. J. Clin. Oncol. 40, 9015\u20139015 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2267_CR245","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1158\/2159-8290.CD-21-1615","volume":"12","author":"M Wang","year":"2022","unstructured":"Wang, M. et al. Sunvozertinib, a selective EGFR inhibitor for previously treated non\u2013small cell lung cancer with EGFR exon 20 insertion mutations. Cancer Discov 12, 1676\u20131689 (2022).","journal-title":"Cancer Discov"},{"key":"2267_CR246","first-page":"509","volume":"15","author":"F Kong","year":"2023","unstructured":"Kong, F. et al. Traditional Chinese medicines for non-small cell lung cancer: therapies and mechanisms. Chin. Herb. Med. 15, 509\u2013515 (2023).","journal-title":"Chin. Herb. Med."},{"key":"2267_CR247","doi-asserted-by":"publisher","first-page":"e13708","DOI":"10.1111\/cpr.13708","volume":"57","author":"AHP Wong","year":"2024","unstructured":"Wong, A. H. P. et al. Impact of CD151 overexpression on prognosis and therapy in non\u2010small cell lung cancer patients lacking EGFR mutations. Cell Prolif 57, e13708 (2024).","journal-title":"Cell Prolif"},{"key":"2267_CR248","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1177\/10600280211041384","volume":"56","author":"N Campbell","year":"2022","unstructured":"Campbell, N., Kalabalik-Hoganson, J. & Frey, K. Vericiguat: a novel oral soluble guanylate cyclase stimulator for the treatment of heart failure. Ann. Pharmacother. 56, 600\u2013608 (2022).","journal-title":"Ann. Pharmacother."},{"key":"2267_CR249","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1007\/s40265-020-01427-4","volume":"80","author":"A Markham","year":"2020","unstructured":"Markham, A. Pralsetinib: first approval. Drugs. 80, 1865\u20131870 (2020).","journal-title":"Drugs."},{"key":"2267_CR250","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.annonc.2022.08.002","volume":"33","author":"F Griesinger","year":"2022","unstructured":"Griesinger, F. et al. Safety and efficacy of pralsetinib in RET fusion\u2013positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial. Ann. Oncol. 33, 1168\u20131178 (2022).","journal-title":"Ann. Oncol."},{"key":"2267_CR251","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/S1470-2045(21)00247-3","volume":"22","author":"JF Gainor","year":"2021","unstructured":"Gainor, J. F. et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study. Lancet Oncol 22, 959\u2013969 (2021).","journal-title":"Lancet Oncol"},{"key":"2267_CR252","doi-asserted-by":"publisher","first-page":"5452","DOI":"10.1158\/1078-0432.CCR-21-0967","volume":"27","author":"J Kim","year":"2021","unstructured":"Kim, J. et al. FDA approval summary: pralsetinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions. Clin. Cancer Res. 27, 5452\u20135456 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2267_CR253","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1002\/cncr.34897","volume":"129","author":"Q Zhou","year":"2023","unstructured":"Zhou, Q. et al. Efficacy and safety of pralsetinib in patients with advanced RET fusion\u2010positive non\u2013small cell lung cancer. Cancer. 129, 3239\u20133251 (2023).","journal-title":"Cancer."},{"key":"2267_CR254","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","volume":"9","author":"V Subbiah","year":"2021","unstructured":"Subbiah, V. et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study. Lancet Diabetes Endocrinol 9, 491\u2013501 (2021).","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2267_CR255","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1021\/acsptsci.3c00134","volume":"6","author":"K-W Zhu","year":"2023","unstructured":"Zhu, K.-W. Deuremidevir and simnotrelvir\u2013ritonavir for the treatment of COVID-19. ACS Pharmacol. Transl. Sci. 6, 1306\u20131309 (2023).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"2267_CR256","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa2301425","volume":"390","author":"B Cao","year":"2024","unstructured":"Cao, B. et al. Oral Simnotrelvir for adult patients with mild-to-moderate covid-19. N. Engl. J. Med. 390, 230\u2013241 (2024).","journal-title":"N. Engl. J. Med."},{"key":"2267_CR257","doi-asserted-by":"publisher","first-page":"106598","DOI":"10.1016\/j.ejps.2023.106598","volume":"191","author":"X-M Yang","year":"2023","unstructured":"Yang, X.-M. et al. A first-in-human phase 1 study of simnotrelvir, a 3CL-like protease inhibitor for treatment of COVID-19, in healthy adult subjects. Eur. J. Pharm. Sci. 191, 106598 (2023).","journal-title":"Eur. J. Pharm. Sci."},{"key":"2267_CR258","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1080\/14656566.2024.2323597","volume":"25","author":"MW McCarthy","year":"2024","unstructured":"McCarthy, M. W. Simnotrelvir as a potential treatment for COVID-19. Expert Opin. Pharmacother. 25, 233\u2013237 (2024).","journal-title":"Expert Opin. Pharmacother."},{"key":"2267_CR259","first-page":"100838","volume":"38","author":"F Wang","year":"2023","unstructured":"Wang, F. et al. Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial. Lancet. Reg. Health. West. Pac. 38, 100838 (2023).","journal-title":"Lancet. Reg. Health. West. Pac."},{"key":"2267_CR260","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42102-y","volume":"14","author":"X Jiang","year":"2023","unstructured":"Jiang, X. et al. Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir. Nat. Commun. 14, 6463 (2023).","journal-title":"Nat. Commun."},{"key":"2267_CR261","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1056\/NEJMoa2208822","volume":"388","author":"Z Cao","year":"2023","unstructured":"Cao, Z. et al. VV116 versus nirmatrelvir\u2013ritonavir for oral treatment of Covid-19. N. Engl. J. Med. 388, 406\u2013417 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2267_CR262","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1021\/acsptsci.3c00134","volume":"6","author":"K-W Zhu","year":"2023","unstructured":"Zhu, K.-W. National Medical Products Administration (NMPA) approves deuremidevir (VV116) and simnotrelvir-ritonavir for mild to moderate COVID-19 in China. ACS Pharmacol. Transl. Sci. 6, 1306\u20131309 (2023).","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"2267_CR263","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.3390\/v15122295","volume":"15","author":"W Liu","year":"2023","unstructured":"Liu, W. et al. Remdesivir derivative VV116 is a potential broad-spectrum inhibitor of both human and animal coronaviruses. Viruses. 15, 2295 (2023).","journal-title":"Viruses."},{"key":"2267_CR264","first-page":"489","volume":"47","author":"M Juan","year":"2023","unstructured":"Juan, M. & Yali, P. Clinical Research and development of deuremidevir hydrobromide tablets for the treatment of COVID-19. Prog. Pharm. Sci. 47, 489\u2013493 (2023).","journal-title":"Prog. Pharm. Sci."},{"key":"2267_CR265","doi-asserted-by":"publisher","first-page":"102359","DOI":"10.1016\/j.eclinm.2023.102359","volume":"67","author":"Y Zhan","year":"2024","unstructured":"Zhan, Y. et al. Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial. Eclinicalmedicine. 67, 102359 (2024).","journal-title":"Eclinicalmedicine."},{"key":"2267_CR266","doi-asserted-by":"publisher","first-page":"1449583","DOI":"10.3389\/fphar.2024.1449583","volume":"15","author":"K Wang","year":"2024","unstructured":"Wang, K. et al. Model informed dose regimen optimizing in development of leritrelvir for the treatment of mild or moderate COVID-19. Front. Pharmacol. 15, 1449583 (2024).","journal-title":"Front. Pharmacol."},{"key":"2267_CR267","doi-asserted-by":"publisher","first-page":"107096","DOI":"10.1016\/j.ijantimicag.2024.107096","volume":"63","author":"B Zheng","year":"2024","unstructured":"Zheng, B. et al. Small-molecule antivirals treatment for COVID-19: a systematic review and network meta-analysis. Int. J. Antimicrob. Agents. 63, 107096 (2024).","journal-title":"Int. J. Antimicrob. Agents."},{"key":"2267_CR268","doi-asserted-by":"publisher","first-page":"124038","DOI":"10.1016\/j.jchromb.2024.124038","volume":"1235","author":"Z-l Xu","year":"2024","unstructured":"Xu, Z.-l et al. A validated LC-MS\/MS method for determination of six Anti-SARS-CoV-2 drugs in plasma and its application for a pharmacokinetic study in rats. J. Chromatogr. B. 1235, 124038 (2024).","journal-title":"J. Chromatogr. B."},{"key":"2267_CR269","first-page":"539","volume":"39","author":"W Zhang","year":"2023","unstructured":"Zhang, W. et al. Efficacy and safety of the 12-week sofosbuvir-coblopasvir regimen in treatment of chronic hepatitis C. J. Clin. Hepatobiliary Dis. 39, 539\u2013545 (2023).","journal-title":"J. Clin. Hepatobiliary Dis."},{"key":"2267_CR270","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/jvh.13208","volume":"27","author":"H Rao","year":"2020","unstructured":"Rao, H. et al. Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis. J. Viral Hepat. 27, 45\u201351 (2020).","journal-title":"J. Viral Hepat."},{"key":"2267_CR271","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1111\/liv.14633","volume":"40","author":"Y Gao","year":"2020","unstructured":"Gao, Y. et al. Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: a single\u2010arm, open\u2010label, phase 3 trial. Liver Int 40, 2685\u20132693 (2020).","journal-title":"Liver Int"},{"key":"2267_CR272","first-page":"1304","volume":"37","author":"L Jinfeng","year":"2021","unstructured":"Jinfeng, L. et al. Tolerance and pharmacokinetics of coblopasvir hydrochloride capsules in patients with hepatitis C virus infection. J. Clin. Hepatobiliary Dis. 37, 1304\u20131308 (2021).","journal-title":"J. Clin. Hepatobiliary Dis."},{"key":"2267_CR273","doi-asserted-by":"publisher","first-page":"123813","DOI":"10.1016\/j.ijpharm.2024.123813","volume":"653","author":"C Zhao","year":"2024","unstructured":"Zhao, C. et al. Uncovering the mechanism of Tenofovir amibufenamide fumarate punch sticking by combining direct compression experiment and computational simulation. Int. J. Pharm. 653, 123813 (2024).","journal-title":"Int. J. Pharm."},{"key":"2267_CR274","first-page":"100","volume":"28","author":"L Ya-ping","year":"2023","unstructured":"Ya-ping, L. et al. Early efficacy of tenofovir amibufenamide (TMF) in the treatment of patients with chronic hepatitis B: a real-word multicenter clinical study. Chin. Hepatol. 28, 100 (2023).","journal-title":"Chin. Hepatol."},{"key":"2267_CR275","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.2147\/DDDT.S419084","volume":"17","author":"J Liu","year":"2023","unstructured":"Liu, J. et al. Effect of food on the pharmacokinetics of tenofovir amibufenamide: a phase I, randomized, open-label, two-period crossover trial in healthy adult subjects. Drug Des. Devel. Ther. 17, 3061\u20133072 (2023).","journal-title":"Drug Des. Devel. Ther."},{"key":"2267_CR276","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.3748\/wjg.v30.i26.3261","volume":"30","author":"L-Y Meng","year":"2024","unstructured":"Meng, L.-Y., Yang, C.-T., Bao, J.-F. & Huang, J.-S. Effectiveness and safety of tenofovir amibufenamide in chronic hepatitis B patients. World J. Gastroenterol. 30, 3261 (2024).","journal-title":"World J. Gastroenterol."},{"key":"2267_CR277","doi-asserted-by":"publisher","first-page":"5907","DOI":"10.3748\/wjg.v29.i44.5907","volume":"29","author":"W-T Peng","year":"2023","unstructured":"Peng, W.-T. et al. Tenofovir amibufenamide vs tenofovir alafenamide for treating chronic hepatitis B: a real-world study. World J. Gastroenterol. 29, 5907 (2023).","journal-title":"World J. Gastroenterol."},{"key":"2267_CR278","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1111\/apt.16611","volume":"54","author":"Z Liu","year":"2021","unstructured":"Liu, Z. et al. Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B. Aliment. Pharmacol. Ther. 54, 1134\u20131149 (2021).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"2267_CR279","first-page":"649","volume":"11","author":"Z Liu","year":"2023","unstructured":"Liu, Z. et al. 96-week treatment of tenofovir amibufenamide and tenofovir disoproxil fumarate in chronic hepatitis B patients. J. Clin. Transl. Hepatol. 11, 649 (2023).","journal-title":"J. Clin. Transl. Hepatol."},{"key":"2267_CR280","doi-asserted-by":"publisher","first-page":"1165990","DOI":"10.3389\/fphar.2023.1165990","volume":"14","author":"L Li","year":"2023","unstructured":"Li, L. et al. Effectiveness and safety of tenofovir amibufenamide and its comparison with tenofovir alafenamide in patients with chronic hepatitis B: results from a retrospective real-world study. Front. Pharmacol. 14, 1165990 (2023).","journal-title":"Front. Pharmacol."},{"key":"2267_CR281","first-page":"1097","volume":"10","author":"X Han","year":"2024","unstructured":"Han, X. et al. Population pharmacokinetics of Ainuovirine and exposure\u2013response analysis in human immunodeficiency virus-infected individuals. Chin. Med. J. 10, 1097 (2024).","journal-title":"Chin. Med. J."},{"key":"2267_CR282","first-page":"101143","volume":"49","author":"F Zhang","year":"2024","unstructured":"Zhang, F. et al. Switch to fixed-dose ainuovirine, lamivudine, and tenofovir DF versus elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed people living with HIV-1: the 48-week results of the SPRINT trial, a multi-centre, randomised, double-blind, active-controlled, phase 3, non-inferiority trial. Lancet. Reg. Health. West. Pac. 49, 101143 (2024).","journal-title":"Lancet. Reg. Health. West. Pac."},{"key":"2267_CR283","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1007\/s40121-023-00877-z","volume":"12","author":"X Xie","year":"2023","unstructured":"Xie, X. et al. Pharmacokinetics and safety of ainuovirine\/lamivudine\/tenofovir combination tablets in young and elderly patients with human immunodeficiency virus-1 infection. Infect. Dis. Ther. 12, 2457\u20132469 (2023).","journal-title":"Infect. Dis. Ther."},{"key":"2267_CR284","doi-asserted-by":"publisher","first-page":"e01668","DOI":"10.1128\/aac.01668-23","volume":"68","author":"C Wang","year":"2024","unstructured":"Wang, C. et al. Efficacy and effect on lipid profiles of switching to ainuovirine-based regimen versus continuing efavirenz-based regimen in people with HIV-1: 24-week results from a real-world, retrospective, multi-center cohort study. Antimicrob. Agents Chemother. 68, e01668\u201301623 (2024).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2267_CR285","doi-asserted-by":"publisher","first-page":"176","DOI":"10.5582\/bst.2024.01070","volume":"18","author":"H Long","year":"2024","unstructured":"Long, H. et al. Efficacy and effect on lipid profiles of Ainuovirine-based regimen versus Efavirenz-based regimen in treatment-na\u00efve people with HIV-1 at week 24: a real-world, retrospective, multi-center cohort study. Biosci. Trends. 18, 176\u2013186 (2024).","journal-title":"Biosci. Trends."},{"key":"2267_CR286","first-page":"100769","volume":"36","author":"B Su","year":"2023","unstructured":"Su, B. et al. Efficacy and safety of ainuovirine versus efavirenz combination therapies with lamivudine\/tenofovir disoproxil fumarate for medication of treatment-na\u00efve HIV-1-positive adults: week 48 results of a randomized controlled phase 3 clinical trial followed by an open-label setting until week 96. Lancet. Reg. Health. West. Pac. 36, 100769 (2023).","journal-title":"Lancet. Reg. Health. West. Pac."},{"key":"2267_CR287","doi-asserted-by":"publisher","first-page":"1277059","DOI":"10.3389\/fmed.2023.1277059","volume":"10","author":"Q Zhang","year":"2024","unstructured":"Zhang, Q. et al. Impacts of ainuovirine-based and efavirenz-based antiretroviral therapies on the lipid profile of HIV\/AIDS patients in southern China: a real-world study. Front. Med. 10, 1277059 (2024).","journal-title":"Front. Med."},{"key":"2267_CR288","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/cpdd.1309","volume":"13","author":"L Huang","year":"2024","unstructured":"Huang, L. et al. Pharmacokinetic and bioequivalence evaluation of single\u2010tablet and separate\u2010tablet regimens for ainuovirine, lamivudine, and tenofovir disoproxil fumarate in Chinese healthy subjects. Clin. Pharmacol. Drug Dev. 13, 70\u201376 (2024).","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"2267_CR289","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1080\/14740338.2023.2233411","volume":"23","author":"R Chen","year":"2024","unstructured":"Chen, R. et al. Expert consensus on the clinical application of ormutivimab injection for use against the rabies virus. Expert Opin. Drug Saf 23, 755\u2013762 (2024).","journal-title":"Expert Opin. Drug Saf"},{"key":"2267_CR290","doi-asserted-by":"publisher","first-page":"102267","DOI":"10.1016\/j.tmaid.2022.102267","volume":"46","author":"LL Zhai","year":"2022","unstructured":"Zhai, L. L. et al. Efficacy of ormutivimab, a novel recombinant human anti-rabies monoclonal antibody, in post-exposure prophylaxis animal models. Travel Med. Infect. Dis. 46, 102267 (2022).","journal-title":"Travel Med. Infect. Dis."},{"key":"2267_CR291","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.3390\/vaccines10081218","volume":"10","author":"J Zhang","year":"2022","unstructured":"Zhang, J. et al. Population pharmacodynamic analyses of human anti-rabies virus monoclonal antibody (Ormutivimab) in healthy adult subjects. Vaccines. 10, 1218 (2022).","journal-title":"Vaccines."},{"key":"2267_CR292","doi-asserted-by":"publisher","first-page":"6153","DOI":"10.1016\/j.vaccine.2022.09.022","volume":"40","author":"L Li","year":"2022","unstructured":"Li, L. et al. Neutralizing antibody activity, safety and immunogenicity of human anti-rabies virus monoclonal antibody (Ormutivimab) in Chinese healthy adults: a phase IIb randomized, double-blind, parallel-controlled study. Vaccine. 40, 6153\u20136162 (2022).","journal-title":"Vaccine."},{"key":"2267_CR293","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ijid.2023.05.017","volume":"134","author":"X Liu","year":"2023","unstructured":"Liu, X. et al. Comparing recombinant human rabies monoclonal antibody (ormutivimab) with human rabies immunoglobulin (HRIG) for postexposure prophylaxis: a phase III, randomized, double-blind, non-inferiority trial. Int. J. Infect. Dis. 134, 53\u201362 (2023).","journal-title":"Int. J. Infect. Dis."},{"key":"2267_CR294","unstructured":"Crescioli, S. et al. in MAbs. 2297450 (Taylor & Francis)."},{"key":"2267_CR295","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40265-023-01985-3","volume":"84","author":"S Dhillon","year":"2024","unstructured":"Dhillon, S. Narlumosbart: First Approval. Drugs. 84, 105\u2013109 (2024).","journal-title":"Drugs."},{"key":"2267_CR296","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s00774-020-01175-1","volume":"39","author":"H Yasuda","year":"2021","unstructured":"Yasuda, H. Discovery of the RANKL\/RANK\/OPG system. J. Bone Miner. Metab. 39, 2\u201311 (2021).","journal-title":"J. Bone Miner. Metab."},{"key":"2267_CR297","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson, M. J. et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 387, 2220\u20132231 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2267_CR298","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1200\/JCO.20.03175","volume":"39","author":"M Hutchings","year":"2021","unstructured":"Hutchings, M. et al. Glofitamab, a novel, bivalent CD20-targeting T-cell\u2013engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J. Clin. Oncol. 39, 1959\u20131970 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2267_CR299","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s40265-023-01894-5","volume":"83","author":"M Shirley","year":"2023","unstructured":"Shirley, M. Glofitamab: first approval. Drugs. 83, 935\u2013941 (2023).","journal-title":"Drugs."},{"key":"2267_CR300","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1080\/10428194.2021.1953016","volume":"62","author":"A Minson","year":"2021","unstructured":"Minson, A. & Dickinson, M. Glofitamab CD20-TCB bispecific antibody. Leuk. Lymphoma. 62, 3098\u20133108 (2021).","journal-title":"Leuk. Lymphoma."},{"key":"2267_CR301","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1182\/blood-2020-136044","volume":"136","author":"M Hutchings","year":"2020","unstructured":"Hutchings, M. et al. Glofitamab step-up dosing induces high response rates in patients with hard-to-treat refractory or relapsed non-Hodgkin lymphoma. Blood. 136, 46\u201348 (2020).","journal-title":"Blood."},{"key":"2267_CR302","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1182\/blood-2021-148359","volume":"138","author":"M Hutchings","year":"2021","unstructured":"Hutchings, M. et al. Glofitamab (Glofit) in combination with polatuzumab vedotin (Pola): phase Ib\/II preliminary data support manageable safety and encouraging efficacy in relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL). Blood. 138, 525 (2021).","journal-title":"Blood."},{"key":"2267_CR303","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/hon.3164_446","volume":"41","author":"W Townsend","year":"2023","unstructured":"Townsend, W. et al. Glofitamab plus immunochemotherapy demonstrates durable efficacy with manageable safety in relapsed\/refractory non-Hodgkin lymphoma (R\/R NHL): update of a Phase Ib study. Hematol. Oncol. 41, 595\u2013597 (2023).","journal-title":"Hematol. Oncol."},{"key":"2267_CR304","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/hon.3163_28","volume":"41","author":"C Carlo-Stella","year":"2023","unstructured":"Carlo-Stella, C. et al. Glofitamab monotherapy induces durable complete remissions and has a manageable safety profile in patients with Richter\u2019s transformation. Hematol. Oncol. 41, 63\u201365 (2023).","journal-title":"Hematol. Oncol."},{"key":"2267_CR305","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1182\/blood-2023-174081","volume":"142","author":"MS Topp","year":"2023","unstructured":"Topp, M. S. et al. Glofitamab plus R-CHOP induces high response rates with a manageable safety profile in patients with Previously untreated diffuse large B-Cell lymphoma (DLBCL): a 12-month analysis from a phase ib study. Blood. 142, 3085 (2023).","journal-title":"Blood."},{"key":"2267_CR306","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1182\/blood-2021-148778","volume":"138","author":"F Morschhauser","year":"2021","unstructured":"Morschhauser, F. et al. Glofitamab as monotherapy and in combination with obinutuzumab induces high complete response rates in patients (pts) with multiple relapsed or refractory (R\/R) follicular lymphoma (FL). Blood. 138, 128 (2021).","journal-title":"Blood."},{"key":"2267_CR307","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1177\/10600280241252688","volume":"59","author":"GN Pathak","year":"2024","unstructured":"Pathak, G. N. et al. Spesolimab: a review of the first IL-36 blocker approved for generalized pustular psoriasis. Ann. Pharmacother. 59, 174\u2013183 (2024).","journal-title":"Ann. Pharmacother."},{"key":"2267_CR308","unstructured":"MPR. Spevigo Gets Expanded Approval for Generalized Pustular Psoriasis https:\/\/www.empr.com\/home\/news\/spevigo-gets-expanded-approval-for-generalized-pustular-psoriasis\/> (2025)"},{"key":"2267_CR309","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/ijd.16941","volume":"63","author":"V Palaniappan","year":"2024","unstructured":"Palaniappan, V. et al. Spesolimab: a comprehensive review on the anti\u2010IL\u201036 receptor antibody in dermatology. Int. J. Dermatol. 63, 88\u201393 (2024).","journal-title":"Int. J. Dermatol."},{"key":"2267_CR310","doi-asserted-by":"crossref","unstructured":"Nielsen, V. W., Yao, Y., Egeberg, A. & Thomsen, S. F. Spesolimab. Anti-IL-36R monoclonal antibody, treatment of generalized pustular psoriasis, treatment of immune-mediated inflammatory diseases. Drugs Fut. 48, NA-NA (2023).","DOI":"10.1358\/dof.2023.48.3.3500035"},{"key":"2267_CR311","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","volume":"401","author":"B King","year":"2023","unstructured":"King, B. et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b\u20133 trial. Lancet. 401, 1518\u20131529 (2023).","journal-title":"Lancet."},{"key":"2267_CR312","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2147\/DDDT.S334727","volume":"16","author":"HA Ram\u00edrez-Mar\u00edn","year":"2023","unstructured":"Ram\u00edrez-Mar\u00edn, H. A. & Tosti, A. Evaluating the therapeutic potential of ritlecitinib for the treatment of alopecia areata. Drug Des. Devel. Ther 16, 363\u2013374 (2023).","journal-title":"Drug Des. Devel. Ther"},{"key":"2267_CR313","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","volume":"85","author":"B King","year":"2021","unstructured":"King, B. et al. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. J. Am. Acad. Dermatol. 85, 379\u2013387 (2021).","journal-title":"J. Am. Acad. Dermatol."},{"key":"2267_CR314","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.jaci.2021.10.036","volume":"149","author":"E Guttman-Yassky","year":"2022","unstructured":"Guttman-Yassky, E. et al. Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers. J. Allergy Clin. Immunol. 149, 1318\u20131328 (2022).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2267_CR315","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1080\/13543784.2021.2012149","volume":"30","author":"S Eisman","year":"2021","unstructured":"Eisman, S. & Sinclair, R. Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata. Expert Opin. Investig. Drugs. 30, 1169\u20131174 (2021).","journal-title":"Expert Opin. Investig. Drugs."},{"key":"2267_CR316","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1080\/13543784.2022.2056836","volume":"31","author":"T Markati","year":"2022","unstructured":"Markati, T., Fisher, G., Ramdas, S. & Servais, L. Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA). Expert Opin. Investig. Drugs. 31, 451\u2013461 (2022).","journal-title":"Expert Opin. Investig. Drugs."},{"key":"2267_CR317","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1007\/s00415-023-11560-1","volume":"270","author":"M Oskoui","year":"2023","unstructured":"Oskoui, M. et al. Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA). J. Neurol. 270, 2531\u20132546 (2023).","journal-title":"J. Neurol."},{"key":"2267_CR318","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s40265-020-01410-z","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon, S. Risdiplam: first approval. Drugs. 80, 1853\u20131858 (2020).","journal-title":"Drugs."},{"key":"2267_CR319","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1212\/WNL.94.15_supplement.1260","volume":"94","author":"E Mercuri","year":"2020","unstructured":"Mercuri, E. et al. SUNFISH Part 2: efficacy and safety of risdiplam (RG7916) in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)(1260). Neurology. 94, 1260 (2020).","journal-title":"Neurology."},{"key":"2267_CR320","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s40263-022-00910-8","volume":"36","author":"J Paik","year":"2022","unstructured":"Paik, J. Risdiplam: a review in spinal muscular atrophy. CNS Drugs 36, 401\u2013410 (2022).","journal-title":"CNS Drugs"},{"key":"2267_CR321","unstructured":"Ratni, H. et al. (ACS Publications, 2018)."},{"key":"2267_CR322","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/cells8010024","volume":"8","author":"N Behrangi","year":"2019","unstructured":"Behrangi, N., Fischbach, F. & Kipp, M. Mechanism of siponimod: anti-inflammatory and neuroprotective mode of action. Cells. 8, 24 (2019).","journal-title":"Cells."},{"key":"2267_CR323","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","volume":"391","author":"L Kappos","year":"2018","unstructured":"Kappos, L. et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 391, 1263\u20131273 (2018).","journal-title":"Lancet."},{"key":"2267_CR324","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1001\/jamaneurol.2016.1451","volume":"73","author":"L Kappos","year":"2016","unstructured":"Kappos, L. et al. Safety and efficacy of siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis: dose-blinded, randomized extension of the phase 2 BOLD study. JAMA Neurol 73, 1089\u20131098 (2016).","journal-title":"JAMA Neurol"},{"key":"2267_CR325","doi-asserted-by":"crossref","unstructured":"Cao, L. et al. Siponimod for multiple sclerosis. Cochrane Database Syst. Rev. (2021).","DOI":"10.1002\/14651858.CD013647.pub2"},{"key":"2267_CR326","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s40263-022-00927-z","volume":"36","author":"SL Cohan","year":"2022","unstructured":"Cohan, S. L. et al. The two sides of siponimod: evidence for brain and immune mechanisms in multiple sclerosis. CNS Drugs 36, 703\u2013719 (2022).","journal-title":"CNS Drugs"},{"key":"2267_CR327","doi-asserted-by":"publisher","first-page":"5093","DOI":"10.1007\/s00415-022-11166-z","volume":"269","author":"R Gold","year":"2022","unstructured":"Gold, R. et al. Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study. J. Neurol. 269, 5093\u20135104 (2022).","journal-title":"J. Neurol."},{"key":"2267_CR328","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1080\/13543784.2019.1676725","volume":"28","author":"AD Goodman","year":"2019","unstructured":"Goodman, A. D., Anadani, N. & Gerwitz, L. Siponimod in the treatment of multiple sclerosis. Expert Opin. Investig. Drugs. 28, 1051\u20131057 (2019).","journal-title":"Expert Opin. Investig. Drugs."},{"key":"2267_CR329","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s40265-019-01140-x","volume":"79","author":"ZT Al-Salama","year":"2019","unstructured":"Al-Salama, Z. T. Siponimod: first global approval. Drugs. 79, 1009\u20131015 (2019).","journal-title":"Drugs."},{"key":"2267_CR330","doi-asserted-by":"crossref","unstructured":"Kappos, L. et al. Efficacy of siponimod in secondary progressive multiple sclerosis: results of the phase 3 study (CT. 002). Neurology. 88, CT. 002, (2017).","DOI":"10.1212\/WNL.88.16_supplement.CT.002"},{"key":"2267_CR331","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s40263-020-00771-z","volume":"34","author":"LJ Scott","year":"2020","unstructured":"Scott, L. J. Siponimod: a review in secondary progressive multiple sclerosis. CNS Drugs 34, 1191\u20131200 (2020).","journal-title":"CNS Drugs"},{"key":"2267_CR332","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong, P. W. et al. Vericiguat in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 382, 1883\u20131893 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2267_CR333","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1001\/jama.2015.15734","volume":"314","author":"M Gheorghiade","year":"2015","unstructured":"Gheorghiade, M. et al. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial. JAMA. 314, 2251\u20132262 (2015).","journal-title":"JAMA."},{"key":"2267_CR334","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1093\/eurheartj\/ehw593","volume":"38","author":"B Pieske","year":"2017","unstructured":"Pieske, B. et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur. Heart J. 38, 1119\u20131127 (2017).","journal-title":"Eur. Heart J."},{"key":"2267_CR335","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s10741-021-10146-1","volume":"27","author":"A Aimo","year":"2022","unstructured":"Aimo, A. et al. The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction. Heart Fail. Rev. 27, 1165\u20131171 (2022).","journal-title":"Heart Fail. Rev."},{"key":"2267_CR336","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1001\/jama.2020.15922","volume":"324","author":"PW Armstrong","year":"2020","unstructured":"Armstrong, P. W. et al. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial. JAMA. 324, 1512\u20131521 (2020).","journal-title":"JAMA."},{"key":"2267_CR337","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.3390\/biomedicines10102471","volume":"10","author":"F Vannuccini","year":"2022","unstructured":"Vannuccini, F., Campora, A., Barilli, M. & Palazzuoli, A. Vericiguat in heart failure: characteristics, scientific evidence and potential clinical applications. Biomedicines. 10, 2471 (2022).","journal-title":"Biomedicines."},{"key":"2267_CR338","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s40265-021-01496-z","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham, A. & Duggan, S. Vericiguat: first approval. Drugs. 81, 721\u2013726 (2021).","journal-title":"Drugs."},{"key":"2267_CR339","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s11886-021-01580-6","volume":"23","author":"CM Lombardi","year":"2021","unstructured":"Lombardi, C. M. et al. Vericiguat for heart failure with reduced ejection fraction. Curr. Cardiol. Rep. 23, 144 (2021).","journal-title":"Curr. Cardiol. Rep."},{"key":"2267_CR340","doi-asserted-by":"publisher","first-page":"1001127","DOI":"10.59717\/j.xinn-life.2024.100127","volume":"3","author":"Q Cai","year":"2025","unstructured":"Cai, Q. et al. Empowering immune responses against cancer by IL-21-driven T cell reprogramming. Innov. Life 3, 1001127 (2025).","journal-title":"Innov. Life"},{"key":"2267_CR341","doi-asserted-by":"publisher","first-page":"3557","DOI":"10.1182\/blood-2021-148358","volume":"138","author":"Y Song","year":"2021","unstructured":"Song, Y. et al. Relmacabtagene autoleucel CD19 CART therapy for adults with heavily-pretreated relapsed\/refractory large B-cell lymphoma in China. Blood. 138, 3557 (2021).","journal-title":"Blood."},{"key":"2267_CR342","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1182\/blood-2020-136038","volume":"136","author":"J Zhu","year":"2020","unstructured":"Zhu, J. et al. Clinical response of cd19 car-t cells (relmacabtagene autoleucel, relma-cel) in adults with heavily-pre-treated relapsed\/refractory (r\/r) large b-cell lymphoma in China. Blood. 136, 39\u201340 (2020).","journal-title":"Blood."},{"key":"2267_CR343","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/cam4.3686","volume":"10","author":"Z Ying","year":"2021","unstructured":"Ying, Z. et al. Relmacabtagene autoleucel (relma\u2010cel) CD19 CAR\u2010T therapy for adults with heavily pretreated relapsed\/refractory large B\u2010cell lymphoma in China. Cancer Med 10, 999\u20131011 (2021).","journal-title":"Cancer Med"},{"key":"2267_CR344","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41409-022-01888-z","volume":"58","author":"Z Ying","year":"2023","unstructured":"Ying, Z. et al. Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed\/refractory B-cell non-Hodgkin\u2019s lymphoma: 2-year results of a phase 1 trial. Bone Marrow Transplant 58, 288\u2013294 (2023).","journal-title":"Bone Marrow Transplant"},{"key":"2267_CR345","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.jcyt.2022.10.011","volume":"25","author":"Z Ying","year":"2023","unstructured":"Ying, Z. et al. Long-term outcomes of relmacabtagene autoleucel in Chinese patients with relapsed\/refractory large B-cell lymphoma: updated results of the RELIANCE study. Cytotherapy. 25, 521\u2013529 (2023).","journal-title":"Cytotherapy."},{"key":"2267_CR346","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1182\/blood-2022-165002","volume":"140","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. Sustained remission and decreased severity of CAR T-cell related adverse events: a pivotal study report of CNCT19 (inaticabtagene autoleucel) treatment in adult patients with relapsed\/refractory B-cell acute lymphoblastic leukemia (R\/R B-Cell ALL) in China. Blood. 140, 1598\u20131600 (2022).","journal-title":"Blood."},{"key":"2267_CR347","first-page":"836","volume":"9","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. Inaticabtagene autoleucel ((CNCT19), a CD19-directed chimeric antigen receptor T-cell therapy in adult relapsed or refractory B-cell acute lymphoblastic leukaemia: a multicenter, open-label, single-arm, phase 2 study. Lancet 9, 836\u2013843 (2024).","journal-title":"Lancet"},{"key":"2267_CR348","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s40291-023-00673-y","volume":"27","author":"SJ Keam","year":"2023","unstructured":"Keam, S. J. Equecabtagene autoleucel: first approval. Mol. Diagn. Ther. 27, 781\u2013787 (2023).","journal-title":"Mol. Diagn. Ther."},{"key":"2267_CR349","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1182\/blood-2023-173427","volume":"142","author":"C Li","year":"2023","unstructured":"Li, C. et al. Efficacy outcomes and characteristics of patients with multiple myeloma (MM) who achieved sustained minimal residual disease negativity after treatment with equecabtagene autoleucel (Eque-cel, CT103A) in Fumanba-1. Blood. 142, 761 (2023).","journal-title":"Blood."},{"key":"2267_CR350","unstructured":"Finance, I. & Newswire, P. in PR Newswire (2024)."},{"key":"2267_CR351","unstructured":"Administration, N. M. P. National Medical Products Administration353, <https:\/\/www.nmpa.gov.cn\/> (2024)."},{"key":"2267_CR352","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.hlife.2024.09.002","volume":"2","author":"C Guo","year":"2024","unstructured":"Guo, C. et al. Comparison of antigen-specific B cell responses reveals disparity in immunogenicity and memory B cell formation across COVID-19 vaccine platforms. hLife 2, 625\u2013640 (2024).","journal-title":"hLife"},{"key":"2267_CR353","doi-asserted-by":"crossref","unstructured":"Yan, L. et al. Boosting CAR-T cell therapy with CRISPR technology. hLife, (2024).","DOI":"10.1016\/j.hlife.2024.06.002"},{"key":"2267_CR354","first-page":"157","volume":"15","author":"K Jia","year":"2023","unstructured":"Jia, K. et al. New insights for infection mechanism and potential targets of COVID-19: three Chinese patent medicines and three Chinese medicine formulas as promising therapeutic approaches. Chin. Herb. Med. 15, 157\u2013168 (2023).","journal-title":"Chin. Herb. Med."},{"key":"2267_CR355","doi-asserted-by":"crossref","unstructured":"Wang, F.-Z. et al. Kinetics and factors associated with 12-month persistence of neutralizing antibody induced by two inactivated COVID-19 Vaccines. Lancet (2022).","DOI":"10.2139\/ssrn.4065610"},{"key":"2267_CR356","unstructured":"World Health Organization, Annexes to the interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm: grading of evidence: evidence to recommendation tables, first issued 07 May 2021, updated 28 October 2021 (World Health Organization, 2021)."},{"key":"2267_CR357","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07069-z","volume":"22","author":"T Ferenci","year":"2022","unstructured":"Ferenci, T. & Sarkadi, B. RBD-specific antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine. BMC Infect. Dis. 22, 87 (2022).","journal-title":"BMC Infect. Dis."},{"key":"2267_CR358","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S1473-3099(20)30987-7","volume":"21","author":"Z Wu","year":"2021","unstructured":"Wu, Z. et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial. Lancet Infect. Dis. 21, 803\u2013812 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"2267_CR359","doi-asserted-by":"publisher","first-page":"556","DOI":"10.3390\/vaccines10040556","volume":"10","author":"KT-W Lai","year":"2022","unstructured":"Lai, K. T.-W. et al. Safety and immunogenicity of a booster vaccination by CoronaVac or BNT162b2 in previously two-dose inactivated virus vaccinated individuals with negative neutralizing antibody. Vaccines. 10, 556 (2022).","journal-title":"Vaccines."},{"key":"2267_CR360","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","volume":"398","author":"MD Tanriover","year":"2021","unstructured":"Tanriover, M. D. et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 398, 213\u2013222 (2021).","journal-title":"Lancet."},{"key":"2267_CR361","doi-asserted-by":"publisher","first-page":"2096970","DOI":"10.1080\/21645515.2022.2096970","volume":"18","author":"L Jin","year":"2022","unstructured":"Jin, L. et al. CoronaVac: a review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2. Hum. Vaccin. Immunother. 18, 2096970 (2022).","journal-title":"Hum. Vaccin. Immunother."},{"key":"2267_CR362","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S0140-6736(21)02834-8","volume":"399","author":"RB Kennedy","year":"2022","unstructured":"Kennedy, R. B. Efficacy of an adenovirus type 5 vectored SARS-CoV-2 vaccine. Lancet. 399, 212 (2022).","journal-title":"Lancet."},{"key":"2267_CR363","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0140-6736(21)02753-7","volume":"399","author":"SA Halperin","year":"2022","unstructured":"Halperin, S. A. et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. Lancet. 399, 237\u2013248 (2022).","journal-title":"Lancet."},{"key":"2267_CR364","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","volume":"395","author":"F-C Zhu","year":"2020","unstructured":"Zhu, F.-C. et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 395, 1845\u20131854 (2020).","journal-title":"Lancet."},{"key":"2267_CR365","doi-asserted-by":"publisher","first-page":"656","DOI":"10.3390\/vaccines10050656","volume":"10","author":"S Guzm\u00e1n-L\u00f3pez","year":"2022","unstructured":"Guzm\u00e1n-L\u00f3pez, S. et al. Clinical and immunologic efficacy of the recombinant adenovirus type-5-vectored (CanSino Bio) Vaccine in University professors during the COVID-19 Delta wave. Vaccines. 10, 656 (2022).","journal-title":"Vaccines."},{"key":"2267_CR366","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S1473-3099(21)00127-4","volume":"21","author":"S Yang","year":"2021","unstructured":"Yang, S. et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect. Dis. 21, 1107\u20131119 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"2267_CR367","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S1473-3099(21)00127-4","volume":"21","author":"S Yang","year":"2021","unstructured":"Yang, S. et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 21, 1107\u20131119 (2021).","journal-title":"Lancet Infect Dis."},{"key":"2267_CR368","unstructured":"Chen, F. & Ya, G. In COVID-19 Vaccines-Current State and Perspectives (IntechOpen, 2023)."},{"key":"2267_CR369","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.3390\/vaccines10091529","volume":"10","author":"V Parreno","year":"2022","unstructured":"Parreno, V. et al. Probiotic as adjuvant significantly improves protection of the Lanzhou trivalent rotavirus vaccine against heterologous challenge in a gnotobiotic pig model of human rotavirus infection and disease. Vaccines. 10, 1529 (2022).","journal-title":"Vaccines."},{"key":"2267_CR370","doi-asserted-by":"publisher","first-page":"e24989","DOI":"10.1002\/jcla.24989","volume":"37","author":"Y Wang","year":"2023","unstructured":"Wang, Y. et al. Application of the cell\u2010based RT\u2010qPCR assay (C\u2010QPA) for potency detection of the novel trivalent rotavirus vaccine in China. J. Clin. Lab. Anal. 37, e24989 (2023).","journal-title":"J. Clin. Lab. Anal."},{"key":"2267_CR371","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.3390\/vaccines10111873","volume":"10","author":"J Zhang","year":"2022","unstructured":"Zhang, J. et al. The epidemiology of influenza and the associated vaccines development in China: a review. Vaccines. 10, 1873 (2022).","journal-title":"Vaccines."},{"key":"2267_CR372","doi-asserted-by":"publisher","first-page":"103229","DOI":"10.1016\/j.jdeveco.2023.103229","volume":"167","author":"H Geng","year":"2024","unstructured":"Geng, H. & Shi, C. M. Health policy, price regulation, and innovation: evidence from China\u2019s vaccine industry. J. Dev. Econ. 167, 103229 (2024).","journal-title":"J. Dev. Econ."},{"key":"2267_CR373","doi-asserted-by":"publisher","first-page":"4649","DOI":"10.2147\/RMHP.S338701","volume":"14","author":"Z Meng","year":"2021","unstructured":"Meng, Z., Shan, S. & Zhang, R. Chinaas COVID-19 vaccination strategy and its impact on the global pandemic. Risk Manag. Healthc. Policy 14, 4649\u20134655 (2021).","journal-title":"Risk Manag. Healthc. Policy"},{"key":"2267_CR374","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1007\/s40265-021-01574-2","volume":"81","author":"HA Blair","year":"2021","unstructured":"Blair, H. A. Sotorasib: first approval. Drugs. 81, 1573\u20131579 (2021).","journal-title":"Drugs."},{"key":"2267_CR375","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","volume":"383","author":"DS Hong","year":"2020","unstructured":"Hong, D. S. et al. KRASG12C inhibition with sotorasib in advanced solid tumors. N. Engl. J. Med. 383, 1207\u20131217 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2267_CR376","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis, F. et al. Sotorasib for lung cancers with KRAS p. G12C mutation. N. Engl. J. Med. 384, 2371\u20132381 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2267_CR377","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2208470","volume":"388","author":"JH Strickler","year":"2023","unstructured":"Strickler, J. H. et al. Sotorasib in KRAS p. G12C\u2013mutated advanced pancreatic cancer. N. Engl. J. Med. 388, 33\u201343 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2267_CR378","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1158\/1078-0432.CCR-21-3074","volume":"28","author":"EC Nakajima","year":"2022","unstructured":"Nakajima, E. C. et al. FDA approval summary: sotorasib for KRAS G12C-mutated metastatic NSCLC. Clin. Cancer Res. 28, 1482\u20131486 (2022).","journal-title":"Clin. Cancer Res."},{"key":"2267_CR379","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","volume":"401","author":"AJ de Langen","year":"2023","unstructured":"de Langen, A. J. et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. Lancet 401, 733\u2013746 (2023).","journal-title":"Lancet"},{"key":"2267_CR380","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1021\/acs.accounts.2c00479","volume":"55","author":"BA Lanman","year":"2022","unstructured":"Lanman, B. A., Parsons, A. T. & Zech, S. G. Addressing atropisomerism in the development of sotorasib, a covalent inhibitor of KRAS G12C: structural, analytical, and synthetic considerations. Acc. Chem. Res. 55, 2892\u20132903 (2022).","journal-title":"Acc. Chem. Res."},{"key":"2267_CR381","first-page":"470","volume":"18","author":"P Sidaway","year":"2021","unstructured":"Sidaway, P. Sotorasib effective in KRAS-mutant NSCLC. Nat. Rev. Clin. Oncol. 18, 470\u2013470 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2267_CR382","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1056\/NEJMoa2309160","volume":"391","author":"A Fraissenon","year":"2024","unstructured":"Fraissenon, A. et al. Sotorasib for vascular malformations associated with KRAS G12C mutation. N. Engl. J. Med. 391, 334\u2013342 (2024).","journal-title":"N. Engl. J. Med."},{"key":"2267_CR383","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","volume":"389","author":"MG Fakih","year":"2023","unstructured":"Fakih, M. G. et al. Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C. N. Engl. J. Med. 389, 2125\u20132139 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2267_CR384","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(21)00605-7","volume":"23","author":"MG Fakih","year":"2022","unstructured":"Fakih, M. G. et al. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol. 23, 115\u2013124 (2022).","journal-title":"Lancet Oncol."},{"key":"2267_CR385","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41591-023-02717-6","volume":"30","author":"Y Kuboki","year":"2024","unstructured":"Kuboki, Y. et al. Sotorasib with panitumumab in chemotherapy-refractory KRAS G12C-mutated colorectal cancer: a phase 1b trial. Nat. Med. 30, 265\u2013270 (2024).","journal-title":"Nat. Med."},{"key":"2267_CR386","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s11523-022-00922-w","volume":"17","author":"A Lee","year":"2022","unstructured":"Lee, A. Sotorasib: a review in KRAS G12C mutation-positive non-small cell lung cancer. Target. Oncol. 17, 727\u2013733 (2022).","journal-title":"Target. Oncol."},{"key":"2267_CR387","first-page":"12","volume":"43","author":"JE Mann","year":"2021","unstructured":"Mann, J. E. Sotorasib (Lumakras\u2122). Oncol. Times 43, 12\u201317 (2021).","journal-title":"Oncol. Times"},{"key":"2267_CR388","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1016\/j.jtho.2023.05.013","volume":"18","author":"A Chour","year":"2023","unstructured":"Chour, A. et al. Brief report: severe sotorasib-related hepatotoxicity and non-liver adverse events associated with sequential anti\u2013programmed cell death (Ligand) 1 and sotorasib therapy in KRASG12C-mutant lung cancer. J. Thorac. Oncol. 18, 1408\u20131415 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"2267_CR389","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1158\/2159-8290.CD-23-1138","volume":"14","author":"DA Rubinson","year":"2024","unstructured":"Rubinson, D. A. et al. Sotorasib is a Pan-RAS G12C inhibitor capable of driving clinical response in NRAS G12C cancers. Cancer Discov 14, 727\u2013736 (2024).","journal-title":"Cancer Discov"},{"key":"2267_CR390","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.jtho.2021.04.015","volume":"16","author":"T Koga","year":"2021","unstructured":"Koga, T. et al. KRAS secondary mutations that confer acquired resistance to KRAS G12C inhibitors, sotorasib and adagrasib, and overcoming strategies: insights from in vitro experiments. J. Thorac. Oncol. 16, 1321\u20131332 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"2267_CR391","doi-asserted-by":"publisher","first-page":"e2300030","DOI":"10.1200\/PO.23.00030","volume":"7","author":"R Thummalapalli","year":"2023","unstructured":"Thummalapalli, R. et al. Clinical and genomic features of response and toxicity to Sotorasib in a real-world cohort of patients with advanced KRAS g12c-mutant non\u2013small cell lung cancer. JCO Precis. Oncol. 7, e2300030 (2023).","journal-title":"JCO Precis. Oncol."},{"key":"2267_CR392","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1016\/j.jtho.2021.01.321","volume":"16","author":"B Li","year":"2021","unstructured":"Li, B. et al. PS01. 07 registrational phase 2 trial of sotorasib in KRAS p. G12C mutant NSCLC: first disclosure of the codebreak 100 primary analysis. J. Thorac. Oncol. 16, S61 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"2267_CR393","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1200\/JCO.22.02524","volume":"41","author":"GK Dy","year":"2023","unstructured":"Dy, G. K. et al. Long-term outcomes and molecular correlates of sotorasib efficacy in patients with pretreated KRAS G12C-mutated non\u2013small-cell lung cancer: 2-year analysis of CodeBreaK 100. J. Clin. Oncol. 41, 3311\u20133317 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2267_CR394","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s40265-020-01374-0","volume":"80","author":"A Markham","year":"2020","unstructured":"Markham, A. Lurbinectedin: first approval. Drugs. 80, 1345\u20131353 (2020).","journal-title":"Drugs."},{"key":"2267_CR395","doi-asserted-by":"publisher","first-page":"932105","DOI":"10.3389\/fonc.2022.932105","volume":"12","author":"A Manzo","year":"2022","unstructured":"Manzo, A. et al. Lurbinectedin in small cell lung cancer. Front. Oncol. 12, 932105 (2022).","journal-title":"Front. Oncol."},{"key":"2267_CR396","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","volume":"21","author":"J Trigo","year":"2020","unstructured":"Trigo, J. et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 21, 645\u2013654 (2020).","journal-title":"Lancet Oncol."},{"key":"2267_CR397","doi-asserted-by":"publisher","first-page":"175883592110205","DOI":"10.1177\/17588359211020529","volume":"13","author":"S Patel","year":"2021","unstructured":"Patel, S., Petty, W. J. & Sands, J. M. An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer. Ther. Adv. Med. Oncol. 13, 17588359211020529 (2021).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"2267_CR398","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1158\/1078-0432.CCR-20-3901","volume":"27","author":"S Singh","year":"2021","unstructured":"Singh, S. et al. FDA approval summary: lurbinectedin for the treatment of metastatic small cell lung cancer. Clin. Cancer Res. 27, 2378\u20132382 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2267_CR399","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/bjc.2017.205","volume":"117","author":"C Belgiovine","year":"2017","unstructured":"Belgiovine, C. et al. Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models. Br. J. Cancer. 117, 628\u2013638 (2017).","journal-title":"Br. J. Cancer."},{"key":"2267_CR400","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.lungcan.2020.10.003","volume":"150","author":"V Subbiah","year":"2020","unstructured":"Subbiah, V. et al. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. Lung Cancer 150, 90\u201396 (2020).","journal-title":"Lung Cancer"},{"key":"2267_CR401","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.2217\/fon-2020-1212","volume":"17","author":"J Baena","year":"2021","unstructured":"Baena, J. et al. Lurbinectedin in the treatment of relapsed small cell lung cancer. Future Oncol 17, 2279\u20132289 (2021).","journal-title":"Future Oncol"},{"key":"2267_CR402","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S2213-2600(22)00309-5","volume":"11","author":"SP Aix","year":"2023","unstructured":"Aix, S. P. et al. Combination lurbinectedin and doxorubicin versus physician\u2019s choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial. Lancet Respir. Med. 11, 74\u201386 (2023).","journal-title":"Lancet Respir. Med."},{"key":"2267_CR403","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3390\/molecules29020331","volume":"29","author":"A Povo-Retana","year":"2024","unstructured":"Povo-Retana, A. et al. Trabectedin and lurbinectedin modulate the interplay between cells in the tumour microenvironment\u2014progresses in their use in combined cancer therapy. Molecules. 29, 331 (2024).","journal-title":"Molecules."},{"key":"2267_CR404","doi-asserted-by":"publisher","first-page":"914342","DOI":"10.3389\/fonc.2022.914342","volume":"12","author":"A Gadducci","year":"2022","unstructured":"Gadducci, A. & Cosio, S. Trabectedin and lurbinectedin: mechanisms of action, clinical impact, and future perspectives in uterine and soft tissue sarcoma, ovarian carcinoma, and endometrial carcinoma. Front. Oncol. 12, 914342 (2022).","journal-title":"Front. Oncol."},{"key":"2267_CR405","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ejca.2022.06.024","volume":"172","author":"F Longo-Mu\u00f1oz","year":"2022","unstructured":"Longo-Mu\u00f1oz, F. et al. Lurbinectedin in patients with pretreated neuroendocrine tumours: results from a phase II basket study. Eur. J. Cancer. 172, 340\u2013348 (2022).","journal-title":"Eur. J. Cancer."},{"key":"2267_CR406","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1177\/1060028020983014","volume":"55","author":"LT Shinn","year":"2021","unstructured":"Shinn, L. T., Vo, K. A. & Reeves, D. J. Lurbinectedin: a new treatment option for relapsed\/refractory small-cell lung cancer. Ann. Pharmacother. 55, 1172\u20131179 (2021).","journal-title":"Ann. Pharmacother."},{"key":"2267_CR407","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1158\/1078-0432.CCR-13-1880","volume":"20","author":"ME Elez","year":"2014","unstructured":"Elez, M. E. et al. First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors. Clin. Cancer Res. 20, 2205\u20132214 (2014).","journal-title":"Clin. Cancer Res."},{"key":"2267_CR408","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1158\/1078-0432.CCR-22-0696","volume":"28","author":"V Subbiah","year":"2022","unstructured":"Subbiah, V. et al. Antitumor activity of lurbinectedin, a selective inhibitor of oncogene transcription, in patients with relapsed Ewing sarcoma: results of a basket phase II study. Clin. Cancer Res. 28, 2762\u20132770 (2022).","journal-title":"Clin. Cancer Res."},{"key":"2267_CR409","doi-asserted-by":"publisher","first-page":"e1656502","DOI":"10.1080\/2162402X.2019.1656502","volume":"8","author":"W Xie","year":"2019","unstructured":"Xie, W. et al. Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity. Oncoimmunology. 8, e1656502 (2019).","journal-title":"Oncoimmunology."},{"key":"2267_CR410","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1093\/annonc\/mdx357","volume":"28","author":"E Calvo","year":"2017","unstructured":"Calvo, E. et al. Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study. Ann. Oncol. 28, 2559\u20132566 (2017).","journal-title":"Ann. Oncol."},{"key":"2267_CR411","doi-asserted-by":"publisher","first-page":"e17313","DOI":"10.15252\/emmm.202217313","volume":"15","author":"CW Schultz","year":"2023","unstructured":"Schultz, C. W. et al. ATR inhibition augments the efficacy of lurbinectedin in small\u2010cell lung cancer. EMBO Mol. Med. 15, e17313 (2023).","journal-title":"EMBO Mol. Med."},{"key":"2267_CR412","doi-asserted-by":"publisher","first-page":"851790","DOI":"10.3389\/fonc.2022.851790","volume":"12","author":"P Allavena","year":"2022","unstructured":"Allavena, P. et al. Effects of the anti-tumor agents trabectedin and lurbinectedin on immune cells of the tumor microenvironment. Front. Oncol. 12, 851790 (2022).","journal-title":"Front. Oncol."},{"key":"2267_CR413","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1158\/1535-7163.MCT-16-0172","volume":"15","author":"G Santamar\u00eda Nu\u00f1ez","year":"2016","unstructured":"Santamar\u00eda Nu\u00f1ez, G. et al. Lurbinectedin specifically triggers the degradation of phosphorylated RNA polymerase II and the formation of DNA breaks in cancer cells. Mol. Cancer Ther. 15, 2399\u20132412 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"2267_CR414","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40265-021-01473-6","volume":"81","author":"YN Lamb","year":"2021","unstructured":"Lamb, Y. N. Inclisiran: first approval. Drugs. 81, 389\u2013395 (2021).","journal-title":"Drugs."},{"key":"2267_CR415","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","volume":"376","author":"KK Ray","year":"2017","unstructured":"Ray, K. K. et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N. Engl. J. Med. 376, 1430\u20131440 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2267_CR416","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray, K. K. et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N. Engl. J. Med. 382, 1507\u20131519 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2267_CR417","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","volume":"382","author":"FJ Raal","year":"2020","unstructured":"Raal, F. J. et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N. Engl. J. Med. 382, 1520\u20131530 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2267_CR418","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","volume":"11","author":"KK Ray","year":"2023","unstructured":"Ray, K. K. et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol. 11, 109\u2013119 (2023).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2267_CR419","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/eurheartj\/ehac594","volume":"44","author":"KK Ray","year":"2023","unstructured":"Ray, K. K. et al. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur. Heart J. 44, 129\u2013138 (2023).","journal-title":"Eur. Heart J."},{"key":"2267_CR420","doi-asserted-by":"publisher","first-page":"100127","DOI":"10.1016\/j.ahjo.2022.100127","volume":"13","author":"AF Cicero","year":"2022","unstructured":"Cicero, A. F. et al. Efficacy and safety of inclisiran a newly approved FDA drug: a systematic review and pooled analysis of available clinical studies. Am. Heart J. Plus Cardiol. Res. Pract. 13, 100127 (2022).","journal-title":"Am. Heart J. Plus Cardiol. Res. Pract."},{"key":"2267_CR421","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.amjcard.2020.08.018","volume":"134","author":"SA Khan","year":"2020","unstructured":"Khan, S. A., Naz, A., Masood, M. Q. & Shah, R. Meta-analysis of inclisiran for the treatment of hypercholesterolemia. Am. J. Cardiol. 134, 69\u201373 (2020).","journal-title":"Am. J. Cardiol."},{"key":"2267_CR422","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jacl.2019.11.001","volume":"14","author":"K Dyrbu\u015b","year":"2020","unstructured":"Dyrbu\u015b, K. et al. Inclisiran\u2014new hope in the management of lipid disorders? J. Clin. Lipidol. 14, 16\u201327 (2020).","journal-title":"J. Clin. Lipidol."},{"key":"2267_CR423","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s11883-022-01056-0","volume":"24","author":"A Pirillo","year":"2022","unstructured":"Pirillo, A. & Catapano, A. L. Inclisiran: how widely and when should we use it? Curr. Atheroscler. Rep. 24, 803\u2013811 (2022).","journal-title":"Curr. Atheroscler. Rep."},{"key":"2267_CR424","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40259-019-00399-6","volume":"34","author":"CA German","year":"2020","unstructured":"German, C. A. & Shapiro, M. D. Small interfering RNA therapeutic inclisiran: a new approach to targeting PCSK9. Biodrugs. 34, 1\u20139 (2020).","journal-title":"Biodrugs."},{"key":"2267_CR425","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1001\/jamacardio.2019.3502","volume":"4","author":"KK Ray","year":"2019","unstructured":"Ray, K. K. et al. Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels: one-year follow-up of the ORION-1 randomized clinical trial. JAMA Cardiol 4, 1067\u20131075 (2019).","journal-title":"JAMA Cardiol"},{"key":"2267_CR426","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2217\/fca-2018-0067","volume":"14","author":"RM Stoekenbroek","year":"2018","unstructured":"Stoekenbroek, R. M., Kallend, D., Wijngaard, P. L. & Kastelein, J. J. Inclisiran for the treatment of cardiovascular disease: the ORION clinical development program. Future Cardiol. 14, 433\u2013442 (2018).","journal-title":"Future Cardiol."},{"key":"2267_CR427","doi-asserted-by":"publisher","first-page":"112227","DOI":"10.1016\/j.biopha.2021.112227","volume":"143","author":"P Scicchitano","year":"2021","unstructured":"Scicchitano, P. et al. Inclisiran in lipid management: a literature overview and future perspectives. Biomed. Pharmacother. 143, 112227 (2021).","journal-title":"Biomed. Pharmacother."},{"key":"2267_CR428","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2337\/dc18-1491","volume":"42","author":"LA Leiter","year":"2019","unstructured":"Leiter, L. A. et al. Inclisiran lowers LDL-C and PCSK9 irrespective of diabetes status: the ORION-1 randomized clinical trial. Diabetes Care 42, 173\u2013176 (2019).","journal-title":"Diabetes Care"},{"key":"2267_CR429","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/13543784.2018.1442435","volume":"27","author":"T Nishikido","year":"2018","unstructured":"Nishikido, T. & Ray, K. K. Inclisiran for the treatment of dyslipidemia. Expert Opin. Investig. Drugs. 27, 287\u2013294 (2018).","journal-title":"Expert Opin. Investig. Drugs."},{"key":"2267_CR430","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.jacc.2020.12.058","volume":"77","author":"RS Wright","year":"2021","unstructured":"Wright, R. S. et al. Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis. J. Am. Coll. Cardiol. 77, 1182\u20131193 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2267_CR431","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/diseases6030063","volume":"6","author":"CE Kosmas","year":"2018","unstructured":"Kosmas, C. E. et al. Inclisiran: a new promising agent in the management of hypercholesterolemia. Diseases. 6, 63 (2018).","journal-title":"Diseases."},{"key":"2267_CR432","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2147\/VHRM.S338424","volume":"19","author":"MS Albosta","year":"2023","unstructured":"Albosta, M. S. et al. Inclisiran: a new strategy for LDL-C lowering and prevention of atherosclerotic cardiovascular disease. Vasc. Health Risk Manag 19, 421\u2013431 (2023).","journal-title":"Vasc. Health Risk Manag"},{"key":"2267_CR433","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.cmi.2021.08.007","volume":"28","author":"T Gils","year":"2022","unstructured":"Gils, T. et al. Pretomanid for tuberculosis: a systematic review. Clin. Microbiol. Infect. 28, 31\u201342 (2022).","journal-title":"Clin. Microbiol. Infect."},{"key":"2267_CR434","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1007\/s40265-019-01207-9","volume":"79","author":"SJ Keam","year":"2019","unstructured":"Keam, S. J. Pretomanid: first approval. Drugs. 79, 1797\u20131803 (2019).","journal-title":"Drugs."},{"key":"2267_CR435","doi-asserted-by":"publisher","first-page":"106953","DOI":"10.1016\/j.ijantimicag.2023.106953","volume":"62","author":"TVA Nguyen","year":"2023","unstructured":"Nguyen, T. V. A. et al. Pretomanid resistance: an update on emergence, mechanisms and relevance for clinical practice. Int. J. Antimicrob. Agents 62, 106953 (2023).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"2267_CR436","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa2119430","volume":"387","author":"F Conradie","year":"2022","unstructured":"Conradie, F. et al. Bedaquiline\u2013pretomanid\u2013linezolid regimens for drug-resistant tuberculosis. N. Engl. J. Med. 387, 810\u2013823 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2267_CR437","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jgar.2022.09.001","volume":"31","author":"G Fekadu","year":"2022","unstructured":"Fekadu, G. et al. Pretomanid development and its clinical roles in treating tuberculosis. J. Glob. Antimicrob. Resist. 31, 175\u2013184 (2022).","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"2267_CR438","doi-asserted-by":"publisher","first-page":"100128","DOI":"10.1016\/j.crphar.2022.100128","volume":"3","author":"S Occhineri","year":"2022","unstructured":"Occhineri, S. et al. Pretomanid for tuberculosis treatment: an update for clinical purposes. Curr. Res. Pharmacol. Drug Discov. 3, 100128 (2022).","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"2267_CR439","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.jinf.2023.01.039","volume":"86","author":"N Koehler","year":"2023","unstructured":"Koehler, N. et al. Pretomanid-resistant tuberculosis. J. Infect. 86, 520\u2013524 (2023).","journal-title":"J. Infect."},{"key":"2267_CR440","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s40267-020-00743-9","volume":"36","author":"M Shirley","year":"2020","unstructured":"Shirley, M. Pretomanid in drug-resistant tuberculosis: a profile of its use. Drugs Ther. Perspect. 36, 273\u2013279 (2020).","journal-title":"Drugs Ther. Perspect."},{"key":"2267_CR441","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ijtb.2020.09.003","volume":"68","author":"U Deb","year":"2021","unstructured":"Deb, U. & Biswas, S. Pretomanid: the latest USFDA-approved anti-tuberculosis drug. Indian J. Tuberc. 68, 287\u2013291 (2021).","journal-title":"Indian J. Tuberc."},{"key":"2267_CR442","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1164\/rccm.202208-1475OC","volume":"207","author":"KE Dooley","year":"2023","unstructured":"Dooley, K. E. et al. Assessing pretomanid for tuberculosis (APT), a randomized phase 2 trial of pretomanid-containing regimens for drug-sensitive tuberculosis: 12-week results. Am. J. Respir. Crit. Care Med. 207, 929\u2013935 (2023).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2267_CR443","doi-asserted-by":"publisher","unstructured":"Salinger, D. H., Subramoney, V., Everitt, D. & Nedelman, J. R. Population pharmacokinetics of the antituberculosis agent pretomanid. Antimicrob. Agents Chemother. 63, https:\/\/doi.org\/10.1128\/aac.00907-00919 (2019).","DOI":"10.1128\/aac.00907-00919"},{"key":"2267_CR444","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-23110-1","volume":"8","author":"R Baptista","year":"2018","unstructured":"Baptista, R. et al. Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824). Sci. Rep. 8, 5084 (2018).","journal-title":"Sci. Rep."},{"key":"2267_CR445","doi-asserted-by":"publisher","unstructured":"Nedelman, J. R. et al. An exposure-response perspective on the clinical dose of pretomanid. Antimicrob. Agents Chemother. 65, https:\/\/doi.org\/10.1128\/aac.01121-01120 (2020).","DOI":"10.1128\/aac.01121-01120"},{"key":"2267_CR446","doi-asserted-by":"publisher","unstructured":"Lyons, M. A. Modeling and simulation of pretomanid pharmacodynamics in pulmonary tuberculosis patients. Antimicrob. Agents Chemother. 63, https:\/\/doi.org\/10.1128\/aac.00732-00719 (2019).","DOI":"10.1128\/aac.00732-00719"},{"key":"2267_CR447","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1093\/jac\/dkab505","volume":"77","author":"SE Mudde","year":"2022","unstructured":"Mudde, S. E. et al. Delamanid or pretomanid? A Solomonic judgement! J. Antimicrob. Chemother. 77, 880\u2013902 (2022).","journal-title":"J. Antimicrob. Chemother."},{"key":"2267_CR448","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.2147\/DDDT.S281639","volume":"15","author":"SL Stancil","year":"2021","unstructured":"Stancil, S. L., Mirzayev, F. & Abdel-Rahman, S. M. Profiling pretomanid as a therapeutic option for TB infection: evidence to date. Drug Des. Devel. Ther 15, 2815\u20132830 (2021).","journal-title":"Drug Des. Devel. Ther"},{"key":"2267_CR449","doi-asserted-by":"publisher","unstructured":"Ignatius, E. H. et al. Pretomanid pharmacokinetics in the presence of rifamycins: interim results from a randomized trial among patients with tuberculosis. Antimicrob. Agents Chemother. 65, https:\/\/doi.org\/10.1128\/aac.01196-01120 (2021).","DOI":"10.1128\/aac.01196-01120"},{"key":"2267_CR450","doi-asserted-by":"publisher","first-page":"e0002283","DOI":"10.1371\/journal.pgph.0002283","volume":"3","author":"J Timm","year":"2023","unstructured":"Timm, J. et al. Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid. PLOS Glob. Public Health 3, e0002283 (2023).","journal-title":"PLOS Glob. Public Health"},{"key":"2267_CR451","doi-asserted-by":"crossref","unstructured":"Rahman, A., Chhabra, S. & Parkesh, R. in Drug Discovery Stories 623\u2013645 (Elsevier, 2025).","DOI":"10.1016\/B978-0-443-23932-8.00034-0"},{"key":"2267_CR452","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/S2213-2600(19)30363-7","volume":"7","author":"L McKenna","year":"2019","unstructured":"McKenna, L. & Furin, J. Are pretomanid-containing regimens for tuberculosis a victory or a victory narrative? Lancet Respir. Med. 7, 999\u20131000 (2019).","journal-title":"Lancet Respir. Med."},{"key":"2267_CR453","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s40265-022-01704-4","volume":"82","author":"S Dhillon","year":"2022","unstructured":"Dhillon, S. Tebentafusp: first approval. Drugs. 82, 703\u2013710 (2022).","journal-title":"Drugs."},{"key":"2267_CR454","doi-asserted-by":"publisher","first-page":"971","DOI":"10.3390\/cancers11070971","volume":"11","author":"BE Damato","year":"2019","unstructured":"Damato, B. E., Dukes, J., Goodall, H. & Carvajal, R. D. Tebentafusp: T cell redirection for the treatment of metastatic uveal melanoma. Cancers. 11, 971 (2019).","journal-title":"Cancers."},{"key":"2267_CR455","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","volume":"385","author":"P Nathan","year":"2021","unstructured":"Nathan, P. et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N. Engl. J. Med. 385, 1196\u20131206 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2267_CR456","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","volume":"389","author":"JC Hassel","year":"2023","unstructured":"Hassel, J. C. et al. Three-year overall survival with tebentafusp in metastatic uveal melanoma. N. Engl. J. Med. 389, 2256\u20132266 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2267_CR457","doi-asserted-by":"publisher","first-page":"175883592311601","DOI":"10.1177\/17588359231160140","volume":"15","author":"S Howlett","year":"2023","unstructured":"Howlett, S., Carter, T. J., Shaw, H. M. & Nathan, P. D. Tebentafusp: a first-in-class treatment for metastatic uveal melanoma. Ther. Adv. Med. Oncol. 15, 17588359231160140 (2023).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"2267_CR458","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-20-1247","volume":"26","author":"MR Middleton","year":"2020","unstructured":"Middleton, M. R. et al. Tebentafusp, a TCR\/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma. Clin. Cancer Res. 26, 5869\u20135878 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2267_CR459","doi-asserted-by":"publisher","first-page":"2374647","DOI":"10.1080\/21645515.2024.2374647","volume":"20","author":"Y Dian","year":"2024","unstructured":"Dian, Y. et al. Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: a systematic review and meta-analysis. Hum. Vaccin. Immunother. 20, 2374647 (2024).","journal-title":"Hum. Vaccin. Immunother."},{"key":"2267_CR460","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/s41571-021-00572-3","volume":"18","author":"D Killock","year":"2021","unstructured":"Killock, D. Tebentafusp for uveal melanoma. Nat. Rev. Clin. Oncol. 18, 747\u2013747 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2267_CR461","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1038\/s41591-022-02015-7","volume":"28","author":"RD Carvajal","year":"2022","unstructured":"Carvajal, R. D. et al. Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial. Nat. Med. 28, 2364\u20132373 (2022).","journal-title":"Nat. Med."},{"key":"2267_CR462","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1200\/JCO.21.01805","volume":"40","author":"RD Carvajal","year":"2022","unstructured":"Carvajal, R. D. et al. Phase I study of safety, tolerability, and efficacy of tebentafusp using a step-up dosing regimen and expansion in patients with metastatic uveal melanoma. J. Clin. Oncol. 40, 1939\u20131948 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2267_CR463","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.3390\/cancers15133430","volume":"15","author":"D Tomsitz","year":"2023","unstructured":"Tomsitz, D. et al. Tebentafusp in patients with metastatic uveal melanoma: a real-life retrospective multicenter study. Cancers. 15, 3430 (2023).","journal-title":"Cancers."},{"key":"2267_CR464","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2147\/DDDT.S368954","volume":"17","author":"K Montazeri","year":"2023","unstructured":"Montazeri, K., Pattanayak, V. & Sullivan, R. J. Tebentafusp in the treatment of metastatic uveal melanoma: patient selection and special considerations. Drug Des. Devel. Ther 17, 333\u2013339 (2023).","journal-title":"Drug Des. Devel. Ther"},{"key":"2267_CR465","doi-asserted-by":"publisher","first-page":"101408","DOI":"10.1016\/j.tranon.2022.101408","volume":"20","author":"T Olivier","year":"2022","unstructured":"Olivier, T. & Prasad, V. Tebentafusp in first-line melanoma trials: an outperforming outlier. Transl. Oncol. 20, 101408 (2022).","journal-title":"Transl. Oncol."},{"key":"2267_CR466","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1080\/14737140.2022.2124971","volume":"22","author":"LN Chen","year":"2022","unstructured":"Chen, L. N. & Carvajal, R. D. Tebentafusp for the treatment of HLA-A* 02: 01\u2013positive adult patients with unresectable or metastatic uveal melanoma. Expert Rev. Anticancer Ther. 22, 1017\u20131027 (2022).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"2267_CR467","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1080\/14712598.2022.2031970","volume":"22","author":"AW Liu","year":"2022","unstructured":"Liu, A. W., Wei, A. Z., Maniar, A. B. & Carvajal, R. D. Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors. Expert Opin. Biol. Ther. 22, 997\u20131004 (2022).","journal-title":"Expert Opin. Biol. Ther."},{"key":"2267_CR468","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2174\/0113894501280380231214105255","volume":"25","author":"KA Balushi","year":"2024","unstructured":"Balushi, K. A. et al. Tebentafusp as a promising drug for the treatment of uveal melanoma. Curr. Drug Targets 25, 149\u2013157 (2024).","journal-title":"Curr. Drug Targets"},{"key":"2267_CR469","doi-asserted-by":"crossref","unstructured":"Kozani, P. S., Kozani, P. S. & Sheikhi, A. Tebentafusp: the first FDA-approved monoclonal antibody for cancer treatment in 2022. Trends Med. Sci. 1, e123546 (2021).","DOI":"10.5812\/tms.123546"},{"key":"2267_CR470","doi-asserted-by":"crossref","unstructured":"Hassel, J. C. et al. Tebentafusp induces a T-cell\u2013driven rash in melanocyte-bearing skin as an adverse event consistent with the mechanism of action. J. Invest. Dermatol. 145, 559\u2013572 (2024).","DOI":"10.1016\/j.jid.2024.03.048"},{"key":"2267_CR471","doi-asserted-by":"publisher","first-page":"102543","DOI":"10.1016\/j.ctrv.2023.102543","volume":"115","author":"A Petzold","year":"2023","unstructured":"Petzold, A. et al. Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment. Cancer Treat. Rev. 115, 102543 (2023).","journal-title":"Cancer Treat. Rev."},{"key":"2267_CR472","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.annonc.2023.11.013","volume":"35","author":"J Piulats","year":"2024","unstructured":"Piulats, J. et al. Overall survival from Tebentafusp versus Nivolumab plus Ipilimumab in first-line metastatic Uveal Melanoma: a propensity score-weighted analysis. Ann. Oncol. 35, 317\u2013326 (2024).","journal-title":"Ann. Oncol."},{"key":"2267_CR473","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","volume":"20","author":"J Diaz-Manera","year":"2021","unstructured":"Diaz-Manera, J. et al. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. Lancet Neurol. 20, 1012\u20131026 (2021).","journal-title":"Lancet Neurol."},{"key":"2267_CR474","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1007\/s40265-021-01600-3","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon, S. Avalglucosidase alfa: first approval. Drugs. 81, 1803\u20131809 (2021).","journal-title":"Drugs."},{"key":"2267_CR475","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.nmd.2018.12.004","volume":"29","author":"LD Pena","year":"2019","unstructured":"Pena, L. D. et al. Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-na\u00efve and alglucosidase alfa-treated patients with late-onset Pompe disease: a phase 1, open-label, multicenter, multinational, ascending dose study. Neuromuscul. Disord. 29, 167\u2013186 (2019).","journal-title":"Neuromuscul. Disord."},{"key":"2267_CR476","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1001\/jamaneurol.2023.0552","volume":"80","author":"PS Kishnani","year":"2023","unstructured":"Kishnani, P. S. et al. Efficacy and safety of avalglucosidase alfa in patients with late-onset Pompe disease after 97 weeks: a phase 3 randomized clinical trial. JAMA Neurol. 80, 558\u2013567 (2023).","journal-title":"JAMA Neurol."},{"key":"2267_CR477","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/14737175.2024.2306855","volume":"24","author":"C Angelini","year":"2024","unstructured":"Angelini, C. Evaluating avalglucosidase alfa for the management of late-onset Pompe disease. Expert Rev. Neurother. 24, 259\u2013266 (2024).","journal-title":"Expert Rev. Neurother."},{"key":"2267_CR478","doi-asserted-by":"publisher","first-page":"100328","DOI":"10.1016\/j.gim.2022.10.010","volume":"25","author":"PS Kishnani","year":"2023","unstructured":"Kishnani, P. S. et al. Safety and efficacy of avalglucosidase alfa in individuals with infantile-onset Pompe disease enrolled in the phase 2, open-label Mini-COMET study: the 6-month primary analysis report. Genet. Med. 25, 100328 (2023).","journal-title":"Genet. Med."},{"key":"2267_CR479","doi-asserted-by":"publisher","first-page":"e536","DOI":"10.1212\/WNL.0000000000200746","volume":"99","author":"MM Dimachkie","year":"2022","unstructured":"Dimachkie, M. M. et al. Long-term safety and efficacy of avalglucosidase alfa in patients with late-onset Pompe disease. Neurology. 99, e536\u2013e548 (2022).","journal-title":"Neurology."},{"key":"2267_CR480","doi-asserted-by":"publisher","first-page":"1309146","DOI":"10.3389\/fgene.2024.1309146","volume":"15","author":"C Carter","year":"2024","unstructured":"Carter, C., Boggs, T., Case, L. E. & Kishnani, P. Real-world outcomes from a series of patients with late onset Pompe disease who switched from alglucosidase alfa to avalglucosidase alfa. Front. Genet. 15, 1309146 (2024).","journal-title":"Front. Genet."},{"key":"2267_CR481","first-page":"101126","volume":"40","author":"A Fiumara","year":"2024","unstructured":"Fiumara, A. et al. Avalglucosidase alfa in infantile-onset Pompe disease: a snapshot of real-world experience in Italy. Mol. Genet. Metab. Rep. 40, 101126 (2024).","journal-title":"Mol. Genet. Metab. Rep."},{"key":"2267_CR482","doi-asserted-by":"publisher","first-page":"108121","DOI":"10.1016\/j.ymgme.2023.108121","volume":"141","author":"A Toscano","year":"2024","unstructured":"Toscano, A. et al. Effect of avalglucosidase alfa on disease-specific and general patient-reported outcomes in treatment-na\u00efve adults with late-onset Pompe disease compared with alglucosidase alfa: meaningful change analyses from the Phase 3 COMET trial. Mol. Genet. Metab. 141, 108121 (2024).","journal-title":"Mol. Genet. Metab."},{"key":"2267_CR483","doi-asserted-by":"publisher","first-page":"S348","DOI":"10.1016\/j.gim.2022.01.566","volume":"24","author":"D Kronn","year":"2022","unstructured":"Kronn, D. et al. OP016: Mini-COMET: safety and efficacy of\u2265 97 weeks\u2019 avalglucosidase alfa in infantile-onset Pompe disease participants previously treated with alglucosidase alfa. Genet. Med. 24, S348\u2013S349 (2022).","journal-title":"Genet. Med."},{"key":"2267_CR484","first-page":"101109","volume":"40","author":"T Mozaffar","year":"2024","unstructured":"Mozaffar, T. et al. Efficacy of avalglucosidase alfa on forced vital capacity percent predicted in treatment-na\u00efve patients with late-onset Pompe disease: a pooled analysis of clinical trials. Mol. Genet. Metab. Rep. 40, 101109 (2024).","journal-title":"Mol. Genet. Metab. Rep."},{"key":"2267_CR485","doi-asserted-by":"crossref","unstructured":"de Visser, M. & Argov, Z. Vol. 99, 183\u2013184 (AAN Enterprises, 2022).","DOI":"10.1212\/WNL.0000000000200821"},{"key":"2267_CR486","doi-asserted-by":"publisher","first-page":"e16292","DOI":"10.1111\/ene.16292","volume":"31","author":"C Tard","year":"2024","unstructured":"Tard, C. et al. Real\u2010life effectiveness 1 year after switching to avalglucosidase alfa in late\u2010onset Pompe disease patients worsening on alglucosidase alfa therapy: a French cohort study. Eur. J. Neurol 31, e16292 (2024).","journal-title":"Eur. J. Neurol"},{"key":"2267_CR487","doi-asserted-by":"publisher","first-page":"S151","DOI":"10.1016\/j.nmd.2023.07.338","volume":"33","author":"P Kishnani","year":"2023","unstructured":"Kishnani, P. et al. P374 COMET: effects of avalglucosidase alfa and treatment switch from alglucosidase alfa on week 145 QMFT individual item responses. Neuromuscul. Disord. 33, S151\u2013S152 (2023).","journal-title":"Neuromuscul. Disord."},{"key":"2267_CR488","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.1212\/WNL.96.15_supplement.4195","volume":"96","author":"H Kushlaf","year":"2021","unstructured":"Kushlaf, H. et al. Efficacy and safety results of the Avalglucosidase alfa phase 3 COMET Trial in late-onset Pompe disease patients (4195). Neurology 96, 4195 (2021).","journal-title":"Neurology"},{"key":"2267_CR489","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.nmd.2024.07.727","volume":"43","author":"L Potters","year":"2024","unstructured":"Potters, L. et al. 660P Safety and efficacy of switching to avalglucosidase alfa in patients with late-onset Pompe disease previously deteriorating on alglucosidase alfa. Neuromuscul. Disord 43, S1 (2024).","journal-title":"Neuromuscul. Disord"},{"key":"2267_CR490","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s10928-023-09874-8","volume":"50","author":"G Tiraboschi","year":"2023","unstructured":"Tiraboschi, G. et al. Population pharmacokinetic modeling and dosing simulation of avalglucosidase alfa for selecting alternative dosing regimen in pediatric patients with late-onset pompe disease. J. Pharmacokinet. Pharmacodyn. 50, 461\u2013474 (2023).","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"2267_CR491","doi-asserted-by":"publisher","first-page":"S152","DOI":"10.1016\/j.nmd.2023.07.341","volume":"33","author":"B Schoser","year":"2023","unstructured":"Schoser, B. et al. P377 Patients in the Pompe registry who switched from alglucosidase alfa to avalglucosidase alfa: real-world experience. Neuromuscul. Disord. 33, S152 (2023).","journal-title":"Neuromuscul. Disord."},{"key":"2267_CR492","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa2004215","volume":"383","author":"FJ Raal","year":"2020","unstructured":"Raal, F. J. et al. Evinacumab for homozygous familial hypercholesterolemia. N. Engl. J. Med. 383, 711\u2013720 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2267_CR493","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3390\/jcm12010168","volume":"12","author":"B Sosnowska","year":"2022","unstructured":"Sosnowska, B. et al. Evinacumab, an ANGPTL3 inhibitor, in the treatment of dyslipidemia. J. Clin. Med. 12, 168 (2022).","journal-title":"J. Clin. Med."},{"key":"2267_CR494","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","volume":"383","author":"RS Rosenson","year":"2020","unstructured":"Rosenson, R. S. et al. Evinacumab in patients with refractory hypercholesterolemia. N. Engl. J. Med. 383, 2307\u20132319 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2267_CR495","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s40265-021-01516-y","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham, A. Evinacumab: first approval. Drugs. 81, 1101\u20131105 (2021).","journal-title":"Drugs."},{"key":"2267_CR496","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/FJC.0000000000001073","volume":"78","author":"M Jin","year":"2021","unstructured":"Jin, M. et al. Efficacy and safety of evinacumab for the treatment of hypercholesterolemia: a meta-analysis. J. Cardiovasc. Pharmacol. 78, 394\u2013402 (2021).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"2267_CR497","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41591-023-02222-w","volume":"29","author":"RS Rosenson","year":"2023","unstructured":"Rosenson, R. S. et al. Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial. Nat. Med. 29, 729\u2013737 (2023).","journal-title":"Nat. Med."},{"key":"2267_CR498","doi-asserted-by":"publisher","first-page":"e13836","DOI":"10.1111\/cts.13836","volume":"17","author":"R Dingman","year":"2024","unstructured":"Dingman, R. et al. Evinacumab: m502echanism of action, clinical, and translational science. Clin. Transl. Sci. 17, e13836 (2024).","journal-title":"Clin. Transl. Sci."},{"key":"2267_CR499","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1001\/jamacardio.2023.2921","volume":"8","author":"RS Rosenson","year":"2023","unstructured":"Rosenson, R. S. et al. Longer-term efficacy and safety of evinacumab in patients with refractory hypercholesterolemia. JAMA Cardiol. 8, 1070\u20131076 (2023).","journal-title":"JAMA Cardiol."},{"key":"2267_CR500","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1080\/14779072.2021.1955349","volume":"19","author":"BA Warden","year":"2021","unstructured":"Warden, B. A. & Duell, P. B. Evinacumab for treatment of familial hypercholesterolemia. Expert Rev. Cardiovasc. Ther. 19, 739\u2013751 (2021).","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"2267_CR501","unstructured":"Patel, N., Parmar, M. & Patel, P. Evinacumab (2023)."},{"key":"2267_CR502","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/14712598.2022.2090242","volume":"22","author":"A Pirillo","year":"2022","unstructured":"Pirillo, A. & Catapano, A. L. Evinacumab: a new option in the treatment of homozygous familial hypercholesterolemia. Expert Opin. Biol. Ther. 22, 813\u2013820 (2022).","journal-title":"Expert Opin. Biol. Ther."},{"key":"2267_CR503","doi-asserted-by":"publisher","first-page":"100648","DOI":"10.1016\/j.jacadv.2023.100648","volume":"2","author":"FJ Raal","year":"2023","unstructured":"Raal, F. J. et al. The long-term efficacy and safety of Evinacumab in patients with homozygous familial hypercholesterolemia. JACC Adv. 2, 100648 (2023).","journal-title":"JACC Adv."},{"key":"2267_CR504","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jacc.2021.04.091","volume":"78","author":"Z Ahmad","year":"2021","unstructured":"Ahmad, Z. et al. Inhibition of angiopoietin-like protein 3 with evinacumab in subjects with high and severe hypertriglyceridemia. J. Am. Coll. Cardiol. 78, 193\u2013195 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2267_CR505","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.123.065529","volume":"149","author":"A Wiegman","year":"2024","unstructured":"Wiegman, A. et al. Evinacumab for pediatric patients with homozygous familial hypercholesterolemia. Circulation. 149, 343\u2013353 (2024).","journal-title":"Circulation."},{"key":"2267_CR506","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/CRD.0000000000000522","volume":"32","author":"RT White","year":"2024","unstructured":"White, R. T., Sankey, K. H. & Nawarskas, J. J. Evinacumab-dgnb (Evkeeza-REGN1500), a novel lipid-lowering therapy for homozygous familial hypercholesterolemia. Cardiol. Rev. 32, 180\u2013185 (2024).","journal-title":"Cardiol. Rev."},{"key":"2267_CR507","doi-asserted-by":"crossref","unstructured":"Surma, S., Roma\u0144czyk, M. & Filipiak, K. J. Evinacumab\u2013The new kid on the block. Is it important for cardiovascular prevention? Int. J. Cardiol. Cardiovasc. Risk Prev. 11, 200107 (2021).","DOI":"10.1016\/j.ijcrp.2021.200107"},{"key":"2267_CR508","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1161\/ATVBAHA.120.315204","volume":"41","author":"LF Reeskamp","year":"2021","unstructured":"Reeskamp, L. F. et al. ANGPTL3 inhibition with evinacumab results in faster clearance of IDL and LDL apoB in patients with homozygous familial hypercholesterolemia\u2014brief report. Arterioscler. Thromb. Vasc. Biol. 41, 1753\u20131759 (2021).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2267_CR509","doi-asserted-by":"publisher","first-page":"104624","DOI":"10.1016\/j.amsu.2022.104624","volume":"82","author":"AA Asghar","year":"2022","unstructured":"Asghar, A. A., Khabir, Y. & Hashmi, M. R. Zynteglo: Betibeglogene autotemcel-an innovative therapy for \u00e1-thalassemia patients. Ann. Med. Surg 82, 104624 (2022).","journal-title":"Ann. Med. Surg"},{"key":"2267_CR510","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/cpt.1639","volume":"107","author":"M Schuessler\u2010Lenz","year":"2019","unstructured":"Schuessler\u2010Lenz, M., Enzmann, H. & Vamvakas, S. Regulators\u2019 advice can make a difference: European Medicines Agency approval of Zynteglo for beta thalassemia. Clin. Pharmacol. Ther. 107, 492 (2019).","journal-title":"Clin. Pharmacol. Ther."},{"key":"2267_CR511","unstructured":"Gauldie, J. & Verhovsek, M. The applications of zynteglo in treating transfusion dependent beta-thalassemia. Meducator. 45, 3690 (2024)."},{"key":"2267_CR512","doi-asserted-by":"publisher","first-page":"656","DOI":"10.3390\/hematolrep16040064","volume":"16","author":"J Malay","year":"2024","unstructured":"Malay, J. et al. Gene therapy: a revolutionary step in treating thalassemia. Hematol Rep 16, 656\u2013668 (2024).","journal-title":"Hematol Rep"},{"key":"2267_CR513","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1080\/14740338.2020.1741546","volume":"19","author":"I Cavero","year":"2020","unstructured":"Cavero, I. et al. 19th Annual Meeting of the Safety Pharmacology Society: regulatory and safety perspectives for advanced therapy medicinal products (cellular and gene therapy products). Expert Opin. Drug Saf 19, 553\u2013558 (2020).","journal-title":"Expert Opin. Drug Saf"},{"key":"2267_CR514","doi-asserted-by":"publisher","first-page":"25","DOI":"10.20517\/rdodj.2023.19","volume":"2","author":"N Petitpain","year":"2023","unstructured":"Petitpain, N. et al. Pharmacovigilance of gene therapy medicinal products. Rare Dis. Orphan Drugs J 2, 25 (2023).","journal-title":"Rare Dis. Orphan Drugs J"},{"key":"2267_CR515","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.jcyt.2023.05.006","volume":"25","author":"FA R\u00f3s","year":"2023","unstructured":"R\u00f3s, F. A. et al. A systematic review of clinical trials for gene therapies for \u03b2-hemoglobinopathy around the world. Cytotherapy. 25, 1300\u20131306 (2023).","journal-title":"Cytotherapy."},{"key":"2267_CR516","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/thalassrep13010004","volume":"13","author":"A Eleftheriou","year":"2023","unstructured":"Eleftheriou, A. et al. Juggling between the cost and value of new therapies: does science still serve patient needs? Thalassemia Rep. 13, 33\u201337 (2023).","journal-title":"Thalassemia Rep."},{"key":"2267_CR517","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1089\/hum.2023.29251.bfs","volume":"34","author":"A Philippidis","year":"2023","unstructured":"Philippidis, A. BioMarin\u2019s ROCTAVIAN wins food and drug administration approval as first gene therapy for severe hemophilia A. Hum. Gene Ther. 34, 665\u2013668 (2023).","journal-title":"Hum. Gene Ther."},{"key":"2267_CR518","doi-asserted-by":"publisher","first-page":"5179","DOI":"10.1182\/bloodadvances.2023011847","volume":"8","author":"BJ Samelson-Jones","year":"2024","unstructured":"Samelson-Jones, B. J., Small, J. C. & George, L. A. Roctavian gene therapy for hemophilia A. Blood Adv. 8, 5179\u20135189 (2024).","journal-title":"Blood Adv."},{"key":"2267_CR519","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s40265-022-01788-y","volume":"82","author":"HA Blair","year":"2022","unstructured":"Blair, H. A. Valoctocogene roxaparvovec: first approval. Drugs. 82, 1505\u20131510 (2022).","journal-title":"Drugs."},{"key":"2267_CR520","unstructured":"Myshko, D. FDA approves $2.9 million gene therapy for hemophilia A. Formulary Watch (2023)."},{"key":"2267_CR521","unstructured":"Johnson, V. A slow embrace: hemophilia\u2019s gradual adoption of gene therapy. Victoria (2024)."},{"key":"2267_CR522","unstructured":"Myshko, D. Alex Jung: it\u2019s time to think differently about specialty drugs. Formulary Watch (2023)."},{"key":"2267_CR523","unstructured":"Myshko, D. 3 New, and high-cost, gene therapies are expected this year. Formulary Watch (2023)."},{"key":"2267_CR524","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 396, 839\u2013852 (2020).","journal-title":"Lancet."},{"key":"2267_CR525","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1080\/14712598.2021.1933939","volume":"21","author":"C Iragavarapu","year":"2021","unstructured":"Iragavarapu, C. & Hildebrandt, G. Lisocabtagene Maraleucel for the treatment of B-cell lymphoma. Expert Opin. Biol. Ther. 21, 1151\u20131156 (2021).","journal-title":"Expert Opin. Biol. Ther."},{"key":"2267_CR526","doi-asserted-by":"publisher","first-page":"698607","DOI":"10.3389\/fonc.2021.698607","volume":"11","author":"J Meng","year":"2021","unstructured":"Meng, J. et al. Efficacy and safety of CAR-T cell products axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel for the treatment of hematologic malignancies: a systematic review and meta-analysis. Front. Oncol. 11, 698607 (2021).","journal-title":"Front. Oncol."},{"key":"2267_CR527","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","volume":"23","author":"A Sehgal","year":"2022","unstructured":"Sehgal, A. et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 23, 1066\u20131077 (2022).","journal-title":"Lancet Oncol."},{"key":"2267_CR528","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1182\/blood-2019-127508","volume":"134","author":"JS Abramson","year":"2019","unstructured":"Abramson, J. S. et al. Pivotal safety and efficacy results from transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed\/refractory (R\/R) large B cell lymphomas. Blood 134, 241 (2019).","journal-title":"Blood"},{"key":"2267_CR529","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1182\/blood-2021-147913","volume":"138","author":"M Kamdar","year":"2021","unstructured":"Kamdar, M. et al. Lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, versus standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (Pts) with relapsed or refractory (R\/R) large B-cell lymphoma (LBCL): results from the randomized phase 3 transform study. Blood 138, 91 (2021).","journal-title":"Blood"},{"key":"2267_CR530","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1182\/bloodadvances.2024014164","volume":"9","author":"PA Riedell","year":"2024","unstructured":"Riedell, P. A. et al. Lisocabtagene maraleucel for relapsed\/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis. Blood Adv 9, 1232\u20131241 (2024).","journal-title":"Blood Adv"},{"key":"2267_CR531","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood.2022018730","volume":"141","author":"JS Abramson","year":"2023","unstructured":"Abramson, J. S. et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 141, 1675\u20131684 (2023).","journal-title":"Blood."},{"key":"2267_CR532","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","volume":"402","author":"T Siddiqi","year":"2023","unstructured":"Siddiqi, T. et al. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1\u20132 study. Lancet 402, 641\u2013654 (2023).","journal-title":"Lancet"},{"key":"2267_CR533","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2217\/fon-2022-0774","volume":"19","author":"F St-Pierre","year":"2023","unstructured":"St-Pierre, F. & Gordon, L. I. Lisocabtagene maraleucel in the treatment of relapsed\/refractory large B-cell lymphoma. Future Oncol. 19, 19\u201328 (2023).","journal-title":"Future Oncol."},{"key":"2267_CR534","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2022","unstructured":"Kamdar, M. et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 399, 2294\u20132308 (2022).","journal-title":"Lancet"},{"key":"2267_CR535","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1182\/blood-2023-184862","volume":"142","author":"PA Riedell","year":"2023","unstructured":"Riedell, P. A. et al. Lisocabtagene maraleucel in relapsed\/refractory large B-cell lymphoma: real world analysis from the cell therapy consortium. Blood 142, 617 (2023).","journal-title":"Blood"},{"key":"2267_CR536","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.jcyt.2022.03.013","volume":"24","author":"J Teoh","year":"2022","unstructured":"Teoh, J. & Brown, L. F. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19+ hematologic indications. Cytotherapy 24, 962\u2013973 (2022).","journal-title":"Cytotherapy"},{"key":"2267_CR537","doi-asserted-by":"crossref","unstructured":"Morschhauser, F. et al. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. Nat. Med. 30, 2199\u20132207 (2024).","DOI":"10.1038\/s41591-024-02986-9"},{"key":"2267_CR538","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1182\/blood-2024-199723","volume":"144","author":"MSO Bobillo","year":"2024","unstructured":"Bobillo, M. S. O. et al. Real-World (RW) outcomes of lisocabtagene maraleucel (liso-cel) as second-line (2L) therapy in patients (pts) with relapsed or refractory (R\/R) large B-cell lymphoma (LBCL): first results from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry. Blood. 144, 470 (2024).","journal-title":"Blood."},{"key":"2267_CR539","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.hemonc.2021.09.004","volume":"15","author":"MA Kharfan-Dabaja","year":"2022","unstructured":"Kharfan-Dabaja, M. A. et al. Lisocabtagene maraleucel in relapsed or refractory diffuse large B cell lymphoma: what is the evidence? Hematol. Oncol. Stem Cell Ther. 15, 168\u2013175 (2022).","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"2267_CR540","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1158\/1078-0432.CCR-23-2967","volume":"30","author":"M Elmacken","year":"2024","unstructured":"Elmacken, M. et al. FDA approval summary: lisocabtagene maraleucel for second-line treatment of large B-Cell lymphoma. Clin. Cancer Res. 30, 2309\u20132316 (2024).","journal-title":"Clin. Cancer Res."},{"key":"2267_CR541","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3324\/haematol.2023.283162","volume":"109","author":"LI Gordon","year":"2023","unstructured":"Gordon, L. I. et al. Lisocabtagene maraleucel for second-line relapsed or refractory large B-cell lymphoma: patient-reported outcomes from the PILOT study. Haematologica 109, 857 (2023).","journal-title":"Haematologica"},{"key":"2267_CR542","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1182\/blood-2023-179529","volume":"142","author":"T Siddiqi","year":"2023","unstructured":"Siddiqi, T. et al. Lisocabtagene Maraleucel (liso-cel) in R\/R CLL\/SLL: 24-month median follow-up of TRANSCEND CLL 004. Blood 142, 330 (2023).","journal-title":"Blood"},{"key":"2267_CR543","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1182\/blood-2019-127150","volume":"134","author":"J Teoh","year":"2019","unstructured":"Teoh, J. et al. Lisocabtagene maraleucel (liso-cel) manufacturing process control and robustness across CD19+ hematological malignancies. Blood 134, 593 (2019).","journal-title":"Blood"},{"key":"2267_CR544","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.hlife.2024.05.005","volume":"2","author":"W Zhang","year":"2024","unstructured":"Zhang, W. et al. BCMA-CD19 bispecific CAR-T therapy in refractory chronic inflammatory demyelinating polyneuropathy. hLife 2, 434\u2013438 (2024).","journal-title":"hLife"},{"key":"2267_CR545","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2267_CR546","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2217\/fon-2021-1090","volume":"18","author":"LD Anderson Jr","year":"2022","unstructured":"Anderson, L. D. Jr Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma. Future Oncol. 18, 277\u2013289 (2022).","journal-title":"Future Oncol."},{"key":"2267_CR547","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1200\/JCO.22.01365","volume":"41","author":"DK Hansen","year":"2023","unstructured":"Hansen, D. K. et al. Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium. J. Clin. Oncol. 41, 2087\u20132097 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2267_CR548","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1158\/1078-0432.CCR-21-3803","volume":"28","author":"P Sharma","year":"2022","unstructured":"Sharma, P. et al. FDA approval summary: idecabtagene vicleucel for relapsed or refractory multiple myeloma. Clin. Cancer Res. 28, 1759\u20131764 (2022).","journal-title":"Clin. Cancer Res."},{"key":"2267_CR549","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/01.COT.0000753336.18581.7d","volume":"43","author":"A Robinson","year":"2021","unstructured":"Robinson, A. Idecabtagene Vicleucel (Abecma\u00ae). Oncol. Times 43, 21 (2021).","journal-title":"Oncol. Times"},{"key":"2267_CR550","doi-asserted-by":"publisher","first-page":"204062072110196","DOI":"10.1177\/20406207211019622","volume":"12","author":"A Oriol","year":"2021","unstructured":"Oriol, A. et al. The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma. Ther. Adv. Hematol. 12, 20406207211019622 (2021).","journal-title":"Ther. Adv. Hematol."},{"key":"2267_CR551","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","volume":"29","author":"Y Lin","year":"2023","unstructured":"Lin, Y. et al. Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nat. Med. 29, 2286\u20132294 (2023).","journal-title":"Nat. Med."},{"key":"2267_CR552","first-page":"26","volume":"136","author":"Y Lin","year":"2020","unstructured":"Lin, Y. et al. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in patients with relapsed and refractory multiple myeloma: updated results from phase 1 CRB-401 study. Blood 136, 26\u201327 (2020).","journal-title":"Blood"},{"key":"2267_CR553","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1182\/blood-2020-139009","volume":"136","author":"SZ Usmani","year":"2020","unstructured":"Usmani, S. Z. et al. KarMMa-4: idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, in high-risk newly diagnosed multiple myeloma. Blood 136, 18\u201319 (2020).","journal-title":"Blood"},{"key":"2267_CR554","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/S2152-2650(21)02101-7","volume":"21","author":"LD Anderson Jr","year":"2021","unstructured":"Anderson, L. D. Jr et al. OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa. Clin. Lymphoma Myeloma Leuk. 21, S17\u2013S18 (2021).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"2267_CR555","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1182\/blood-2020-137156","volume":"136","author":"M Delforge","year":"2020","unstructured":"Delforge, M. et al. KarMMa-3: a phase 3 study of idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy vs standard regimens in relapsed and refractory multiple myeloma. Blood. 136, 24\u201325 (2020).","journal-title":"Blood."},{"key":"2267_CR556","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/17474086.2022.2081147","volume":"15","author":"J Davis","year":"2022","unstructured":"Davis, J., McGann, M., Shockley, A. & Hashmi, H. Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophie\u2019s choice for patients with relapsed refractory multiple myeloma. Expert Rev. Hematol. 15, 473\u2013475 (2022).","journal-title":"Expert Rev. Hematol."},{"key":"2267_CR557","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/blood-2020-134319","volume":"136","author":"NS Raje","year":"2020","unstructured":"Raje, N. S. et al. Idecabtagene vicleucel (ide-cel, bb2121) in relapsed and refractory multiple myeloma: analyses of high-risk subgroups in the KarMMa study. Blood 136, 37\u201338 (2020).","journal-title":"Blood"},{"key":"2267_CR558","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1182\/blood-2023-181762","volume":"142","author":"S Sidana","year":"2023","unstructured":"Sidana, S. et al. Real world outcomes with idecabtagene vicleucel (ide-cel) CAR-T cell therapy for relapsed\/refractory multiple myeloma. Blood 142, 1027 (2023).","journal-title":"Blood"},{"key":"2267_CR559","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/14712598.2024.2433518","volume":"25","author":"K Mancuso","year":"2025","unstructured":"Mancuso, K. et al. Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma. Expert Opin. Biol. Ther. 25, 27\u201346 (2025).","journal-title":"Expert Opin. Biol. Ther."},{"key":"2267_CR560","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1182\/blood-2023-173970","volume":"142","author":"MV Dhodapkar","year":"2023","unstructured":"Dhodapkar, M. V. et al. Efficacy and safety of idecabtagene vicleucel (ide-cel) in patients with clinical high-risk newly diagnosed multiple myeloma (NDMM) with an inadequate response to frontline autologous stem cell transplantation (ASCT): KarMMa-2 cohort 2c extended follow-up. Blood 142, 2101 (2023).","journal-title":"Blood"},{"key":"2267_CR561","doi-asserted-by":"publisher","first-page":"4759","DOI":"10.1182\/blood-2024-202467","volume":"144","author":"M Maulhardt","year":"2024","unstructured":"Maulhardt, M. et al. Efficacy of idecabtagene vicleucel (ide-cel) in patients with relapsed\/refractory multiple myeloma and prior central nervous system manifestation: a retrospective real-world analysis. Blood. 144, 4759 (2024).","journal-title":"Blood."},{"key":"2267_CR562","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s12185-023-03538-6","volume":"117","author":"D Minakata","year":"2023","unstructured":"Minakata, D. et al. Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma. Int. J. Hematol. 117, 729\u2013737 (2023).","journal-title":"Int. J. Hematol."},{"key":"2267_CR563","doi-asserted-by":"publisher","first-page":"777","DOI":"10.3324\/haematol.2023.283940","volume":"109","author":"S Sidana","year":"2023","unstructured":"Sidana, S. et al. Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed\/refractory multiple myeloma with renal impairment. Haematologica. 109, 777 (2023).","journal-title":"Haematologica."},{"key":"2267_CR564","doi-asserted-by":"crossref","unstructured":"Tartof, S. Y. et al. Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case-control study. Lancet Respir Med. 10, 689\u2013699 (2022)","DOI":"10.1016\/S2213-2600(22)00101-1"},{"key":"2267_CR565","doi-asserted-by":"crossref","unstructured":"Abu-Raddad, L. J. et al. Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. J. Travel Med. 28, taab083 (2021).","DOI":"10.1093\/jtm\/taab083"},{"key":"2267_CR566","first-page":"301","volume":"46","author":"D Guerra-Est\u00e9vez","year":"2022","unstructured":"Guerra-Est\u00e9vez, D. et al. Self-reported adverse events within the seven days following the Spikevax\u00ae(Moderna) vaccination. Farm. Hosp. 46, 301\u2013307 (2022).","journal-title":"Farm. Hosp."},{"key":"2267_CR567","doi-asserted-by":"crossref","unstructured":"Cunningham, H. C., Dunn, J. & Durr, D. An examination of moderna. J. Appl. Bus. Econ. 26, (2024).","DOI":"10.33423\/jabe.v26i5.7357"},{"key":"2267_CR568","doi-asserted-by":"publisher","first-page":"917905","DOI":"10.3389\/fimmu.2022.917905","volume":"13","author":"T Adjobimey","year":"2022","unstructured":"Adjobimey, T. et al. Comparison of IgA, IgG, and neutralizing antibody responses following immunization with Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm\u2019s COVID-19 vaccines. Front. Immunol. 13, 917905 (2022).","journal-title":"Front. Immunol."},{"key":"2267_CR569","unstructured":"Infectiohn Control Today. Spikevax booster\u2019s efficacy falling behind omicron-targeting booster candidates. https:\/\/www.infectioncontroltoday.com\/view\/spikevax-booster-s-efficacy-falling-behind-omicron-targeting-booster-candidates (2022)."},{"key":"2267_CR570","unstructured":"Halsey, G. Moderna investigational dual Flu\/COVID-19 vaccine shows positive phase 1\/2 results. Patient Care. 5, NA-NA (2023)."},{"key":"2267_CR571","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/JCP.0000000000001522","volume":"42","author":"C Kn\u00f6chel","year":"2022","unstructured":"Kn\u00f6chel, C., Hefner, G., Stiehl, T. & Schmidbauer, W. Elevated clozapine blood concentrations after second COVID-19 vaccination with Spikevax (COVID-19 vaccine Moderna). J. Clin. Psychopharmacol. 42, 317\u2013320 (2022).","journal-title":"J. Clin. Psychopharmacol."},{"key":"2267_CR572","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1159\/000526375","volume":"183","author":"P Kralickova","year":"2022","unstructured":"Kralickova, P. et al. Immunogenicity and safety of the spikevax\u00ae(Moderna) mRNA SARS-CoV-2 vaccine in patients with primary humoral immunodeficiency. Int. Arch. Allergy Immunol. 183, 1297\u20131310 (2022).","journal-title":"Int. Arch. Allergy Immunol."},{"key":"2267_CR573","unstructured":"Infection Control Today. Moderna\u2019s vaccine showing robust response against 4 influenza strains. https:\/\/www.infectioncontroltoday.com\/view\/moderna-s-vaccine-showing-robust-response-against-4-influenza-strains (2023)."},{"key":"2267_CR574","doi-asserted-by":"publisher","first-page":"1229716","DOI":"10.3389\/fpubh.2023.1229716","volume":"11","author":"L Reynolds","year":"2023","unstructured":"Reynolds, L., Dewey, C., Asfour, G. & Little, M. Vaccine efficacy against SARS-CoV-2 for Pfizer BioNTech, Moderna, and AstraZeneca vaccines: a systematic review. Front. Public Health 11, 1229716 (2023).","journal-title":"Front. Public Health"},{"key":"2267_CR575","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s40259-023-00623-4","volume":"37","author":"DI Stanisic","year":"2023","unstructured":"Stanisic, D. I. & Good, M. F. Malaria vaccines: progress to date. Biodrugs. 37, 737\u2013756 (2023).","journal-title":"Biodrugs."},{"key":"2267_CR576","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1345\/aph.1AQ634","volume":"46","author":"KJ Wilby","year":"2012","unstructured":"Wilby, K. J., Lau, T. T., Gilchrist, S. E. & Ensom, M. H. Mosquirix (RTS, S): a novel vaccine for the prevention of Plasmodium falciparum malaria. Ann. Pharmacother. 46, 384\u2013393 (2012).","journal-title":"Ann. Pharmacother."},{"key":"2267_CR577","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s40267-016-0290-9","volume":"32","author":"GM Keating","year":"2016","unstructured":"Keating, G. M. RTS, S\/AS01 malaria vaccine (Mosquirix\u2122): a guide to its use. Drugs Ther. Perspect. 32, 143\u2013148 (2016).","journal-title":"Drugs Ther. Perspect."},{"key":"2267_CR578","first-page":"892","volume":"3","author":"JP Sahoo","year":"2021","unstructured":"Sahoo, J. P., Mishra, P., Sahoo, S. & Samal, K. C. Historic moment: WHO approves the world\u2019s first malaria vaccine \u201cMosquirix or RTS, S\/AS01\u201d. Biotica Res. Today 3, 892\u2013896 (2021).","journal-title":"Biotica Res. Today"},{"key":"2267_CR579","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40267-022-00937-3","volume":"38","author":"YY Syed","year":"2022","unstructured":"Syed, Y. Y. RTS, S\/AS01 malaria vaccine (Mosquirix\u00ae): a profile of its use. Drugs Ther. Perspect. 38, 373\u2013381 (2022).","journal-title":"Drugs Ther. Perspect."},{"key":"2267_CR580","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/vaccines10050713","volume":"10","author":"AY Nadeem","year":"2022","unstructured":"Nadeem, A. Y. et al. Mosquirix\u2122 RTS, S\/AS01 vaccine development, immunogenicity, and efficacy. Vaccines. 10, 713 (2022).","journal-title":"Vaccines."},{"key":"2267_CR581","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1080\/21645515.2019.1669415","volume":"16","author":"MB Laurens","year":"2020","unstructured":"Laurens, M. B. RTS, S\/AS01 vaccine (Mosquirix\u2122): an overview. Hum. Vaccin. Immunother. 16, 480\u2013489 (2020).","journal-title":"Hum. Vaccin. Immunother."},{"key":"2267_CR582","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1177\/2168479018779373","volume":"53","author":"A Vaggelas","year":"2019","unstructured":"Vaggelas, A. & Seimetz, D. Expediting drug development: FDA\u2019s new regenerative medicine advanced therapy designation. Ther. Innov. Regul. Sci. 53, 364\u2013373 (2019).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"2267_CR583","unstructured":"Food & Drug Law Institue. FDA sharpens its focus on regenerative medicine regulation. https:\/\/www.fdli.org\/2017\/08\/fda-sharpens-focus-regenerative-medicine-regulation (2017)."},{"key":"2267_CR584","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jcyt.2019.04.002","volume":"21","author":"M Mendicino","year":"2019","unstructured":"Mendicino, M. et al. Current state of US Food and Drug Administration regulation for cellular and gene therapy products: potential cures on the horizon. Cytotherapy. 21, 699\u2013724 (2019).","journal-title":"Cytotherapy."},{"key":"2267_CR585","doi-asserted-by":"publisher","first-page":"e2114531","DOI":"10.1001\/jamanetworkopen.2021.14531","volume":"4","author":"MP Lythgoe","year":"2021","unstructured":"Lythgoe, M. P. & Middleton, P. Comparison of COVID-19 vaccine approvals at the US Food and Drug administration, European Medicines Agency, and health Canada. JAMA Netw. Open 4, e2114531\u2013e2114531 (2021).","journal-title":"JAMA Netw. Open"},{"key":"2267_CR586","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.15190\/d.2021.1","volume":"9","author":"A Fortner","year":"2021","unstructured":"Fortner, A. & Schumacher, D. First COVID-19 vaccines receiving the US FDA and EMA emergency use authorization. Discoveries 9, e122 (2021).","journal-title":"Discoveries"},{"key":"2267_CR587","unstructured":"Ballentine, C. Sulfanilamide disaster. FDA Consum. 5, NA-NA (1981)."},{"key":"2267_CR588","doi-asserted-by":"crossref","unstructured":"Woolf, A. D. in History of Modern Clinical Toxicology 139\u2013148 (Elsevier, 2022).","DOI":"10.1016\/B978-0-12-822218-8.00045-4"},{"key":"2267_CR589","first-page":"1","volume":"8","author":"A Moghissi","year":"2020","unstructured":"Moghissi, A. et al. Regulatory science education: the need for generalization. J. Regul. Sci. 8, 1\u20137 (2020).","journal-title":"J. Regul. Sci."},{"key":"2267_CR590","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1056\/NEJMp0903764","volume":"360","author":"MA Hamburg","year":"2009","unstructured":"Hamburg, M. A. & Sharfstein, J. M. The FDA as a public health agency. N. Engl. J. Med. 360, 2493\u20132495 (2009).","journal-title":"N. Engl. J. Med."},{"key":"2267_CR591","first-page":"50","volume":"5","author":"AA Moghissi","year":"2017","unstructured":"Moghissi, A. A., Calderone, R. A., McBride, D. K. & Jaeger, L. Innovation in regulatory science: metrics for evaluation of regulatory science claims based on best available regulatory science. J. Regul. Sci. 5, 50\u201358 (2017).","journal-title":"J. Regul. Sci."},{"key":"2267_CR592","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/cpt.1354","volume":"105","author":"M Lee","year":"2019","unstructured":"Lee, M., Ly, H., M\u00f6ller, C. C. & Ringel, M. S. Innovation in regulatory science is meeting evolution of clinical evidence generation. Clin. Pharmacol. Ther. 105, 886\u2013898 (2019).","journal-title":"Clin. Pharmacol. Ther."},{"key":"2267_CR593","first-page":"4","volume":"2","author":"J Zhao","year":"2024","unstructured":"Zhao, J. Strategies and prospects for the construction of an excellent regulatory system for traditional Chinese medicine. CFDA Mag 2, 4\u201315 (2024).","journal-title":"CFDA Mag"},{"key":"2267_CR594","first-page":"749","volume":"58","author":"J Zhao","year":"2023","unstructured":"Zhao, J. Regulatory science of traditional Chinese medicine: contribute to a higher level of scientific supervision of traditional Chinese medicine. J. Chin. Pharm. Sci. 58, 749\u2013761 (2023).","journal-title":"J. Chin. Pharm. Sci."},{"key":"2267_CR595","first-page":"396","volume":"38","author":"J Zhao","year":"2024","unstructured":"Zhao, J. & Huang, L. Regulatory science of traditional Chinese medicine: an emerging convergence science in development. Bull. Natl. Nat. Sci. Found. China 38, 396\u2013405 (2024).","journal-title":"Bull. Natl. Nat. Sci. Found. China"},{"key":"2267_CR596","first-page":"6","volume":"15","author":"R Yao","year":"2023","unstructured":"Yao, R., He, C. & Xiao, P. \u2018Food and medicine Continuum\u2019in the East and West: old tradition and current regulation. Chin. Herb. Med. 15, 6\u201314 (2023).","journal-title":"Chin. Herb. Med."},{"key":"2267_CR597","unstructured":"NMPA, T. Notice on the Issuance of the Pilot Program for Optimizing the Review and Approval of Clinical Trials for Innovative Drugs by the National Medical Products Administration <https:\/\/www.gov.cn\/zhengce\/zhengceku\/202408\/content_6965736.htm> (2024)."},{"key":"2267_CR598","first-page":"4","volume":"06","author":"S Zhou","year":"2024","unstructured":"Zhou, S., Yang, Z., Song, Y. & Huang, G. Reform and development of evaluation and approval of innovative drugs in China: a case study of anti-tumor drugs. CFDA Mag. 06, 4\u201315 (2024).","journal-title":"CFDA Mag."},{"key":"2267_CR599","doi-asserted-by":"publisher","first-page":"100043","DOI":"10.59717\/j.xinn-life.2023.100043","volume":"1","author":"X Huang","year":"2023","unstructured":"Huang, X. & Cao, X. Innovative drugs bring continuous benefits to cancer patients. Innov. Life 1, 100043 (2023).","journal-title":"Innov. Life"},{"key":"2267_CR600","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S1470-2045(22)00135-8","volume":"23","author":"DJ Benjamin","year":"2022","unstructured":"Benjamin, D. J., Prasad, V. & Lythgoe, M. P. FDA decisions on new oncological drugs. Lancet Oncol. 23, 585\u2013586 (2022).","journal-title":"Lancet Oncol."},{"key":"2267_CR601","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S1470-2045(22)00136-X","volume":"23","author":"G Li","year":"2022","unstructured":"Li, G. et al. FDA decisions on new oncological drugs. Lancet Oncol 23, 583\u2013585 (2022).","journal-title":"Lancet Oncol"},{"key":"2267_CR602","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ejca.2022.03.030","volume":"169","author":"MP Lythgoe","year":"2022","unstructured":"Lythgoe, M. P. & Sullivan, R. Approved anti-PD-1 monoclonal antibodies in China: a bridge too far for US approval. Eur. J. Cancer 169, 103\u2013105 (2022).","journal-title":"Eur. J. Cancer"},{"key":"2267_CR603","unstructured":"BeiGene. TEVIMBRA approved in U.S. for first-line treatment of gastric and gastroesophageal junction cancers in combination with chemotherapy, <https:\/\/ir.beigene.com\/news\/tevimbra-approved-in-u-s-for-first-line-treatment-of-gastric-and-gastroesophageal-junction-cancers-in-combination\/cedb475b-fcfe-47a4-8afe-8a501d9cf849\/> (2024)."},{"key":"2267_CR604","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S1470-2045(23)00026-8","volume":"24","author":"MP Lythgoe","year":"2023","unstructured":"Lythgoe, M. P. et al. The rise of immuno-oncology in China: a challenge to western dominance? Lancet Oncol. 24, 439\u2013441 (2023).","journal-title":"Lancet Oncol."},{"key":"2267_CR605","doi-asserted-by":"crossref","unstructured":"Zhang, Y. et al. Overall survival benefits of cancer drugs approved in China from 2005 to 2020. JAMA Netw. Open 5, e2225973\u2013e2225973 (2022).","DOI":"10.1001\/jamanetworkopen.2022.25973"},{"key":"2267_CR606","unstructured":"FDA. Fast track, breakthrough therapy, accelerated approval, priority review, <https:\/\/www.fda.gov\/patients\/learn-about-drug-and-device-approvals\/fast-track-breakthrough-therapy-accelerated-approval-priority-review> (2023)."},{"key":"2267_CR607","unstructured":"Piachaud-Moustakis, B. Improvements to EMA\u2019s PRIME designation scheme. Pharm. Tech. Euro. 35, 7\u20138 (2023)."},{"key":"2267_CR608","first-page":"47","volume":"10","author":"A Ozaki","year":"2020","unstructured":"Ozaki, A. et al. Japan\u2019s drug regulation framework: aiming for better health or bigger profits? Int. J. Health Policy Manag. 10, 47 (2020).","journal-title":"Int. J. Health Policy Manag."},{"key":"2267_CR609","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1007\/s43441-019-00019-z","volume":"54","author":"E Kajiwara","year":"2020","unstructured":"Kajiwara, E. & Shikano, M. Considerations and regulatory challenges for innovative medicines in expedited approval programs: breakthrough therapy and Sakigake designation. Ther. Innov. Regul. Sci. 54, 814\u2013820 (2020).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"2267_CR610","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1007\/s43441-019-00100-7","volume":"54","author":"ET Muensterman","year":"2020","unstructured":"Muensterman, E. T., Luo, Y. & Parker, J. M. Breakthrough therapy, PRIME and Sakigake: a comparison between neuroscience and oncology in obtaining preferred regulatory status. Ther. Innov. Regul. Sci. 54, 658\u2013666 (2020).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"2267_CR611","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/oncolo\/oyad041","volume":"28","author":"Y Maruyama","year":"2023","unstructured":"Maruyama, Y. et al. Regulatory issues: PMDA\u2013review of sakigake designation products: oncolytic virus therapy with delytact injection (Teserpaturev) for Malignant glioma. Oncologist 28, 664\u2013670 (2023).","journal-title":"Oncologist"},{"key":"2267_CR612","doi-asserted-by":"crossref","unstructured":"Nagasaka, M. & Ou, S.-h. I. ORIENT-31 as the Sakigake \u201cCharging Samurai\u201d born of IMpower150 but will MARIPOSA-2 IMPRESS in the \u201cMeiji Modernization\u201d of post-3G EGFR TKI progression? Lung Cancer. 13, 13\u201321 (2022).","DOI":"10.2147\/LCTT.S355503"},{"key":"2267_CR613","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1111\/bcp.14807","volume":"87","author":"M Tanaka","year":"2021","unstructured":"Tanaka, M. et al. Achievements and challenges of the Sakigake designation system in Japan. Br. J. Clin. Pharmacol. 87, 4027\u20134035 (2021).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"2267_CR614","unstructured":"Forbes. U.S., China advance discussions on pact to accelerate cancer drug trials <https:\/\/www.forbes.com\/sites\/russellflannery\/2022\/12\/17\/us-china-advance-discussions-on-pact-to-accelerate-cancer-drug-trials\/> (2022)."},{"key":"2267_CR615","unstructured":"Xinhua. Chinese-made innovative drugs hit 100-billion-yuan market scale: report <https:\/\/english.news.cn\/20241116\/5001bddba977483b9b50a2046bcb788b\/c.html?utm_source=chatgpt.com> (2024)."},{"key":"2267_CR616","unstructured":"CHINADAILY. Chinese-made new drugs big hit overseas <https:\/\/global.chinadaily.com.cn\/a\/202407\/24\/WS66a062c7a31095c51c50fa01.html?utm_source=chatgpt.com> (2024)."},{"key":"2267_CR617","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1182\/blood-2022-157497","volume":"140","author":"J Ma","year":"2022","unstructured":"Ma, J. et al. Phase I study of the anti-BTLA antibody tifcemalimab as a single agent or in combination with toripalimab in relapsed\/refractory lymphomas. Blood 140, 3716\u20133717 (2022).","journal-title":"Blood"},{"key":"2267_CR618","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s40265-019-01076-2","volume":"79","author":"SJ Keam","year":"2019","unstructured":"Keam, S. J. Toripalimab: first global approval. Drugs 79, 573\u2013578 (2019).","journal-title":"Drugs"},{"key":"2267_CR619","doi-asserted-by":"publisher","first-page":"362936","DOI":"10.1200\/JCO.2022.40.36_suppl.362936","volume":"40","author":"J Wang","year":"2022","unstructured":"Wang, J. et al. Final progression-free survival, interim overall survival, and biomarker analyses of CHOICE-01: a phase III study of toripalimab versus placebo in combination with first-line chemotherapy for advanced NSCLC without EGFR\/ALK mutations. J. Clin. Oncol. 40, 362936\u2013362936 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2267_CR620","first-page":"LBA1013","volume":"41","author":"Z Jiang","year":"2023","unstructured":"Jiang, Z. et al. TORCHLIGHT: a randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel (nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC). J. Hematol. Oncol. 41, LBA1013 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"2267_CR621","doi-asserted-by":"publisher","first-page":"e15083","DOI":"10.1200\/JCO.2020.38.15_suppl.e15083","volume":"38","author":"C Ren","year":"2020","unstructured":"Ren, C. et al. Clinical response and biomarker analysis of a phase II basket trial of toripalimab, a PD-1 mAb in combination with standard chemotherapy as a first-line treatment for patients with solid tumors. J. Clin. Oncol. 38, e15083\u2013e15083 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2267_CR622","doi-asserted-by":"publisher","first-page":"9003","DOI":"10.1200\/JCO.2023.41.16_suppl.9003","volume":"41","author":"J Wang","year":"2023","unstructured":"Wang, J. et al. Final overall survival and biomarker analyses of CHOICE-01: a double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR\/ALK mutations. J. Clin. Oncol. 41, 9003\u20139003 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2267_CR623","doi-asserted-by":"publisher","first-page":"e21618","DOI":"10.1200\/JCO.2020.38.15_suppl.e21618","volume":"38","author":"S Ren","year":"2020","unstructured":"Ren, S. et al. A multi-center phase II study of toripalimab with chemotherapy in patients with EGFR mutant advanced NSCLC patients resistant to EGFR TKIs: efficacy and biomarker analysis. J. Clin. Oncol. 38, e21618\u2013e21618 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2267_CR624","doi-asserted-by":"publisher","first-page":"9028","DOI":"10.1200\/JCO.2022.40.16_suppl.9028","volume":"40","author":"J Wang","year":"2022","unstructured":"Wang, J. et al. Final progression-free survival, interim overall survival, and biomarker analyses of CHOICE-01: a phase 3 study of toripalimab versus placebo in combination with first-line chemotherapy for advanced NSCLC without EGFR\/ALK mutations. J. Clin. Oncol. 40, 9028\u20139028 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2267_CR625","doi-asserted-by":"crossref","unstructured":"Xu, R.-h. et al. JUPITER-02: randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC). J. Clin. Oncol. 39, LBA2-LBA2 (2021).","DOI":"10.1200\/JCO.2021.39.15_suppl.LBA2"},{"key":"2267_CR626","doi-asserted-by":"publisher","first-page":"CT226","DOI":"10.1158\/1538-7445.AM2022-CT226","volume":"82","author":"H-Q Mai","year":"2022","unstructured":"Mai, H.-Q. et al. Abstract CT226: final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma. Cancer Res. 82, CT226\u2013CT226 (2022).","journal-title":"Cancer Res."},{"key":"2267_CR627","doi-asserted-by":"publisher","first-page":"S998","DOI":"10.1016\/j.annonc.2021.08.1886","volume":"32","author":"B Gao","year":"2021","unstructured":"Gao, B. et al. 1284P Sitravatinib+ tislelizumab in patients with anti-PD-(L) 1 refractory\/resistant metastatic NSCLC. Ann. Oncol. 32, S998 (2021).","journal-title":"Ann. Oncol."},{"key":"2267_CR628","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/cas.14681","volume":"112","author":"D Ye","year":"2021","unstructured":"Ye, D. et al. Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma. Cancer Sci. 112, 305\u2013313 (2021).","journal-title":"Cancer Sci."},{"key":"2267_CR629","doi-asserted-by":"publisher","first-page":"S817","DOI":"10.1016\/j.annonc.2020.08.1578","volume":"31","author":"J Wang","year":"2020","unstructured":"Wang, J. et al. 1264P Updated analysis of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment of advanced squamous non-small cell lung cancer (SQ NSCLC). Ann. Oncol. 31, S817 (2020).","journal-title":"Ann. Oncol."},{"key":"2267_CR630","doi-asserted-by":"publisher","first-page":"S1430","DOI":"10.1016\/j.annonc.2021.10.140","volume":"32","author":"Y Yang","year":"2021","unstructured":"Yang, Y. et al. 121O rationale 309: a randomized, global, double-blind, phase III trial of tislelizumab (TIS) vs placebo, plus gemcitabine+ cisplatin (GP), as first-line treatment for recurrent\/metastatic nasopharyngeal cancer (RM-NPC). Ann. Oncol. 32, S1430 (2021).","journal-title":"Ann. Oncol."},{"key":"2267_CR631","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1080\/13543784.2020.1833857","volume":"29","author":"S-Y Liu","year":"2020","unstructured":"Liu, S.-Y. & Wu, Y.-L. Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). Expert Opin. Investig. Drugs 29, 1355\u20131364 (2020).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"2267_CR632","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40265-020-01286-z","volume":"80","author":"A Lee","year":"2020","unstructured":"Lee, A. & Keam, S. J. Tislelizumab: first approval. Drugs. 80, 617\u2013624 (2020).","journal-title":"Drugs."},{"key":"2267_CR633","doi-asserted-by":"publisher","first-page":"x28","DOI":"10.1093\/annonc\/mdy487.007","volume":"29","author":"S Sandhu","year":"2018","unstructured":"Sandhu, S. et al. Tislelizumab, an anti-PD-1 antibody, in patients with urothelial carcinoma (UC): results from an ongoing phase I\/II study. Ann. Oncol. 29, x28 (2018).","journal-title":"Ann. Oncol."},{"key":"2267_CR634","doi-asserted-by":"publisher","first-page":"S721","DOI":"10.1016\/j.jtho.2019.08.1538","volume":"14","author":"P Barlow","year":"2019","unstructured":"Barlow, P. et al. P2. 04-33 single-agent tislelizumab, an anti-PD-1 antibody: results from a phase 1 expansion cohort in NSCLC patients. J. Thorac. Oncol. 14, S721 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"2267_CR635","doi-asserted-by":"publisher","first-page":"S217","DOI":"10.1016\/j.annonc.2021.05.005","volume":"32","author":"M Ducreux","year":"2021","unstructured":"Ducreux, M. et al. O-1 Results from a global phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with unresectable hepatocellular carcinoma. Ann. Oncol. 32, S217 (2021).","journal-title":"Ann. Oncol."},{"key":"2267_CR636","doi-asserted-by":"publisher","first-page":"x24","DOI":"10.1093\/annonc\/mdy487.042","volume":"29","author":"S Deva","year":"2018","unstructured":"Deva, S. et al. A phase Ia\/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors. Ann. Oncol. 29, x24\u2013x25 (2018).","journal-title":"Ann. Oncol."},{"key":"2267_CR637","doi-asserted-by":"crossref","unstructured":"Gong, J. et al. Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial. Cancer Immunol. Immunother. 71,1897\u20131908 (2022).","DOI":"10.1007\/s00262-021-03102-3"},{"key":"2267_CR638","doi-asserted-by":"publisher","first-page":"7501","DOI":"10.1200\/JCO.2022.40.16_suppl.7501","volume":"40","author":"H Huang","year":"2022","unstructured":"Huang, H. et al. GEMSTONE-201: preplanned primary analysis of a multicenter, single-arm, phase 2 study of sugemalimab (suge) in patients (pts) with relapsed or refractory extranodal natural killer\/T cell lymphoma (R\/R ENKTL). J. Clin. Oncol. 40, 7501\u20137501 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2267_CR639","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1200\/JCO.22.02367","volume":"41","author":"H Huang","year":"2023","unstructured":"Huang, H. et al. Sugemalimab monotherapy for patients with relapsed or refractory extranodal natural killer\/T-cell lymphoma (GEMSTONE-201): results from a single-arm, multicenter, phase II study. J. Clin. Oncol. 41, 3032\u20133041 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2267_CR640","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/S1470-2045(21)00650-1","volume":"23","author":"C Zhou","year":"2022","unstructured":"Zhou, C. et al. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial. Lancet Oncol 23, 220\u2013233 (2022).","journal-title":"Lancet Oncol"},{"key":"2267_CR641","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1470-2045(21)00630-6","volume":"23","author":"Q Zhou","year":"2022","unstructured":"Zhou, Q. et al. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 23, 209\u2013219 (2022).","journal-title":"Lancet Oncol"},{"key":"2267_CR642","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s40265-022-01693-4","volume":"82","author":"S Dhillon","year":"2022","unstructured":"Dhillon, S. & Duggan, S. Sugemalimab: first approval. Drugs. 82, 593\u2013599 (2022).","journal-title":"Drugs."},{"key":"2267_CR643","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1158\/1535-7163.MCT-17-0368","volume":"17","author":"J Ai","year":"2018","unstructured":"Ai, J. et al. Preclinical evaluation of SCC244 (Glumetinib), a novel, potent, and highly selective inhibitor of c-Met in MET-dependent cancer models. Mol. Cancer Ther. 17, 751\u2013762 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"2267_CR644","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/d41573-024-00079-3","volume":"23","author":"Q Ge","year":"2024","unstructured":"Ge, Q., Zhang, X., Kaitin, K. I. & Shao, L. Development of Chinese innovative drugs in the USA. Nat. Rev. Drug Discov. 23, 421\u2013423 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2267_CR645","unstructured":"BD, M. 2023 China Pharmaceutical Licensing BD Transaction Annual Report <https:\/\/www.yaopower.com\/static\/public\/2024-03\/f7d863c0c5439a364c9df91d839f6084.pdf> (2024)."},{"key":"2267_CR646","unstructured":"Network, C. F. a. D. Domestic innovative drugs set off a going global wave <http:\/\/m.cnpharm.com\/c\/2024-04-03\/1041294.shtml> (2024)."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02267-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02267-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02267-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T23:09:13Z","timestamp":1753139353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02267-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":646,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2267"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02267-y","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"assertion":[{"value":"26 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"220"}}